Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1p_wp262

Request ID: cder_mpl1r_wp262
Request Description: In this report, we assessed the utilization pattern of hormonal contraceptives (HC) among individuals with live-birth or stillbirth delivery in the 12 months postpartum period in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) tool, QRP version 13.1.1

Data Source: We distributed this request to six Sentinel Data Partners (DP) data on June 24, 2024. The study period included data from January 1, 2012 to January 31, 2024. Please see **Appendix** A for a list of available data for each Data Partner.

Study Design: Using the Sentinel Distributed Database (SDD), we identified cohorts of patients who had live-birth or stillbirth deliveries. We assessed the weekly utilization of hormonal contraceptives in the 12 months postpartum period through the following approaches:

1. Live-stillbirth cohort: We assessed the weekly use of combined hormonal contraceptives (CHCs) or progestin-only contraceptives (POCs) over 52 weeks following live or stillbirth deliveries. This cohort included patients with live or stillbirth deliveries with or without HC use within 52 weeks after delivery. In addition to weekly consumption of CHCs and POCs, we described demographics (as of the index date) and clinical characteristics for this cohort. The index date was defined as the date of delivery (live or stillbirth), with no history of previous deliveries (live or stillbirth) within the past 365 days.
2. First-CHC-POC cohorts: We examined the timing of initiation of first CHC or POC use within 52 weeks after live or stillbirth deliveries. This analysis included patients who initiated any CHC, oral CHC, patch CHC, vaginal ring CHC, any POC, oral POC, depot-medroxyprogesterone acetate (DMPA) POC, intrauterine devices (IUDs) POC, or implant POC within 365 days postpartum. Separate cohorts were defined for each contraceptive type, and patients were excluded from the contraceptive cohort if any contraceptive other than the index contraceptive type was initiated. The timing of initiation of each contraceptive type was reported in weekly postpartum periods. In addition, demographics and clinical characteristics were described for each contraceptive cohort. The index date was defined as the date of delivery (live or stillbirth), with no history of previous deliveries (live or stillbirth) within the past 365 days and at least one CHC or POC dispensing within 52 weeks after delivery.
3. Interval-HC cohorts: We assessed the interval between the first and second dispensing of CHC or POC contraceptive dispensings within the 12 months postpartum. This analysis included patients initiating any CHC, any POC, and DMPA POC within 42 days after live or stillbirth deliveries and a subsequent dispensing for any contraceptive (CHC or POC) occurring within a year of postpartum. The index date was the date of the first CHC, POC, DMPA POC dispensing with no dispensing of any contraceptives in the 1 year prior.

We allowed reentry and included all qualified index encounters during the study period. This was a Type 2 analysis in the Query Request Package (QRP) documentation.

Overview for Request: cder_mpl1p_wp262

Exposures of Interest: Our exposures of interest were any form of CHC (any, oral, patch, and vaginal ring) or any form of POC (any, oral, DMPA, IUD, and implant) administered or dispensed in any care setting within 365 days postpartum. These were defined using National Drug Codes (NDCs), Healthcare Common Procedure Coding System (HCPCS) procedure codes, and Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes.
Additional details on exposures for each approach are specified below:

Live-stillbirth cohort: We examined the number and percentage of patients who used hormonal contraception (HC) during the 52 weeks postpartum following live-birth or stillbirth delivery. For those using HC, we assessed the type and frequency of HC use per weekly time period.

First-CHC-POC cohorts: Individuals were required to have evidence of receiving at least one CHC or POC within 365 days after live-birth or stillbirth delivery. The first CHC (any, oral, patch, and vaginal ring) or POC (any, oral, DMPA, IUD, and implant) was identified without any prior contraceptive use in the past year.

Interval-HC cohorts: Individuals were required to have evidence of receiving at least one dispensing for any CHC, any POC, and DMPA POC within 42 days after live or stillbirth deliveries and a subsequent dispensing for any contraceptive (CHC or POC) occurring within a year of postpartum. The first initiation of any CHC, any POC, and DMPA POC (index date) was identified without any previous records of CHC or POC use in the past 365 days.

Please see **Appendix** B for the list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, and Tenth Revision, Clinical Modification (ICD-10-CM) codes used to define live-birth or stillbirth deliveries in this request. Please see **Appendix** C for a list of non-proprietary and proprietary names of medical products used to define hormonal contraceptive exposures in this request. Please see **Appendix** D for the list of Healthcare Common Procedure Coding System, Level II (HCPCS) codes used to define hormonal contraceptive exposures in this request.

Cohort Eligibility Criteria: We required members to have medical and drug coverage for a minimum of 365 days before and after each index date; gaps in coverage of up to 45 days were allowed and considered continuous enrollment. Individuals of the following ages were included in the cohorts: 18-24, 25-34, 35-45, 46+ years.
Additional details for each approach are specified below:

Live-stillbirth cohort: We excluded any evidence of prior live-birth or stillbirth deliveries within 365 days before the index date (live-birth or stillbirth delivery).

First-CHC-POC cohorts: Similar to the live-birth or stillbirth delivery cohort, we excluded any evidence of prior live or stillbirth deliveries within 365 days before the index date. Additionally, individuals were required to have received at least one dispensing of CHC or POC within 365 days after the index date. We also excluded patients who had used any contraceptives within 365 days prior to the index date.

Interval-HC cohorts: The index date was defined as the first instance of CHC or POC use. Patients were required to have evidence of live or stillbirth deliveries occurring within 42 days before the index date. We excluded patients who experienced live or stillbirth deliveries within 365 days after the index date. Furthermore, patients were required to have received a second contraceptive within 365 days postpartum.

Please see **Appendix** B for the list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes used to define live-birth or stillbirth deliveries for inclusion specified in this request. **Appendix** C for a list of non-proprietary and proprietary names of medical products, and **Appendix** D for the list of Healthcare Common Procedure Coding System, Level II (HCPCS) codes used to define the first CHC or POC contraceptives in this request.

Overview for Request: cder_mpl1p_wp262

Time to initiation of first CHC or contraceptive for CHC-POC cohorts or time to subsequent contraceptive dispensing for interval-HC cohorts:

For the first-CHC-POC cohorts, where we assessed the initiation of the first CHC or POC in the one year postpartum after live or stillbirth delivery, follow-up began at the time of live or stillbirth delivery and continued until the first occurrence of any of the following: 1) evidence of CHC or POC dispensing of interest; 2) initiation of any contraceptive other than the index type; 3) death; 4) the end of the data provided by each Data Partner; or 5) the end of the query period. Please see Appendix F for a list of non-proprietary and proprietary names of medical products used to assess the initiation of any CHC or POC contraceptives other than the index contraceptive for follow-up assessment.
For the interval-HC cohorts, where we evaluated the interval between the first CHC or POC of interest and a subsequent contraceptive (any type), follow-up began at the time of initiation of the first CHC or POC of interest and continued until the first occurrence of any of the following: 1) evidence of any contraceptive dispensing; 2) death; 3) conclusion of available data from each Data Partner; or 4) completion of the query period.

Please see **Appendix** C for a list of non-proprietary and proprietary names of medical products, and **Appendix** D for a list of procedure codes used to define any CHC or POC contraceptives for follow-up assessment in this request.

Individual Characteristics: For live-stillbirth and first-CHC-POC cohorts, we assessed the following characteristics on index dates: age, sex, race, Hispanic origin, and year. We also assessed the delivery outcomes (including live birth, stillbirth, live birth singleton, live birth multiple, stillbirth singleton, stillbirth multiple, live/stillbirth multiple, and vaginal or C-section deliveries) and the utilization of drospirenone POC for oral POC cohort on the index date. Additionally, we evaluated the removal of IUD or implant relevant for DMPA and IUD POC cohorts. We also examined the use of any CHC, oral CHC, patch CHC, ring CHC, any POC, non-oral POCs, oral POC, no use of CHC, no use of POC, and at least two instances of CHC or POC contraceptive types within 1-365 days after the index.

Please see **Appendix** B, C, D, and E for ICD-9 and ICD-10 codes, procedure codes, and non-proprietary and proprietary names of medical products used for defining covariates.

Please refer to Appendices F, G, H and I for the specifications of parameters used in this request, baseline characteristics used in this request, and combination specifications, and Appendix I for a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse).

Sentinel

Table of Contents

Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in This Report
Table 1a	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024
Table 1b	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for Any Combined Hormonal Contraceptive (CHC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1c	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Oral Combined Hormonal Contraceptive (CHC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1d	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Combined Hormonal Contraceptive (CHC) Patch in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1e	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Combined Hormonal Contraceptive (CHC) Ring in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1f	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for Any Progestin-only Contraceptives (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1g	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Intrauterine Device (IUD) Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1h	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Depot-medroxyprogesterone Acetate (DMPA) Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1i	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Oral Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1j	Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Implant Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1k	Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Combined Hormonal Contraceptive (CHC) in the First 6 Weeks After Live or Stillbirth Delivery and a Subsequent Dispensing or Administration for Any Contraceptive (CHC or Progestin-only Contraceptives [POC]) Within a Year of Post-partum in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1l	Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Progestin-only Contraceptive (POC) in the First 6 Weeks After Live or Stillbirth Deliver and a Subsequent Dispensing or Administration for Any Contraceptive (Combined Hormonal Contraceptive [CHC] or POC) Within a Year of Post-partum in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 1m	Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Depot-medroxyprogesterone Acetate (DMPA) Progestin-only Contraceptives (POC) in the First 6 Weeks After Live or Stillbirth Delivery and a Subsequent Dispensing or Administration for Any Contraceptive (Combined Hormonal Contraceptives [CHC] or POC) within a year of post-partum in the Sentinel Distributed Database from January 1, 2012 to January 31, 2024
Table 2	Summary of Time to End of At-risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Table of Contents

Table 3a	Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 3b	Continous Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 4a	Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 4b	Continuous Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 5a	Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 5b	Continous Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Table 6	Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024
Appendix A	Dates of Available Data for Each Data Partner (DP) As of Request Distribution Date (October 2, 2023)
Appendix B	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request
Appendix C	List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request
Appendix D	List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Used to Define Hormonal Contraceptive Exposures in this Request
Appendix E	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request
Appendix F	Specifications Defining Parameters for This Request
Appendix G	Specifications Defining Baseline Characteristics for This Request
Appendix H	Specifications Defining Combinations for This Request
Appendix I	Design Diagram for This Request

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per National Drug Code (NDC) per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	3,096,104	
Episodes	3,577,468	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	29.7	5.5
Age	**Number**	**Percent[2]**
18-24 years	868,543	24.3%
25-34 years	2,028,019	56.7%
35-45 years	669,081	18.7%
≥ 46 years	11,825	0.3%
Sex		
Female	3,096,104	100.0%
Race[3]		
American Indian or Alaska Native	42,057	1.4%
Asian	104,504	3.4%
Black or African American	423,734	13.7%
Multi-racial	35,053	1.1%
Native Hawaiian or Other Pacific Islander	13,250	0.4%
Unknown	1,442,447	46.6%
White	1,035,059	33.4%
Hispanic origin		
Yes	429,098	13.9%
No	1,520,128	49.1%
Unknown	1,146,878	37.0%
Year		
2012	143,490	4.0%
2013	135,286	3.8%
2014	156,960	4.4%
2015	216,446	6.1%
2016	307,189	8.6%
2017	542,318	15.2%
2018	586,503	16.4%
2019	581,426	16.3%
2020	612,034	17.1%
2021	164,280	4.6%
2022	127,144	3.6%
2023	4,392	0.1%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	3,549,527	99.2%
Still birth	37,767	1.1%
Live Birth Singleton	3,492,774	97.6%
Live Birth Multiple	95,178	2.7%
Still Birth Singleton	34,479	1.0%
Still Birth Multiple	4,975	0.1%
Live and Still Birth Multiple	8,804	0.2%
C-section	986,404	27.6%
Vaginal Delivery	1,831,555	51.2%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	89,137	2.5%
Drospirenone (0,0)	*****	*****
Any Combined Hormonal Contraceptives (CHC)	610,398	17.1%
Oral CHC	524,578	14.7%
Patch CHC	46,618	1.3%
Ring CHC	57,162	1.6%
Any POC	1,048,434	29.3%
Non-oral POCs	578,469	16.2%
Oral POC	518,943	14.5%
No use of CHC	2,967,070	82.9%
No use of POC	2,529,034	70.7%
Any CHC - 2 instances	419,948	11.7%
Oral CHC - 2 instances	356,216	10.0%
Patch CHC - 2 instances	29,283	0.8%
Ring CHC - 2 instances	37,097	1.0%
Any POC - 2 instances	426,729	11.9%
Non-oral POCs - 2 instances	89,042	2.5%
Oral POC - 2 instances	317,600	8.9%
Combined Oral Contraceptives (COC) Week 1	6,784	0.2%
COC Week 2	4,347	0.1%
COC Week 3	7,135	0.2%
COC Week 4	10,417	0.3%
COC Week 5	21,938	0.6%
COC Week 6	58,333	1.6%
COC Week 7	79,461	2.2%
COC Week 8	35,615	1.0%
COC Week 9	29,754	0.8%
COC Week 10	38,396	1.1%
COC Week 11	47,016	1.3%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
COC Week 12	31,661	0.9%
COC Week 13	29,504	0.8%
COC Week 14	36,605	1.0%
COC Week 15	45,145	1.3%
COC Week 16	34,107	1.0%
COC Week 17	33,157	0.9%
COC Week 18	44,596	1.2%
COC Week 19	57,111	1.6%
COC Week 20	40,823	1.1%
COC Week 21	35,272	1.0%
COC Week 22	40,366	1.1%
COC Week 23	46,064	1.3%
COC Week 24	36,920	1.0%
COC Week 25	34,248	1.0%
COC Week 26	39,111	1.1%
COC Week 27	45,084	1.3%
COC Week 28	37,273	1.0%
COC Week 29	36,076	1.0%
COC Week 30	43,718	1.2%
COC Week 31	52,943	1.5%
COC Week 32	42,188	1.2%
COC Week 33	38,356	1.1%
COC Week 34	41,415	1.2%
COC Week 35	46,423	1.3%
COC Week 36	38,617	1.1%
COC Week 37	36,438	1.0%
COC Week 38	40,025	1.1%
COC Week 39	45,437	1.3%
COC Week 40	38,965	1.1%
COC Week 41	37,619	1.1%
COC Week 42	43,401	1.2%
COC Week 43	51,167	1.4%
COC Week 44	41,941	1.2%
COC Week 45	39,016	1.1%
COC Week 46	41,909	1.2%
COC Week 47	46,001	1.3%
COC Week 48	39,655	1.1%
COC Week 49	37,530	1.0%
COC Week 50	40,476	1.1%
COC Week 51	44,642	1.2%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
COC Week 52	39,458	1.1%
Patch Week 1	704	0.0%
Patch Week 2	365	0.0%
Patch Week 3	622	0.0%
Patch Week 4	1,095	0.0%
Patch Week 5	2,316	0.1%
Patch Week 6	4,913	0.1%
Patch Week 7	7,039	0.2%
Patch Week 8	3,430	0.1%
Patch Week 9	3,244	0.1%
Patch Week 10	3,798	0.1%
Patch Week 11	4,365	0.1%
Patch Week 12	3,029	0.1%
Patch Week 13	3,058	0.1%
Patch Week 14	3,319	0.1%
Patch Week 15	3,996	0.1%
Patch Week 16	3,111	0.1%
Patch Week 17	3,153	0.1%
Patch Week 18	3,623	0.1%
Patch Week 19	4,196	0.1%
Patch Week 20	3,364	0.1%
Patch Week 21	3,146	0.1%
Patch Week 22	3,230	0.1%
Patch Week 23	3,679	0.1%
Patch Week 24	3,109	0.1%
Patch Week 25	3,077	0.1%
Patch Week 26	3,126	0.1%
Patch Week 27	3,530	0.1%
Patch Week 28	3,262	0.1%
Patch Week 29	3,008	0.1%
Patch Week 30	3,291	0.1%
Patch Week 31	3,630	0.1%
Patch Week 32	3,237	0.1%
Patch Week 33	3,108	0.1%
Patch Week 34	3,086	0.1%
Patch Week 35	3,357	0.1%
Patch Week 36	3,127	0.1%
Patch Week 37	2,978	0.1%
Patch Week 38	3,031	0.1%
Patch Week 39	3,258	0.1%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Patch Week 40	3,070	0.1%
Patch Week 41	3,007	0.1%
Patch Week 42	3,134	0.1%
Patch Week 43	3,380	0.1%
Patch Week 44	3,085	0.1%
Patch Week 45	3,022	0.1%
Patch Week 46	2,923	0.1%
Patch Week 47	3,212	0.1%
Patch Week 48	3,004	0.1%
Patch Week 49	2,923	0.1%
Patch Week 50	2,893	0.1%
Patch Week 51	3,090	0.1%
Patch Week 52	2,903	0.1%
Ring Week 1	574	0.0%
Ring Week 2	310	0.0%
Ring Week 3	555	0.0%
Ring Week 4	924	0.0%
Ring Week 5	1,990	0.1%
Ring Week 6	5,482	0.2%
Ring Week 7	7,835	0.2%
Ring Week 8	3,502	0.1%
Ring Week 9	2,882	0.1%
Ring Week 10	3,498	0.1%
Ring Week 11	4,470	0.1%
Ring Week 12	3,127	0.1%
Ring Week 13	2,895	0.1%
Ring Week 14	3,376	0.1%
Ring Week 15	4,184	0.1%
Ring Week 16	3,463	0.1%
Ring Week 17	3,259	0.1%
Ring Week 18	4,096	0.1%
Ring Week 19	5,106	0.1%
Ring Week 20	4,210	0.1%
Ring Week 21	3,702	0.1%
Ring Week 22	3,781	0.1%
Ring Week 23	4,257	0.1%
Ring Week 24	3,858	0.1%
Ring Week 25	3,560	0.1%
Ring Week 26	3,756	0.1%
Ring Week 27	4,286	0.1%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Ring Week 28	3,924	0.1%
Ring Week 29	3,689	0.1%
Ring Week 30	4,092	0.1%
Ring Week 31	4,780	0.1%
Ring Week 32	4,332	0.1%
Ring Week 33	3,996	0.1%
Ring Week 34	4,047	0.1%
Ring Week 35	4,324	0.1%
Ring Week 36	4,017	0.1%
Ring Week 37	3,983	0.1%
Ring Week 38	4,018	0.1%
Ring Week 39	4,262	0.1%
Ring Week 40	3,999	0.1%
Ring Week 41	3,969	0.1%
Ring Week 42	4,257	0.1%
Ring Week 43	4,606	0.1%
Ring Week 44	4,269	0.1%
Ring Week 45	4,178	0.1%
Ring Week 46	4,242	0.1%
Ring Week 47	4,249	0.1%
Ring Week 48	4,100	0.1%
Ring Week 49	4,040	0.1%
Ring Week 50	4,197	0.1%
Ring Week 51	4,121	0.1%
Ring Week 52	4,115	0.1%
Intrauterine Device (IUD) Week 1	1,886	0.1%
IUD Week 2	958	0.0%
IUD Week 3	1,883	0.1%
IUD Week 4	2,868	0.1%
IUD Week 5	6,604	0.2%
IUD Week 6	28,155	0.8%
IUD Week 7	51,958	1.5%
IUD Week 8	40,216	1.1%
IUD Week 9	36,153	1.0%
IUD Week 10	26,090	0.7%
IUD Week 11	19,943	0.6%
IUD Week 12	14,453	0.4%
IUD Week 13	11,001	0.3%
IUD Week 14	8,534	0.2%
IUD Week 15	6,890	0.2%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
IUD Week 16	5,507	0.2%
IUD Week 17	4,751	0.1%
IUD Week 18	4,230	0.1%
IUD Week 19	3,887	0.1%
IUD Week 20	3,492	0.1%
IUD Week 21	3,179	0.1%
IUD Week 22	2,877	0.1%
IUD Week 23	2,793	0.1%
IUD Week 24	2,764	0.1%
IUD Week 25	2,472	0.1%
IUD Week 26	2,293	0.1%
IUD Week 27	2,349	0.1%
IUD Week 28	2,161	0.1%
IUD Week 29	2,178	0.1%
IUD Week 30	2,054	0.1%
IUD Week 31	1,955	0.1%
IUD Week 32	1,851	0.1%
IUD Week 33	1,901	0.1%
IUD Week 34	1,791	0.1%
IUD Week 35	1,765	0.0%
IUD Week 36	1,599	0.0%
IUD Week 37	1,639	0.0%
IUD Week 38	1,590	0.0%
IUD Week 39	1,491	0.0%
IUD Week 40	1,422	0.0%
IUD Week 41	1,467	0.0%
IUD Week 42	1,397	0.0%
IUD Week 43	1,386	0.0%
IUD Week 44	1,365	0.0%
IUD Week 45	1,375	0.0%
IUD Week 46	1,381	0.0%
IUD Week 47	1,343	0.0%
IUD Week 48	1,303	0.0%
IUD Week 49	1,327	0.0%
IUD Week 50	1,351	0.0%
IUD Week 51	1,314	0.0%
IUD Week 52	1,321	0.0%
Depot-medroxyprogesterone Acetate (DMPA) Week 1	4,213	0.1%
DMPA Week 2	3,008	0.1%
DMPA Week 3	3,865	0.1%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
DMPA Week 4	4,519	0.1%
DMPA Week 5	7,444	0.2%
DMPA Week 6	16,038	0.4%
DMPA Week 7	19,395	0.5%
DMPA Week 8	7,839	0.2%
DMPA Week 9	5,197	0.1%
DMPA Week 10	3,787	0.1%
DMPA Week 11	3,271	0.1%
DMPA Week 12	4,690	0.1%
DMPA Week 13	5,148	0.1%
DMPA Week 14	4,634	0.1%
DMPA Week 15	3,810	0.1%
DMPA Week 16	3,982	0.1%
DMPA Week 17	5,052	0.1%
DMPA Week 18	7,774	0.2%
DMPA Week 19	10,931	0.3%
DMPA Week 20	8,607	0.2%
DMPA Week 21	5,398	0.2%
DMPA Week 22	4,141	0.1%
DMPA Week 23	3,719	0.1%
DMPA Week 24	3,883	0.1%
DMPA Week 25	4,459	0.1%
DMPA Week 26	4,046	0.1%
DMPA Week 27	4,059	0.1%
DMPA Week 28	3,715	0.1%
DMPA Week 29	4,184	0.1%
DMPA Week 30	5,296	0.1%
DMPA Week 31	6,467	0.2%
DMPA Week 32	7,338	0.2%
DMPA Week 33	5,774	0.2%
DMPA Week 34	4,257	0.1%
DMPA Week 35	3,510	0.1%
DMPA Week 36	3,638	0.1%
DMPA Week 37	3,709	0.1%
DMPA Week 38	3,632	0.1%
DMPA Week 39	3,675	0.1%
DMPA Week 40	3,691	0.1%
DMPA Week 41	3,692	0.1%
DMPA Week 42	4,230	0.1%
DMPA Week 43	4,788	0.1%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
DMPA Week 44	4,807	0.1%
DMPA Week 45	5,578	0.2%
DMPA Week 46	4,510	0.1%
DMPA Week 47	3,742	0.1%
DMPA Week 48	3,383	0.1%
DMPA Week 49	3,330	0.1%
DMPA Week 50	3,388	0.1%
DMPA Week 51	3,419	0.1%
DMPA Week 52	3,243	0.1%
Progestin-Only Pills (POP) Week 1	49,729	1.4%
POP Week 2	9,831	0.3%
POP Week 3	14,437	0.4%
POP Week 4	17,437	0.5%
POP Week 5	40,042	1.1%
POP Week 6	102,807	2.9%
POP Week 7	134,134	3.7%
POP Week 8	49,558	1.4%
POP Week 9	38,764	1.1%
POP Week 10	51,399	1.4%
POP Week 11	67,063	1.9%
POP Week 12	36,339	1.0%
POP Week 13	31,543	0.9%
POP Week 14	40,783	1.1%
POP Week 15	55,942	1.6%
POP Week 16	34,342	1.0%
POP Week 17	31,127	0.9%
POP Week 18	48,033	1.3%
POP Week 19	68,193	1.9%
POP Week 20	38,695	1.1%
POP Week 21	29,813	0.8%
POP Week 22	34,655	1.0%
POP Week 23	44,551	1.2%
POP Week 24	29,431	0.8%
POP Week 25	25,129	0.7%
POP Week 26	29,530	0.8%
POP Week 27	39,189	1.1%
POP Week 28	27,464	0.8%
POP Week 29	24,434	0.7%
POP Week 30	33,666	0.9%
POP Week 31	47,442	1.3%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
POP Week 32	30,248	0.8%
POP Week 33	24,007	0.7%
POP Week 34	26,009	0.7%
POP Week 35	32,527	0.9%
POP Week 36	23,306	0.7%
POP Week 37	20,107	0.6%
POP Week 38	22,548	0.6%
POP Week 39	28,917	0.8%
POP Week 40	21,911	0.6%
POP Week 41	19,569	0.5%
POP Week 42	25,404	0.7%
POP Week 43	34,607	1.0%
POP Week 44	23,902	0.7%
POP Week 45	19,535	0.5%
POP Week 46	20,486	0.6%
POP Week 47	24,993	0.7%
POP Week 48	18,872	0.5%
POP Week 49	16,288	0.5%
POP Week 50	17,603	0.5%
POP Week 51	21,861	0.6%
POP Week 52	16,886	0.5%
IMPL Week 1	6,243	0.2%
Implant (IMPL) Week 2	1,137	0.0%
IMPL Week 3	2,078	0.1%
IMPL Week 4	3,090	0.1%
IMPL Week 5	5,850	0.2%
IMPL Week 6	12,295	0.3%
IMPL Week 7	19,430	0.5%
IMPL Week 8	13,085	0.4%
IMPL Week 9	10,370	0.3%
IMPL Week 10	7,733	0.2%
IMPL Week 11	5,908	0.2%
IMPL Week 12	4,506	0.1%
IMPL Week 13	3,542	0.1%
IMPL Week 14	2,954	0.1%
IMPL Week 15	2,419	0.1%
IMPL Week 16	2,070	0.1%
IMPL Week 17	1,849	0.1%
IMPL Week 18	1,846	0.1%
IMPL Week 19	1,682	0.0%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
IMPL Week 20	1,505	0.0%
IMPL Week 21	1,385	0.0%
IMPL Week 22	1,307	0.0%
IMPL Week 23	1,212	0.0%
IMPL Week 24	1,103	0.0%
IMPL Week 25	1,054	0.0%
IMPL Week 26	997	0.0%
IMPL Week 27	1,014	0.0%
IMPL Week 28	944	0.0%
IMPL Week 29	893	0.0%
IMPL Week 30	954	0.0%
IMPL Week 31	860	0.0%
IMPL Week 32	891	0.0%
IMPL Week 33	762	0.0%
IMPL Week 34	769	0.0%
IMPL Week 35	737	0.0%
IMPL Week 36	742	0.0%
IMPL Week 37	715	0.0%
IMPL Week 38	663	0.0%
IMPL Week 39	690	0.0%
IMPL Week 40	708	0.0%
IMPL Week 41	645	0.0%
IMPL Week 42	607	0.0%
IMPL Week 43	623	0.0%
IMPL Week 44	610	0.0%
IMPL Week 45	619	0.0%
IMPL Week 46	603	0.0%
IMPL Week 47	658	0.0%
IMPL Week 48	617	0.0%
IMPL Week 49	627	0.0%
IMPL Week 50	628	0.0%
IMPL Week 51	633	0.0%
IMPL Week 52	676	0.0%
Any CHC Week 1	8,056	0.2%
Any CHC Week 2	5,022	0.1%
Any CHC Week 3	8,308	0.2%
Any CHC Week 4	12,430	0.3%
Any CHC Week 5	26,234	0.7%
Any CHC Week 6	68,687	1.9%
Any CHC Week 7	94,267	2.6%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Any CHC Week 8	42,524	1.2%
Any CHC Week 9	35,856	1.0%
Any CHC Week 10	45,665	1.3%
Any CHC Week 11	55,813	1.6%
Any CHC Week 12	37,792	1.1%
Any CHC Week 13	35,435	1.0%
Any CHC Week 14	43,272	1.2%
Any CHC Week 15	53,302	1.5%
Any CHC Week 16	40,649	1.1%
Any CHC Week 17	39,546	1.1%
Any CHC Week 18	52,285	1.5%
Any CHC Week 19	66,371	1.9%
Any CHC Week 20	48,374	1.4%
Any CHC Week 21	42,099	1.2%
Any CHC Week 22	47,345	1.3%
Any CHC Week 23	53,969	1.5%
Any CHC Week 24	43,864	1.2%
Any CHC Week 25	40,862	1.1%
Any CHC Week 26	45,973	1.3%
Any CHC Week 27	52,883	1.5%
Any CHC Week 28	44,434	1.2%
Any CHC Week 29	42,755	1.2%
Any CHC Week 30	51,078	1.4%
Any CHC Week 31	61,320	1.7%
Any CHC Week 32	49,725	1.4%
Any CHC Week 33	45,430	1.3%
Any CHC Week 34	48,521	1.4%
Any CHC Week 35	54,077	1.5%
Any CHC Week 36	45,733	1.3%
Any CHC Week 37	43,372	1.2%
Any CHC Week 38	47,051	1.3%
Any CHC Week 39	52,938	1.5%
Any CHC Week 40	46,002	1.3%
Any CHC Week 41	44,566	1.2%
Any CHC Week 42	50,764	1.4%
Any CHC Week 43	59,126	1.7%
Any CHC Week 44	49,269	1.4%
Any CHC Week 45	46,193	1.3%
Any CHC Week 46	49,052	1.4%
Any CHC Week 47	53,427	1.5%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Any CHC Week 48	46,735	1.3%
Any CHC Week 49	44,472	1.2%
Any CHC Week 50	47,547	1.3%
Any CHC Week 51	51,832	1.4%
Any CHC Week 52	46,450	1.3%
Any POC Week 1	62,029	1.7%
Any POC Week 2	14,915	0.4%
Any POC Week 3	22,200	0.6%
Any POC Week 4	27,841	0.8%
Any POC Week 5	59,748	1.7%
Any POC Week 6	158,931	4.4%
Any POC Week 7	224,289	6.3%
Any POC Week 8	110,383	3.1%
Any POC Week 9	90,236	2.5%
Any POC Week 10	88,762	2.5%
Any POC Week 11	95,927	2.7%
Any POC Week 12	59,830	1.7%
Any POC Week 13	51,121	1.4%
Any POC Week 14	56,789	1.6%
Any POC Week 15	68,936	1.9%
Any POC Week 16	45,810	1.3%
Any POC Week 17	42,683	1.2%
Any POC Week 18	61,763	1.7%
Any POC Week 19	84,553	2.4%
Any POC Week 20	52,218	1.5%
Any POC Week 21	39,704	1.1%
Any POC Week 22	42,901	1.2%
Any POC Week 23	52,223	1.5%
Any POC Week 24	37,119	1.0%
Any POC Week 25	33,053	0.9%
Any POC Week 26	36,819	1.0%
Any POC Week 27	46,544	1.3%
Any POC Week 28	34,232	1.0%
Any POC Week 29	31,645	0.9%
Any POC Week 30	41,915	1.2%
Any POC Week 31	56,641	1.6%
Any POC Week 32	40,274	1.1%
Any POC Week 33	32,396	0.9%
Any POC Week 34	32,783	0.9%
Any POC Week 35	38,500	1.1%

Table 1a. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery in the Sentinel Distributed (SDD) Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Any POC Week 36	29,240	0.8%
Any POC Week 37	26,119	0.7%
Any POC Week 38	28,407	0.8%
Any POC Week 39	34,727	1.0%
Any POC Week 40	27,694	0.8%
Any POC Week 41	25,333	0.7%
Any POC Week 42	31,591	0.9%
Any POC Week 43	41,342	1.2%
Any POC Week 44	30,641	0.9%
Any POC Week 45	27,064	0.8%
Any POC Week 46	26,939	0.8%
Any POC Week 47	30,685	0.9%
Any POC Week 48	24,136	0.7%
Any POC Week 49	21,535	0.6%
Any POC Week 50	22,926	0.6%
Any POC Week 51	27,182	0.8%
Any POC Week 52	22,095	0.6%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for Any Combined Hormonal Contraceptive (CHC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	444,220	
Episodes	458,204	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	28.3	5.2
Age	**Number**	**Percent[2]**
18-24 years	143,168	31.2%
25-34 years	257,465	56.2%
35-45 years	57,378	12.5%
≥ 46 years	193	0.0%
Sex		
Female	444,220	100.0%
Race[3]		
American Indian or Alaska Native	3,871	0.9%
Asian	10,396	2.3%
Black or African American	57,542	13.0%
Multi-racial	4,195	0.9%
Native Hawaiian or Other Pacific Islander	1,484	0.3%
Unknown	201,173	45.3%
White	165,559	37.3%
Hispanic origin		
Yes	57,762	13.0%
No	226,216	50.9%
Unknown	160,242	36.1%
Year		
2012	22,189	4.8%
2013	19,846	4.3%
2014	22,050	4.8%
2015	28,449	6.2%
2016	40,754	8.9%
2017	70,137	15.3%
2018	76,012	16.6%
2019	72,842	15.9%
2020	76,163	16.6%
2021	17,388	3.8%
2022	12,020	2.6%
2023	354	0.1%

Table 1b. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for Any Combined Hormonal Contraceptive (CHC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	455,127	99.3%
Still birth	4,301	0.9%
Live Birth Singleton	448,801	97.9%
Live Birth Multiple	11,019	2.4%
Still Birth Singleton	3,955	0.9%
Still Birth Multiple	561	0.1%
Live and Still Birth Multiple	960	0.2%
C-section	125,848	27.5%
Vaginal Delivery	231,812	50.6%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	21,474	4.7%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	458,204	100.0%
Oral CHC	393,798	85.9%
Patch CHC	35,512	7.8%
Ring CHC	41,728	9.1%
Any POC	145,366	31.7%
Non-oral POCs	55,178	12.0%
Oral POC	96,787	21.1%
No use of CHC	0	0.0%
No use of POC	312,838	68.3%
Any CHC - 2 instances	303,555	66.2%
Oral CHC - 2 instances	257,519	56.2%
Patch CHC - 2 instances	21,486	4.7%
Ring CHC - 2 instances	26,082	5.7%
Any POC - 2 instances	71,387	15.6%
Non-oral POCs - 2 instances	9,457	2.1%
Oral POC - 2 instances	59,156	12.9%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1c. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Oral Combined Hormonal Contraceptive (CHC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	382,381	
Episodes	393,798	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	28.5	5.2
Age	**Number**	**Percent[2]**
18-24 years	119,755	30.4%
25-34 years	223,197	56.7%
35-45 years	50,671	12.9%
≥ 46 years	175	0.0%
Sex		
Female	382,381	100.0%
Race[3]		
American Indian or Alaska Native	3,262	0.9%
Asian	8,511	2.2%
Black or African American	45,942	12.0%
Multi-racial	3,615	0.9%
Native Hawaiian or Other Pacific Islander	1,282	0.3%
Unknown	175,979	46.0%
White	143,790	37.6%
Hispanic origin		
Yes	48,255	12.6%
No	191,105	50.0%
Unknown	143,021	37.4%
Year		
2012	20,324	5.2%
2013	18,068	4.6%
2014	20,012	5.1%
2015	25,531	6.5%
2016	35,825	9.1%
2017	59,661	15.2%
2018	64,003	16.3%
2019	61,087	15.5%
2020	63,066	16.0%
2021	15,342	3.9%
2022	10,560	2.7%
2023	319	0.1%

Table 1c. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Oral Combined Hormonal Contraceptive (CHC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	391,077	99.3%
Still birth	3,807	1.0%
Live Birth Singleton	385,565	97.9%
Live Birth Multiple	9,531	2.4%
Still Birth Singleton	3,496	0.9%
Still Birth Multiple	502	0.1%
Live and Still Birth Multiple	884	0.2%
C-section	110,281	28.0%
Vaginal Delivery	200,181	50.8%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	17,395	4.4%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	393,798	100.0%
Oral CHC	393,798	100.0%
Patch CHC	6,090	1.5%
Ring CHC	5,877	1.5%
Any POC	127,383	32.3%
Non-oral POCs	46,861	11.9%
Oral POC	86,084	21.9%
No use of CHC	0	0.0%
No use of POC	266,415	67.7%
Any CHC - 2 instances	262,548	66.7%
Oral CHC - 2 instances	257,519	65.4%
Patch CHC - 2 instances	3,394	0.9%
Ring CHC - 2 instances	3,129	0.8%
Any POC - 2 instances	64,141	16.3%
Non-oral POCs - 2 instances	8,115	2.1%
Oral POC - 2 instances	53,693	13.6%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1d. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Combined Hormonal Contraceptive (CHC) Patch in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	35,104	
Episodes	35,512	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	26.0	5.2
Age	**Number**	**Percent[2]**
18-24 years	17,468	49.2%
25-34 years	15,677	44.1%
35-45 years	*****	*****
≥ 46 years	*****	*****
Sex		
Female	35,104	100.0%
Race[3]		
American Indian or Alaska Native	416	1.2%
Asian	1,602	4.6%
Black or African American	8,738	24.9%
Multi-racial	289	0.8%
Native Hawaiian or Other Pacific Islander	138	0.4%
Unknown	12,477	35.5%
White	11,444	32.6%
Hispanic origin		
Yes	6,592	18.8%
No	22,289	63.5%
Unknown	6,223	17.7%
Year		
2012	*****	*****
2013	492	1.4%
2014	556	1.6%
2015	991	2.8%
2016	2,098	5.9%
2017	5,815	16.4%
2018	7,352	20.7%
2019	7,604	21.4%
2020	8,759	24.7%
2021	786	2.2%
2022	592	1.7%
2023	*****	*****

Table 1d. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Combined Hormonal Contraceptive (CHC) Patch in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	35,272	99.3%
Still birth	306	0.9%
Live Birth Singleton	34,828	98.1%
Live Birth Multiple	848	2.4%
Still Birth Singleton	284	0.8%
Still Birth Multiple	40	0.1%
Live and Still Birth Multiple	28	0.1%
C-section	7,693	21.7%
Vaginal Delivery	16,154	45.5%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	2,273	6.4%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	35,512	100.0%
Oral CHC	6,090	17.1%
Patch CHC	35,512	100.0%
Ring CHC	1,101	3.1%
Any POC	9,490	26.7%
Non-oral POCs	5,112	14.4%
Oral POC	4,970	14.0%
No use of CHC	0	0.0%
No use of POC	26,022	73.3%
Any CHC - 2 instances	24,560	69.2%
Oral CHC - 2 instances	3,361	9.5%
Patch CHC - 2 instances	21,486	60.5%
Ring CHC - 2 instances	544	1.5%
Any POC - 2 instances	3,363	9.5%
Non-oral POCs - 2 instances	946	2.7%
Oral POC - 2 instances	2,157	6.1%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Combined Hormonal Contraceptive (CHC) Ring in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	40,940	
Episodes	41,728	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	28.6	5.1
Age	**Number**	**Percent[2]**
18-24 years	11,909	28.5%
25-34 years	24,621	59.0%
35-45 years	5,185	12.4%
≥ 46 years	13	0.0%
Sex		
Female	40,940	100.0%
Race[3]		
American Indian or Alaska Native	323	0.8%
Asian	569	1.4%
Black or African American	5,352	13.1%
Multi-racial	436	1.1%
Native Hawaiian or Other Pacific Islander	99	0.2%
Unknown	17,838	43.6%
White	16,323	39.9%
Hispanic origin		
Yes	4,794	11.7%
No	21,615	52.8%
Unknown	14,531	35.5%
Year		
2012	1,814	4.3%
2013	1,647	3.9%
2014	1,873	4.5%
2015	2,456	5.9%
2016	3,824	9.2%
2017	6,770	16.2%
2018	7,163	17.2%
2019	6,575	15.8%
2020	6,901	16.5%
2021	1,585	3.8%
2022	1,091	2.6%
2023	29	0.1%

Table 1e. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Combined Hormonal Contraceptive (CHC) Ring in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	41,527	99.5%
Still birth	299	0.7%
Live Birth Singleton	40,973	98.2%
Live Birth Multiple	950	2.3%
Still Birth Singleton	276	0.7%
Still Birth Multiple	33	0.1%
Live and Still Birth Multiple	66	0.2%
C-section	11,056	26.5%
Vaginal Delivery	21,451	51.4%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	2,813	6.7%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	41,728	100.0%
Oral CHC	5,877	14.1%
Patch CHC	1,101	2.6%
Ring CHC	41,728	100.0%
Any POC	12,452	29.8%
Non-oral POCs	5,074	12.2%
Oral POC	8,075	19.4%
No use of CHC	0	0.0%
No use of POC	29,276	70.2%
Any CHC - 2 instances	29,252	70.1%
Oral CHC - 2 instances	3,446	8.3%
Patch CHC - 2 instances	582	1.4%
Ring CHC - 2 instances	26,082	62.5%
Any POC - 2 instances	5,407	13.0%
Non-oral POCs - 2 instances	701	1.7%
Oral POC - 2 instances	4,422	10.6%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1f. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for Any Progestin-only Contraceptives (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	810,752	
Episodes	848,066	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	29.0	5.3
Age	**Number**	**Percent[2]**
18-24 years	232,931	27.5%
25-34 years	486,522	57.4%
35-45 years	128,181	15.1%
≥ 46 years	432	0.1%
Sex		
Female	810,752	100.0%
Race[3]		
American Indian or Alaska Native	9,609	1.2%
Asian	19,529	2.4%
Black or African American	109,899	13.6%
Multi-racial	9,102	1.1%
Native Hawaiian or Other Pacific Islander	3,772	0.5%
Unknown	385,115	47.5%
White	273,726	33.8%
Hispanic origin		
Yes	114,935	14.2%
No	389,573	48.1%
Unknown	306,244	37.8%
Year		
2012	33,732	4.0%
2013	32,314	3.8%
2014	38,712	4.6%
2015	53,555	6.3%
2016	75,024	8.8%
2017	128,925	15.2%
2018	138,420	16.3%
2019	137,291	16.2%
2020	142,727	16.8%
2021	37,901	4.5%
2022	28,517	3.4%
2023	948	0.1%

Table 1f. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for Any Progestin-only Contraceptives (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	845,640	99.7%
Still birth	3,946	0.5%
Live Birth Singleton	834,847	98.4%
Live Birth Multiple	19,350	2.3%
Still Birth Singleton	3,489	0.4%
Still Birth Multiple	452	0.1%
Live and Still Birth Multiple	1,465	0.2%
C-section	212,292	25.0%
Vaginal Delivery	459,313	54.2%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	54,818	6.5%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	145,366	17.1%
Oral CHC	127,383	15.0%
Patch CHC	9,490	1.1%
Ring CHC	12,452	1.5%
Any POC	848,066	100.0%
Non-oral POCs	485,739	57.3%
Oral POC	399,571	47.1%
No use of CHC	702,700	82.9%
No use of POC	0	0.0%
Any CHC - 2 instances	92,697	10.9%
Oral CHC - 2 instances	80,384	9.5%
Patch CHC - 2 instances	5,383	0.6%
Ring CHC - 2 instances	7,211	0.9%
Any POC - 2 instances	322,674	38.0%
Non-oral POCs - 2 instances	73,468	8.7%
Oral POC - 2 instances	233,294	27.5%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1g. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Intrauterine Device (IUD) Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	267,945	
Episodes	275,225	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	29.4	5.2
Age	**Number**	**Percent[2]**
18-24 years	66,984	24.3%
25-34 years	162,513	59.0%
35-45 years	45,607	16.6%
≥ 46 years	121	0.0%
Sex		
Female	267,945	100.0%
Race[3]		
American Indian or Alaska Native	3,043	1.1%
Asian	5,817	2.2%
Black or African American	23,628	8.8%
Multi-racial	3,292	1.2%
Native Hawaiian or Other Pacific Islander	967	0.4%
Unknown	134,917	50.4%
White	96,281	35.9%
Hispanic origin		
Yes	33,011	12.3%
No	118,346	44.2%
Unknown	116,588	43.5%
Year		
2012	11,566	4.2%
2013	10,861	3.9%
2014	13,499	4.9%
2015	18,396	6.7%
2016	26,396	9.6%
2017	41,034	14.9%
2018	41,672	15.1%
2019	41,691	15.1%
2020	42,819	15.6%
2021	15,394	5.6%
2022	11,505	4.2%
2023	392	0.1%

Table 1g. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Intrauterine Device (IUD) Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	274,650	99.8%
Still birth	1,059	0.4%
Live Birth Singleton	270,678	98.3%
Live Birth Multiple	6,756	2.5%
Still Birth Singleton	929	0.3%
Still Birth Multiple	113	0.0%
Live and Still Birth Multiple	537	0.2%
C-section	67,440	24.5%
Vaginal Delivery	160,268	58.2%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	33,877	12.3%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	25,792	9.4%
Oral CHC	21,707	7.9%
Patch CHC	1,906	0.7%
Ring CHC	3,026	1.1%
Any POC	275,225	100.0%
Non-oral POCs	275,225	100.0%
Oral POC	22,909	8.3%
No use of CHC	249,433	90.6%
No use of POC	0	0.0%
Any CHC - 2 instances	13,852	5.0%
Oral CHC - 2 instances	11,307	4.1%
Patch CHC - 2 instances	1,000	0.4%
Ring CHC - 2 instances	1,521	0.6%
Any POC - 2 instances	35,458	12.9%
Non-oral POCs - 2 instances	14,024	5.1%
Oral POC - 2 instances	10,613	3.9%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1h. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Depot-medroxyprogesterone Acetate (DMPA) Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	104,932	
Episodes	106,990	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	27.1	5.7
Age	**Number**	**Percent[2]**
18-24 years	44,960	42.0%
25-34 years	50,622	47.3%
35-45 years	11,373	10.6%
≥ 46 years	35	0.0%
Sex		
Female	104,932	100.0%
Race[3]		
American Indian or Alaska Native	1,742	1.7%
Asian	1,432	1.4%
Black or African American	32,638	31.1%
Multi-racial	888	0.8%
Native Hawaiian or Other Pacific Islander	393	0.4%
Unknown	36,904	35.2%
White	30,935	29.5%
Hispanic origin		
Yes	13,914	13.3%
No	66,115	63.0%
Unknown	24,903	23.7%
Year		
2012	4,053	3.8%
2013	3,074	2.9%
2014	3,529	3.3%
2015	6,183	5.8%
2016	8,655	8.1%
2017	17,300	16.2%
2018	20,550	19.2%
2019	19,594	18.3%
2020	19,921	18.6%
2021	2,392	2.2%
2022	1,683	1.6%
2023	56	0.1%

Table 1h. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for a Depot-medroxyprogesterone Acetate (DMPA) Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	106,404	99.5%
Still birth	804	0.8%
Live Birth Singleton	104,943	98.1%
Live Birth Multiple	2,729	2.6%
Still Birth Singleton	728	0.7%
Still Birth Multiple	92	0.1%
Live and Still Birth Multiple	169	0.2%
C-section	24,735	23.1%
Vaginal Delivery	49,958	46.7%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	2,504	2.3%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	16,225	15.2%
Oral CHC	13,923	13.0%
Patch CHC	1,787	1.7%
Ring CHC	1,093	1.0%
Any POC	106,767	99.8%
Non-oral POCs	106,758	99.8%
Oral POC	6,615	6.2%
No use of CHC	90,765	84.8%
No use of POC	223	0.2%
Any CHC - 2 instances	9,384	8.8%
Oral CHC - 2 instances	7,830	7.3%
Patch CHC - 2 instances	1,011	0.9%
Ring CHC - 2 instances	562	0.5%
Any POC - 2 instances	65,817	61.5%
Non-oral POCs - 2 instances	62,661	58.6%
Oral POC - 2 instances	2,850	2.7%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1i. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Oral Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	383,042	
Episodes	399,571	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	29.9	5.1
Age	**Number**	**Percent[2]**
18-24 years	82,862	20.7%
25-34 years	246,184	61.6%
35-45 years	70,273	17.6%
≥ 46 years	252	0.1%
Sex		
Female	383,042	100.0%
Race[3]		
American Indian or Alaska Native	3,284	0.9%
Asian	10,449	2.7%
Black or African American	42,323	11.0%
Multi-racial	4,388	1.1%
Native Hawaiian or Other Pacific Islander	1,460	0.4%
Unknown	189,616	49.5%
White	131,522	34.3%
Hispanic origin		
Yes	47,777	12.5%
No	172,768	45.1%
Unknown	162,497	42.4%
Year		
2012	18,373	4.6%
2013	18,169	4.5%
2014	21,036	5.3%
2015	25,447	6.4%
2016	34,509	8.6%
2017	58,497	14.6%
2018	62,426	15.6%
2019	61,402	15.4%
2020	65,204	16.3%
2021	19,271	4.8%
2022	14,768	3.7%
2023	469	0.1%

Table 1i. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Oral Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	398,659	99.8%
Still birth	1,616	0.4%
Live Birth Singleton	394,058	98.6%
Live Birth Multiple	8,472	2.1%
Still Birth Singleton	1,411	0.4%
Still Birth Multiple	196	0.0%
Live and Still Birth Multiple	705	0.2%
C-section	105,890	26.5%
Vaginal Delivery	219,581	55.0%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	8,720	2.2%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	96,787	24.2%
Oral CHC	86,084	21.5%
Patch CHC	4,970	1.2%
Ring CHC	8,075	2.0%
Any POC	399,571	100.0%
Non-oral POCs	37,244	9.3%
Oral POC	399,571	100.0%
No use of CHC	302,784	75.8%
No use of POC	0	0.0%
Any CHC - 2 instances	66,673	16.7%
Oral CHC - 2 instances	59,009	14.8%
Patch CHC - 2 instances	2,987	0.7%
Ring CHC - 2 instances	5,007	1.3%
Any POC - 2 instances	253,586	63.5%
Non-oral POCs - 2 instances	4,380	1.1%
Oral POC - 2 instances	233,294	58.4%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1j. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Implant Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	111,616	
Episodes	113,007	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	26.1	5.1
Age	**Number**	**Percent[2]**
18-24 years	53,455	47.3%
25-34 years	52,486	46.4%
35-45 years	7,024	6.2%
≥ 46 years	42	0.0%
Sex		
Female	111,616	100.0%
Race[3]		
American Indian or Alaska Native	2,211	2.0%
Asian	3,091	2.8%
Black or African American	19,357	17.3%
Multi-racial	1,161	1.0%
Native Hawaiian or Other Pacific Islander	1,306	1.2%
Unknown	50,284	45.1%
White	34,206	30.6%
Hispanic origin		
Yes	29,147	26.1%
No	60,142	53.9%
Unknown	22,327	20.0%
Year		
2012	1,279	1.1%
2013	1,760	1.6%
2014	2,657	2.4%
2015	6,220	5.5%
2016	9,704	8.6%
2017	19,807	17.5%
2018	21,841	19.3%
2019	22,379	19.8%
2020	23,070	20.4%
2021	2,436	2.2%
2022	1,792	1.6%
2023	62	0.1%

Table 1j. Aggregated Characteristics of Patients/Episodes with a Live-birth or Stillbirth Delivery and a First Dispensing for an Implant Progestin-only Contraceptive (POC) in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Health Characteristics [0,0]		
Live birth	112,547	99.6%
Still birth	643	0.6%
Live Birth Singleton	111,134	98.3%
Live Birth Multiple	2,531	2.2%
Still Birth Singleton	577	0.5%
Still Birth Multiple	73	0.1%
Live and Still Birth Multiple	119	0.1%
C-section	25,602	22.7%
Vaginal Delivery	53,766	47.6%
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	19,602	17.3%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	14,727	13.0%
Oral CHC	12,574	11.1%
Patch CHC	1,575	1.4%
Ring CHC	1,098	1.0%
Any POC	113,007	100.0%
Non-oral POCs	113,007	100.0%
Oral POC	8,373	7.4%
No use of CHC	98,280	87.0%
No use of POC	0	0.0%
Any CHC - 2 instances	7,209	6.4%
Oral CHC - 2 instances	5,882	5.2%
Patch CHC - 2 instances	764	0.7%
Ring CHC - 2 instances	522	0.5%
Any POC - 2 instances	13,580	12.0%
Non-oral POCs - 2 instances	5,850	5.2%
Oral POC - 2 instances	3,177	2.8%

[1]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1k. Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Combined Hormonal Contraceptive (CHC) in the First 6 Weeks After Live or Stillbirth Delivery[1] and a Subsequent Dispensing or Administration for Any Contraceptive (CHC or Progestin-only Contraceptives [POC]) Within a Year of Post-partum in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	73,901	
Episodes	74,676	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	28.1	5.2
Age	**Number**	**Percent**
18-24 years	24,154	32.3%
25-34 years	41,658	55.8%
35-45 years	8,849	11.8%
≥ 46 years	15	0.0%
Sex		
Female	73,901	100.0%
Race[4]		
American Indian or Alaska Native	510	0.7%
Asian	1,527	2.1%
Black or African American	8,901	12.0%
Multi-racial	574	0.8%
Native Hawaiian or Other Pacific Islander	259	0.4%
Unknown	31,505	42.6%
White	30,625	41.4%
Hispanic origin		
Yes	9,396	12.7%
No	39,990	54.1%
Unknown	24,515	33.2%
Year		
2012	3,002	4.0%
2013	2,870	3.8%
2014	3,374	4.5%
2015	4,179	5.6%
2016	6,838	9.2%
2017	11,877	15.9%
2018	13,046	17.5%
2019	12,199	16.3%
2020	12,931	17.3%
2021	2,601	3.5%
2022	1,704	2.3%
2023	55	0.1%

Table 1k. Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Combined Hormonal Contraceptive (CHC) in the First 6 Weeks After Live or Stillbirth Delivery[1] and a Subsequent Dispensing or Administration for Any Contraceptive (CHC or Progestin-only Contraceptives [POC]) Within a Year of Post-partum in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	1,198	1.6%
drospirenone (0,0)	*****	*****
Any Combined Hormonal Contraceptives (CHC)	70,201	94.0%
Oral CHC	60,227	80.7%
Patch CHC	6,445	8.6%
Ring CHC	5,986	8.0%
Any POC	11,692	15.7%
Non-oral POCs	8,208	11.0%
Oral POC	3,895	5.2%
No use of CHC	4,475	6.0%
No use of POC	62,984	84.3%
Any CHC - 2 instances	58,410	78.2%
Oral CHC - 2 instances	49,696	66.5%
Patch CHC - 2 instances	4,888	6.5%
Ring CHC - 2 instances	4,597	6.2%
Any POC - 2 instances	3,610	4.8%
Non-oral POCs - 2 instances	1,451	1.9%
Oral POC - 2 instances	1,995	2.7%

[1]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC

[2]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1l. Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Progestin-only Contraceptive (POC) in the First 6 Weeks After Live or Stillbirth Delivery[1] and a Subsequent Dispensing or Administration for Any Contraceptive (Combined Hormonal Contraceptive [CHC] or POC) Within a Year of Post-partum in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	192,764	
Episodes	197,517	
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	29.2	5.2
Age	**Number**	**Percent**
18-24 years	49,656	25.1%
25-34 years	118,324	59.9%
35-45 years	29,442	14.9%
≥ 46 years	95	0.0%
Sex		
Female	192,764	100.0%
Race[4]		
American Indian or Alaska Native	1,450	0.8%
Asian	4,037	2.1%
Black or African American	24,059	12.5%
Multi-racial	1,930	1.0%
Native Hawaiian or Other Pacific Islander	768	0.4%
Unknown	90,827	47.1%
White	69,693	36.2%
Hispanic origin		
Yes	23,145	12.0%
No	92,894	48.2%
Unknown	76,725	39.8%
Year		
2012	8,484	4.3%
2013	8,336	4.2%
2014	9,761	4.9%
2015	12,396	6.3%
2016	17,657	8.9%
2017	29,743	15.1%
2018	32,177	16.3%
2019	31,469	15.9%
2020	32,930	16.7%
2021	8,191	4.1%
2022	6,174	3.1%
2023	199	0.1%

Table 1l. Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Progestin-only Contraceptive (POC) in the First 6 Weeks After Live or Stillbirth Delivery[1] and a Subsequent Dispensing or Administration for Any Contraceptive (Combined Hormonal Contraceptive [CHC] or POC) Within a Year of Post-partum in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	9,092	4.6%
drospirenone (0,0)	920	0.5%
Any Combined Hormonal Contraceptives (CHC)	77,288	39.1%
Oral CHC	68,840	34.9%
Patch CHC	4,312	2.2%
Ring CHC	6,152	3.1%
Any POC	169,604	85.9%
Non-oral POCs	47,762	24.2%
Oral POC	131,747	66.7%
No use of CHC	120,229	60.9%
No use of POC	27,913	14.1%
Any CHC - 2 instances	56,167	28.4%
Oral CHC - 2 instances	49,588	25.1%
Patch CHC - 2 instances	2,832	1.4%
Ring CHC - 2 instances	4,117	2.1%
Any POC - 2 instances	121,836	61.7%
Non-oral POCs - 2 instances	19,637	9.9%
Oral POC - 2 instances	99,178	50.2%

[1]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of POC

[2]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Table 1m. Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Depot-medroxyprogesterone Acetate (DMPA) Progestin-only Contraceptives (POC) in the First 6 Weeks After Live or Stillbirth Delivery[1] and a Subsequent Dispensing or Administration for Any Contraceptive (Combined Hormonal Contraceptives [CHC] or POC) Within a Year of Post-partum in the Sentinel Distributed Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Unique patients	28,672	N/A
Episodes	28,860	100.0%
Demographic Characteristics	**Mean**	**Standard Deviation**
Age (years)	27.0	5.6
Age	**Number**	**Percent**
18-24 years	12,249	42.4%
25-34 years	13,724	47.6%
35-45 years	*****	*****
≥ 46 years	*****	*****
Sex		
Female	28,672	100.0%
Race[4]		
American Indian or Alaska Native	303	1.1%
Asian	373	1.3%
Black or African American	7,975	27.8%
Multi-racial	210	0.7%
Native Hawaiian or Other Pacific Islander	110	0.4%
Unknown	10,445	36.4%
White	9,256	32.3%
Hispanic origin		
Yes	3,884	13.5%
No	17,637	61.5%
Unknown	7,151	24.9%
Year		
2012	1,035	3.6%
2013	811	2.8%
2014	963	3.3%
2015	1,625	5.6%
2016	2,377	8.2%
2017	4,582	15.9%
2018	5,446	18.9%
2019	5,372	18.6%
2020	5,440	18.8%
2021	701	2.4%
2022	491	1.7%
2023	17	0.1%

Table 1m. Aggregated Characteristics of Patients/Episodes Receiving Dispensing or Administration for a Depot-medroxyprogesterone Acetate (DMPA) Progestin-only Contraceptives (POC) in the First 6 Weeks After Live or Stillbirth Delivery[1] and a Subsequent Dispensing or Administration for Any Contraceptive (Combined Hormonal Contraceptives [CHC] or POC) Within a Year of Post-partum in the Sentinel Distributed Database from January 1, 2012 to January 31, 2024

Patient Characteristics[1]	Number	Percent[2]
Medical Product Use in the Year After Index [1, 365]		
Progestin-Only Contraceptives (POC) removal	400	1.4%
drospirenone (0,0)	0	0.0%
Any Combined Hormonal Contraceptives (CHC)	6,141	21.3%
Oral CHC	5,191	18.0%
Patch CHC	667	2.3%
Ring CHC	477	1.7%
Any POC	26,224	90.9%
Non-oral POCs	25,572	88.6%
Oral POC	1,290	4.5%
No use of CHC	22,719	78.7%
No use of POC	2,636	9.1%
Any CHC - 2 instances	3,991	13.8%
Oral CHC - 2 instances	3,273	11.3%
Patch CHC - 2 instances	426	1.5%
Ring CHC - 2 instances	306	1.1%
Any POC - 2 instances	18,216	63.1%
Non-oral POCs - 2 instances	17,556	60.8%
Oral POC - 2 instances	644	2.2%

[1]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of DMPA

[2]All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients.

[3]Value represents standard deviation where no % follows the value.

[4]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2. Summary of Time to End of At-risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024[1]

		Occurrence of Outcome of Interest[2]		Occurrence of User-Defined Censoring Criteria[3]	
	Total Number of Episodes	Number of Episodes with Contraceptive Use of Interest	Percent of Episodes with Contraceptive Use of Interest of Total Episodes	Number of Episodes Censored Due to Contraceptive Use Other Than Index	Percent of Episodes Censored Due to Contraceptive Use Other Than Index of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)					
First dispensing for any Combined Hormonal Contraceptives	458,204	344,929	75.3%	117,235	25.6%
First dispensing for an oral CHC	393,798	289,089	73.4%	108,059	27.4%
First dispensing for a patch CHC	35,512	26,373	74.3%	9,505	26.8%
First dispensing for a CHC ring	41,728	29,520	70.7%	12,558	30.1%
First dispensing for any Progestin-Only Contraceptives (POC)	848,066	819,703	96.7%	32,330	3.8%
First dispensing for an Intrauterine Device (IUD) POC	275,225	242,051	87.9%	33,808	12.3%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	106,990	96,185	89.9%	11,343	10.6%
First dispensing for an oral POC	399,571	384,270	96.2%	19,773	4.9%
First dispensing for an implant POC	113,007	98,287	87.0%	15,140	13.4%
Patients initiating on any CHC, any POC, and DMPA POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[4]					
Any CHC	74,676	74,676	100.0%	0	0.0%
Any POC	197,517	197,517	100.0%	0	0.0%
DMPA POC	28,860	28,860	100.0%	0	0.0%

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing

[2]Outcome of interest included first initiaiton of CHC or PC contraceptive among patients with livebirth or stillbirth delivery. For those receving at least 1 dispensing of any CHC, any POC, or DMPA POC, outcome was second dispensing for any contraceptive.

[3]User defined censoring criteria included patients censored due to observance of contraceptive other than the index contraceptive. For example, among cohort idetifying patients with CHC patch, if an oral CHC is observed prior to the index CHC patch then the patient is censored.

[4]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
			0-7 days		8-14 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)						
First dispensing for any CHC	458,204	344,929	5,797	1.7%	3,162	0.9%
First dispensing for an oral CHC	393,798	289,089	4,883	1.7%	2,762	1.0%
First dispensing for a patch CHC	35,512	26,373	520	2.0%	233	0.9%
First dispensing for a CHC ring	41,728	29,520	397	1.3%	167	0.6%
First dispensing for any POC	848,066	819,703	50,773	6.2%	11,471	1.4%
First dispensing for an Intrauterine Device (IUD) POC	275,225	242,051	1,600	0.7%	781	0.3%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	106,990	96,185	3,620	3.8%	2,479	2.6%
First dispensing for an oral POC	399,571	384,270	40,107	10.4%	7,268	1.9%
First dispensing for an implant POC	113,007	98,287	5,443	5.5%	949	1.0%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	15-21 days		22-28 days		29-35 days		36-42 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	5,539	1.6%	8,324	2.4%	17,629	5.1%	47,978	13.9%
First dispensing for an oral CHC	4,754	1.6%	7,007	2.4%	14,764	5.1%	40,694	14.1%
First dispensing for a patch CHC	442	1.7%	737	2.8%	1,595	6.0%	3,456	13.1%
First dispensing for a CHC ring	345	1.2%	581	2.0%	1,269	4.3%	3,836	13.0%
First dispensing for any POC	16,938	2.1%	21,247	2.6%	40,859	5.0%	119,377	14.6%
First dispensing for an Intrauterine Device (IUD) POC	1,519	0.6%	2,339	1.0%	5,353	2.2%	22,992	9.5%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	3,143	3.3%	3,716	3.9%	6,119	6.4%	13,074	13.6%
First dispensing for an oral POC	10,607	2.8%	12,680	3.3%	24,665	6.4%	73,514	19.1%
First dispensing for an implant POC	1,702	1.7%	2,541	2.6%	4,795	4.9%	9,951	10.1%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	36-42 days		43-49 days		50-56 days		57-63 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	47,978	13.9%	65,295	18.9%	25,651	7.4%	15,805	4.6%
First dispensing for an oral CHC	40,694	14.1%	54,959	19.0%	21,492	7.4%	13,126	4.5%
First dispensing for a patch CHC	3,456	13.1%	4,932	18.7%	1,984	7.5%	1,301	4.9%
First dispensing for a CHC ring	3,836	13.0%	5,415	18.3%	2,179	7.4%	1,379	4.7%
First dispensing for any POC	119,377	14.6%	169,541	20.7%	80,124	9.8%	57,006	7.0%
First dispensing for an Intrauterine Device (IUD) POC	22,992	9.5%	42,129	17.4%	31,974	13.2%	28,326	11.7%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	13,074	13.6%	15,679	16.3%	6,342	6.6%	4,060	4.2%
First dispensing for an oral POC	73,514	19.1%	96,244	25.0%	31,623	8.2%	16,697	4.3%
First dispensing for an implant POC	9,951	10.1%	15,708	16.0%	10,309	10.5%	8,000	8.1%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	64-70 days		71-77 days		78-84 days		85-91 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	11,533	3.3%	9,074	2.6%	7,160	2.1%	6,379	1.8%
First dispensing for an oral CHC	9,497	3.3%	7,468	2.6%	5,894	2.0%	5,268	1.8%
First dispensing for a patch CHC	909	3.4%	714	2.7%	539	2.0%	487	1.8%
First dispensing for a CHC ring	1,129	3.8%	893	3.0%	730	2.5%	624	2.1%
First dispensing for any POC	38,775	4.7%	28,662	3.5%	22,443	2.7%	17,826	2.2%
First dispensing for an Intrauterine Device (IUD) POC	19,887	8.2%	14,821	6.1%	10,483	4.3%	7,696	3.2%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	2,857	3.0%	2,435	2.5%	3,571	3.7%	3,648	3.8%
First dispensing for an oral POC	10,216	2.7%	7,112	1.9%	5,194	1.4%	4,009	1.0%
First dispensing for an implant POC	5,869	6.0%	4,349	4.4%	3,246	3.3%	2,502	2.5%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	92-98 days		99-105 days		106-112 days		113-119 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	5,780	1.7%	5,169	1.5%	4,569	1.3%	4,354	1.3%
First dispensing for an oral CHC	4,804	1.7%	4,255	1.5%	3,773	1.3%	3,612	1.2%
First dispensing for a patch CHC	404	1.5%	371	1.4%	306	1.2%	333	1.3%
First dispensing for a CHC ring	574	1.9%	543	1.8%	492	1.7%	409	1.4%
First dispensing for any POC	13,885	1.7%	10,667	1.3%	8,704	1.1%	7,655	0.9%
First dispensing for an Intrauterine Device (IUD) POC	5,775	2.4%	4,499	1.9%	3,532	1.5%	2,957	1.2%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	2,698	2.8%	1,657	1.7%	1,444	1.5%	1,293	1.3%
First dispensing for an oral POC	3,397	0.9%	2,915	0.8%	2,383	0.6%	2,248	0.6%
First dispensing for an implant POC	2,041	2.1%	1,615	1.6%	1,369	1.4%	1,162	1.2%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	120-126 days		127-133 days		134-140 days		141-147 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	4,483	1.3%	4,280	1.2%	3,930	1.1%	3,669	1.1%
First dispensing for an oral CHC	3,712	1.3%	3,528	1.2%	3,230	1.1%	3,080	1.1%
First dispensing for a patch CHC	368	1.4%	349	1.3%	315	1.2%	247	0.9%
First dispensing for a CHC ring	403	1.4%	405	1.4%	385	1.3%	343	1.2%
First dispensing for any POC	7,226	0.9%	6,497	0.8%	5,749	0.7%	5,064	0.6%
First dispensing for an Intrauterine Device (IUD) POC	2,545	1.1%	2,262	0.9%	2,014	0.8%	1,758	0.7%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	1,307	1.4%	1,200	1.2%	1,008	1.0%	903	0.9%
First dispensing for an oral POC	2,247	0.6%	2,037	0.5%	1,851	0.5%	1,610	0.4%
First dispensing for an implant POC	1,130	1.1%	1,013	1.0%	884	0.9%	798	0.8%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	148-154 days		155-161 days		162-168 days		169-175 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	3,548	1.0%	3,427	1.0%	3,338	1.0%	3,277	1.0%
First dispensing for an oral CHC	2,981	1.0%	2,836	1.0%	2,799	1.0%	2,777	1.0%
First dispensing for a patch CHC	235	0.9%	264	1.0%	242	0.9%	231	0.9%
First dispensing for a CHC ring	332	1.1%	327	1.1%	297	1.0%	269	0.9%
First dispensing for any POC	4,522	0.6%	4,255	0.5%	4,160	0.5%	3,798	0.5%
First dispensing for an Intrauterine Device (IUD) POC	1,558	0.6%	1,467	0.6%	1,521	0.6%	1,325	0.5%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	755	0.8%	689	0.7%	712	0.7%	672	0.7%
First dispensing for an oral POC	1,489	0.4%	1,386	0.4%	1,298	0.3%	1,220	0.3%
First dispensing for an implant POC	731	0.7%	714	0.7%	642	0.7%	589	0.6%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	176-182 days		183-189 days		190-196 days		197-203 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	3,170	0.9%	3,033	0.9%	3,002	0.9%	2,921	0.8%
First dispensing for an oral CHC	2,650	0.9%	2,534	0.9%	2,495	0.9%	2,434	0.8%
First dispensing for a patch CHC	220	0.8%	226	0.9%	249	0.9%	220	0.8%
First dispensing for a CHC ring	301	1.0%	273	0.9%	259	0.9%	267	0.9%
First dispensing for any POC	3,503	0.4%	3,420	0.4%	3,195	0.4%	3,191	0.4%
First dispensing for an Intrauterine Device (IUD) POC	1,164	0.5%	1,220	0.5%	1,129	0.5%	1,119	0.5%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	588	0.6%	595	0.6%	533	0.6%	561	0.6%
First dispensing for an oral POC	1,180	0.3%	1,074	0.3%	1,022	0.3%	1,053	0.3%
First dispensing for an implant POC	574	0.6%	533	0.5%	513	0.5%	460	0.5%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	204-210 days		211-217 days		218-224 days		225-231 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	2,794	0.8%	2,743	0.8%	2,768	0.8%	2,714	0.8%
First dispensing for an oral CHC	2,318	0.8%	2,256	0.8%	2,313	0.8%	2,258	0.8%
First dispensing for a patch CHC	198	0.8%	218	0.8%	199	0.8%	217	0.8%
First dispensing for a CHC ring	279	0.9%	269	0.9%	257	0.9%	239	0.8%
First dispensing for any POC	3,054	0.4%	2,847	0.3%	2,724	0.3%	2,594	0.3%
First dispensing for an Intrauterine Device (IUD) POC	1,033	0.4%	975	0.4%	900	0.4%	895	0.4%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	553	0.6%	506	0.5%	462	0.5%	454	0.5%
First dispensing for an oral POC	942	0.2%	926	0.2%	892	0.2%	846	0.2%
First dispensing for an implant POC	528	0.5%	447	0.5%	465	0.5%	398	0.4%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	232-238 days		239-245 days		246-252 days		253-259 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	2,670	0.8%	2,492	0.7%	2,430	0.7%	2,338	0.7%
First dispensing for an oral CHC	2,230	0.8%	2,056	0.7%	2,043	0.7%	1,971	0.7%
First dispensing for a patch CHC	215	0.8%	196	0.7%	181	0.7%	159	0.6%
First dispensing for a CHC ring	225	0.8%	242	0.8%	206	0.7%	210	0.7%
First dispensing for any POC	2,590	0.3%	2,343	0.3%	2,247	0.3%	2,223	0.3%
First dispensing for an Intrauterine Device (IUD) POC	873	0.4%	839	0.3%	721	0.3%	774	0.3%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	471	0.5%	396	0.4%	414	0.4%	371	0.4%
First dispensing for an oral POC	847	0.2%	724	0.2%	737	0.2%	735	0.2%
First dispensing for an implant POC	404	0.4%	387	0.4%	377	0.4%	341	0.3%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	260-266 days		267-273 days		274-280 days		281-287 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	2,406	0.7%	2,377	0.7%	2,342	0.7%	2,238	0.6%
First dispensing for an oral CHC	2,004	0.7%	2,003	0.7%	1,986	0.7%	1,896	0.7%
First dispensing for a patch CHC	172	0.7%	166	0.6%	161	0.6%	154	0.6%
First dispensing for a CHC ring	231	0.8%	208	0.7%	195	0.7%	187	0.6%
First dispensing for any POC	2,044	0.2%	2,075	0.3%	2,043	0.2%	2,024	0.2%
First dispensing for an Intrauterine Device (IUD) POC	714	0.3%	661	0.3%	641	0.3%	672	0.3%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	343	0.4%	356	0.4%	356	0.4%	370	0.4%
First dispensing for an oral POC	650	0.2%	720	0.2%	679	0.2%	654	0.2%
First dispensing for an implant POC	337	0.3%	343	0.3%	366	0.4%	332	0.3%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	288-294 days		295-301 days		302-308 days		309-315 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	2,210	0.6%	2,249	0.7%	2,195	0.6%	2,136	0.6%
First dispensing for an oral CHC	1,860	0.6%	1,889	0.7%	1,836	0.6%	1,833	0.6%
First dispensing for a patch CHC	175	0.7%	168	0.6%	176	0.7%	148	0.6%
First dispensing for a CHC ring	175	0.6%	192	0.7%	183	0.6%	155	0.5%
First dispensing for any POC	1,956	0.2%	1,855	0.2%	1,887	0.2%	1,815	0.2%
First dispensing for an Intrauterine Device (IUD) POC	614	0.3%	609	0.3%	615	0.3%	604	0.2%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	359	0.4%	361	0.4%	335	0.3%	311	0.3%
First dispensing for an oral POC	667	0.2%	589	0.2%	648	0.2%	607	0.2%
First dispensing for an implant POC	317	0.3%	301	0.3%	292	0.3%	299	0.3%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	316-322 days		323-329 days		330-336 days		337-343 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	2,098	0.6%	2,121	0.6%	2,012	0.6%	1,956	0.6%
First dispensing for an oral CHC	1,775	0.6%	1,793	0.6%	1,697	0.6%	1,637	0.6%
First dispensing for a patch CHC	143	0.5%	147	0.6%	134	0.5%	146	0.6%
First dispensing for a CHC ring	180	0.6%	183	0.6%	181	0.6%	173	0.6%
First dispensing for any POC	1,816	0.2%	1,841	0.2%	1,815	0.2%	1,735	0.2%
First dispensing for an Intrauterine Device (IUD) POC	619	0.3%	589	0.2%	568	0.2%	584	0.2%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	349	0.4%	333	0.3%	343	0.4%	329	0.3%
First dispensing for an oral POC	576	0.1%	587	0.2%	588	0.2%	520	0.1%
First dispensing for an implant POC	271	0.3%	330	0.3%	323	0.3%	304	0.3%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3a. Categorical Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	344-350 days		351-357 days		358-365 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)						
First dispensing for any CHC	2,010	0.6%	2,072	0.6%	2,282	0.7%
First dispensing for an oral CHC	1,707	0.6%	1,748	0.6%	1,912	0.7%
First dispensing for a patch CHC	139	0.5%	159	0.6%	173	0.7%
First dispensing for a CHC ring	164	0.6%	165	0.6%	198	0.7%
First dispensing for any POC	1,801	0.2%	1,801	0.2%	2,040	0.2%
First dispensing for an Intrauterine Device (IUD) POC	598	0.2%	543	0.2%	665	0.3%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	339	0.4%	338	0.4%	378	0.4%
First dispensing for an oral POC	552	0.1%	615	0.2%	623	0.2%
First dispensing for an implant POC	312	0.3%	306	0.3%	375	0.4%

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 3b. Continous Summary of Time to Initiation of Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)									
First dispensing for any CHC	458,204	344,929	1	42	54	135	365	99.8	89.0
First dispensing for an oral CHC	393,798	289,089	1	42	54	135	365	99.7	89.2
First dispensing for a patch CHC	35,512	26,373	1	42	54	129	365	97.6	87.9
First dispensing for a CHC ring	41,728	29,520	1	43	59	140	365	103.0	88.1
First dispensing for any POC	848,066	819,703	1	41	48	72	365	69.5	64.0
First dispensing for an Intrauterine Device (IUD) POC	275,225	242,051	1	47	59	84	365	81.2	62.8
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	106,990	96,185	1	40	50	94	365	81.5	75.4
First dispensing for an oral POC	399,571	384,270	1	36	43	54	365	56.5	56.6
First dispensing for an implant POC	113,007	98,287	1	42	55	87	365	79.9	71.7

[1]Represents episodes censored due to occurrence of request-defined event (initiation of a CHC or POC contraceptive type).

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length					
			0-7 days		8-14 days		15-21 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	74,676	74,676	869	1.2%	920	1.2%	2,468	3.3%
Any POC	197,517	197,517	2,210	1.1%	2,726	1.4%	3,224	1.6%
DMPA POC	28,860	28,860	378	1.3%	204	0.7%	194	0.7%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	22-28 days		29-35 days		36-42 days		43-49 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	23,890	32.0%	11,283	15.1%	4,454	6.0%	2,691	3.6%
Any POC	49,633	25.1%	25,168	12.7%	11,984	6.1%	7,300	3.7%
DMPA POC	239	0.8%	256	0.9%	234	0.8%	209	0.7%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	50-56 days		57-63 days		64-70 days		71-77 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	2,354	3.2%	1,657	2.2%	1,122	1.5%	895	1.2%
Any POC	5,932	3.0%	4,059	2.1%	3,071	1.6%	3,028	1.5%
DMPA POC	214	0.7%	202	0.7%	250	0.9%	810	2.8%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

******Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	78-84 days		85-91 days		92-98 days		99-105 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	8,914	11.9%	3,707	5.0%	1,603	2.1%	998	1.3%
Any POC	23,786	12.0%	16,917	8.6%	6,272	3.2%	3,633	1.8%
DMPA POC	5,025	17.4%	9,837	34.1%	3,004	10.4%	1,381	4.8%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	106-112 days		113-119 days		120-126 days		127-133 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	853	1.1%	635	0.9%	483	0.6%	392	0.5%
Any POC	2,955	1.5%	2,180	1.1%	1,897	1.0%	1,517	0.8%
DMPA POC	952	3.3%	695	2.4%	554	1.9%	418	1.4%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	134-140 days		141-147 days		148-154 days		155-161 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	348	0.5%	316	0.4%	274	0.4%	241	0.3%
Any POC	1,319	0.7%	1,193	0.6%	1,087	0.6%	1,008	0.5%
DMPA POC	346	1.2%	277	1.0%	246	0.9%	252	0.9%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

******Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	162-168 days		169-175 days		176-182 days		183-189 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	291	0.4%	240	0.3%	236	0.3%	181	0.2%
Any POC	1,285	0.7%	1,009	0.5%	968	0.5%	814	0.4%
DMPA POC	311	1.1%	244	0.8%	245	0.8%	157	0.5%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	190-196 days		197-203 days		204-210 days		211-217 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	173	0.2%	171	0.2%	157	0.2%	134	0.2%
Any POC	741	0.4%	765	0.4%	699	0.4%	655	0.3%
DMPA POC	126	0.4%	134	0.5%	114	0.4%	108	0.4%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	218-224 days		225-231 days		232-238 days		239-245 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	111	0.1%	148	0.2%	146	0.2%	114	0.2%
Any POC	627	0.3%	616	0.3%	586	0.3%	513	0.3%
DMPA POC	108	0.4%	99	0.3%	83	0.3%	73	0.3%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	246-252 days		253-259 days		260-266 days		267-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	117	0.2%	116	0.2%	101	0.1%	98	0.1%
Any POC	531	0.3%	594	0.3%	529	0.3%	494	0.3%
DMPA POC	98	0.3%	89	0.3%	85	0.3%	60	0.2%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	274-280 days		281-287 days		288-294 days		295-301 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	161	0.2%	101	0.1%	88	0.1%	92	0.1%
Any POC	540	0.3%	439	0.2%	500	0.3%	460	0.2%
DMPA POC	77	0.3%	62	0.2%	74	0.3%	53	0.2%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	302-308 days		309-315 days		316-322 days		323-329 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]								
Any CHC	70	0.1%	70	0.1%	78	0.1%	49	0.1%
Any POC	434	0.2%	408	0.2%	393	0.2%	278	0.1%
DMPA POC	62	0.2%	47	0.2%	56	0.2%	40	0.1%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length					
	330-336 days		337-343 days		344-350 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]						
Any CHC	32	0.0%	12	0.0%	11	0.0%
Any POC	179	0.1%	118	0.1%	108	0.1%
DMPA POC	26	0.1%	20	0.1%	14	0.0%

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4a. Categorical Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	351-357 days		358-365 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year of post-partum[2]				
Any CHC	*****	*****	*****	*****
Any POC	84	0.0%	51	0.0%
DMPA POC	*****	*****	*****	*****

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4b. Continuous Summary of Time to Second Dispensing of Any Contraceptive Within One Year of Post-partum Among Patients Who Received Their First Dispensing or Administration of a Combined Hormonal Contraceptive (CHC), a Progestin Only Contraceptive (POC), or a Depot-medroxyprogesterone Acetate (DMPA) POC Within the First 6 Weeks After Live or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Patients initiating on any Combined Hormonal Contraceptive (CHC), any Progestin Only Contraceptive (POC), and Depot-medroxyprogesterone Acetate (DMPA) POC and a subsequent dispensing for any contraceptive (CHC or POC) within a year ofpost-partum[2]									
Any CHC	74,676	74,676	1	28	34	84	358	57.3	48.7
Any POC	197,517	197,517	1	28	46	88	364	69.9	59.3
DMPA POC	28,860	28,860	1	84	90	101	363	101.8	48.0

[1]Represents episodes censored due to occurrence of request-defined event (dispensing for any contraceptive).

[2]Livebirth or stillbirth delivery was required to be observed in 6 weeks prior to first dispensing or administration of CHC or POC.

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

		Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length				
			0-7 days		8-14 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)						
First dispensing for any CHC	458,204	117,235	11,131	9.5%	2,698	2.3%
First dispensing for an oral CHC	393,798	108,059	9,755	9.0%	2,432	2.3%
First dispensing for a partch CHC	35,512	9,505	1,100	11.6%	249	2.6%
First dispensing for a CHC ring	41,728	12,558	876	7.0%	230	1.8%
First dispensing for any POC	848,066	32,330	918	2.8%	444	1.4%
First dispensing for an Intrauterine Device (IUD) POC	275,225	33,808	2,385	7.1%	719	2.1%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	106,990	11,343	1,265	11.2%	291	2.6%
First dispensing for an oral POC	399,571	19,773	825	4.2%	267	1.4%
First dispensing for an implant POC	113,007	15,140	1,677	11.1%	358	2.4%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	15-21 days		22-28 days		29-35 days		36-42 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	3,905	3.3%	4,541	3.9%	8,100	6.9%	21,892	18.7%
First dispensing for an oral CHC	3,565	3.3%	4,190	3.9%	7,527	7.0%	20,446	18.9%
First dispensing for a partch CHC	350	3.7%	400	4.2%	656	6.9%	1,351	14.2%
First dispensing for a CHC ring	373	3.0%	457	3.6%	833	6.6%	2,175	17.3%
First dispensing for any POC	811	2.5%	1,119	3.5%	2,157	6.7%	4,969	15.4%
First dispensing for an Intrauterine Device (IUD) POC	1,075	3.2%	1,333	3.9%	2,519	7.5%	6,562	19.4%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	470	4.1%	487	4.3%	803	7.1%	1,640	14.5%
First dispensing for an oral POC	390	2.0%	599	3.0%	1,142	5.8%	2,535	12.8%
First dispensing for an implant POC	540	3.6%	627	4.1%	1,079	7.1%	2,301	15.2%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	43-49 days		50-56 days		57-63 days		64-70 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	28,119	24.0%	9,814	8.4%	5,712	4.9%	3,705	3.2%
First dispensing for an oral CHC	26,273	24.3%	8,954	8.3%	5,156	4.8%	3,398	3.1%
First dispensing for a partch CHC	1,735	18.3%	721	7.6%	474	5.0%	362	3.8%
First dispensing for a CHC ring	2,794	22.2%	1,172	9.3%	722	5.7%	448	3.6%
First dispensing for any POC	6,451	20.0%	2,548	7.9%	1,569	4.9%	1,214	3.8%
First dispensing for an Intrauterine Device (IUD) POC	8,168	24.2%	2,852	8.4%	1,560	4.6%	1,019	3.0%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	1,958	17.3%	891	7.9%	598	5.3%	429	3.8%
First dispensing for an oral POC	3,559	18.0%	1,685	8.5%	1,262	6.4%	885	4.5%
First dispensing for an implant POC	2,931	19.4%	1,245	8.2%	791	5.2%	554	3.7%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

******Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	71-77 days		78-84 days		85-91 days		92-98 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	2,678	2.3%	2,105	1.8%	1,630	1.4%	1,243	1.1%
First dispensing for an oral CHC	2,425	2.2%	1,889	1.7%	1,491	1.4%	1,130	1.0%
First dispensing for a partch CHC	255	2.7%	216	2.3%	175	1.8%	145	1.5%
First dispensing for a CHC ring	323	2.6%	262	2.1%	225	1.8%	178	1.4%
First dispensing for any POC	939	2.9%	732	2.3%	670	2.1%	564	1.7%
First dispensing for an Intrauterine Device (IUD) POC	755	2.2%	564	1.7%	529	1.6%	411	1.2%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	329	2.9%	238	2.1%	211	1.9%	181	1.6%
First dispensing for an oral POC	703	3.6%	569	2.9%	444	2.2%	369	1.9%
First dispensing for an implant POC	386	2.5%	352	2.3%	280	1.8%	227	1.5%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	99-105 days		106-112 days		113-119 days		120-126 days	
	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total	Number of Episodes	Percent of Total
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	975	0.8%	770	0.7%	760	0.6%	700	0.6%
First dispensing for an oral CHC	911	0.8%	703	0.7%	722	0.7%	648	0.6%
First dispensing for a partch CHC	112	1.2%	107	1.1%	107	1.1%	91	1.0%
First dispensing for a CHC ring	142	1.1%	118	0.9%	107	0.9%	103	0.8%
First dispensing for any POC	509	1.6%	450	1.4%	424	1.3%	400	1.2%
First dispensing for an Intrauterine Device (IUD) POC	350	1.0%	284	0.8%	238	0.7%	226	0.7%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	122	1.1%	138	1.2%	124	1.1%	98	0.9%
First dispensing for an oral POC	312	1.6%	287	1.5%	239	1.2%	225	1.1%
First dispensing for an implant POC	154	1.0%	159	1.1%	131	0.9%	127	0.8%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	127-133 days		134-140 days		141-147 days		148-154 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	620	0.5%	524	0.4%	476	0.4%	429	0.4%
First dispensing for an oral CHC	587	0.5%	492	0.5%	441	0.4%	403	0.4%
First dispensing for a partch CHC	96	1.0%	62	0.7%	63	0.7%	55	0.6%
First dispensing for a CHC ring	93	0.7%	77	0.6%	68	0.5%	64	0.5%
First dispensing for any POC	352	1.1%	362	1.1%	313	1.0%	297	0.9%
First dispensing for an Intrauterine Device (IUD) POC	202	0.6%	185	0.5%	144	0.4%	145	0.4%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	80	0.7%	78	0.7%	78	0.7%	62	0.5%
First dispensing for an oral POC	209	1.1%	208	1.1%	172	0.9%	171	0.9%
First dispensing for an implant POC	108	0.7%	105	0.7%	90	0.6%	71	0.5%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	155-161 days		162-168 days		169-175 days		176-182 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	396	0.3%	356	0.3%	325	0.3%	315	0.3%
First dispensing for an oral CHC	381	0.4%	347	0.3%	323	0.3%	300	0.3%
First dispensing for a partch CHC	56	0.6%	40	0.4%	47	0.5%	34	0.4%
First dispensing for a CHC ring	67	0.5%	50	0.4%	42	0.3%	53	0.4%
First dispensing for any POC	300	0.9%	255	0.8%	256	0.8%	256	0.8%
First dispensing for an Intrauterine Device (IUD) POC	137	0.4%	119	0.4%	131	0.4%	111	0.3%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	58	0.5%	66	0.6%	54	0.5%	60	0.5%
First dispensing for an oral POC	182	0.9%	159	0.8%	152	0.8%	159	0.8%
First dispensing for an implant POC	76	0.5%	76	0.5%	57	0.4%	65	0.4%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	183-189 days		190-196 days		197-203 days		204-210 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	260	0.2%	258	0.2%	255	0.2%	219	0.2%
First dispensing for an oral CHC	245	0.2%	242	0.2%	250	0.2%	215	0.2%
First dispensing for a partch CHC	37	0.4%	39	0.4%	32	0.3%	37	0.4%
First dispensing for a CHC ring	35	0.3%	54	0.4%	37	0.3%	38	0.3%
First dispensing for any POC	209	0.6%	214	0.7%	200	0.6%	157	0.5%
First dispensing for an Intrauterine Device (IUD) POC	93	0.3%	96	0.3%	83	0.2%	73	0.2%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	38	0.3%	39	0.3%	44	0.4%	29	0.3%
First dispensing for an oral POC	125	0.6%	127	0.6%	124	0.6%	100	0.5%
First dispensing for an implant POC	57	0.4%	48	0.3%	50	0.3%	32	0.2%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	211-217 days		218-224 days		225-231 days		232-238 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	208	0.2%	190	0.2%	162	0.1%	173	0.1%
First dispensing for an oral CHC	209	0.2%	177	0.2%	150	0.1%	171	0.2%
First dispensing for a partch CHC	27	0.3%	25	0.3%	28	0.3%	24	0.3%
First dispensing for a CHC ring	31	0.2%	34	0.3%	37	0.3%	24	0.2%
First dispensing for any POC	181	0.6%	159	0.5%	159	0.5%	155	0.5%
First dispensing for an Intrauterine Device (IUD) POC	68	0.2%	62	0.2%	61	0.2%	59	0.2%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	33	0.3%	22	0.2%	28	0.2%	35	0.3%
First dispensing for an oral POC	117	0.6%	106	0.5%	104	0.5%	101	0.5%
First dispensing for an implant POC	44	0.3%	32	0.2%	41	0.3%	31	0.2%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	239-245 days		246-252 days		253-259 days		260-266 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	148	0.1%	150	0.1%	147	0.1%	116	0.1%
First dispensing for an oral CHC	148	0.1%	143	0.1%	144	0.1%	111	0.1%
First dispensing for a partch CHC	17	0.2%	25	0.3%	16	0.2%	11	0.1%
First dispensing for a CHC ring	25	0.2%	25	0.2%	22	0.2%	23	0.2%
First dispensing for any POC	144	0.4%	132	0.4%	127	0.4%	126	0.4%
First dispensing for an Intrauterine Device (IUD) POC	53	0.2%	57	0.2%	51	0.2%	31	0.1%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	32	0.3%	22	0.2%	20	0.2%	18	0.2%
First dispensing for an oral POC	84	0.4%	84	0.4%	83	0.4%	85	0.4%
First dispensing for an implant POC	29	0.2%	20	0.1%	16	0.1%	23	0.2%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	267-273 days		274-280 days		281-287 days		288-294 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	120	0.1%	108	0.1%	114	0.1%	97	0.1%
First dispensing for an oral CHC	101	0.1%	108	0.1%	101	0.1%	96	0.1%
First dispensing for a partch CHC	26	0.3%	*****	*****	16	0.2%	11	0.1%
First dispensing for a CHC ring	21	0.2%	11	0.1%	20	0.2%	*****	*****
First dispensing for any POC	97	0.3%	122	0.4%	120	0.4%	97	0.3%
First dispensing for an Intrauterine Device (IUD) POC	29	0.1%	34	0.1%	41	0.1%	37	0.1%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	21	0.2%	27	0.2%	25	0.2%	16	0.1%
First dispensing for an oral POC	63	0.3%	77	0.4%	84	0.4%	66	0.3%
First dispensing for an implant POC	20	0.1%	21	0.1%	11	0.1%	16	0.1%

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	295-301 days		302-308 days		309-315 days		316-322 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	73	0.1%	86	0.1%	65	0.1%	69	0.1%
First dispensing for an oral CHC	73	0.1%	84	0.1%	63	0.1%	67	0.1%
First dispensing for a partch CHC	*****	*****	*****	*****	*****	*****	*****	*****
First dispensing for a CHC ring	*****	*****	11	0.1%	*****	*****	*****	*****
First dispensing for any POC	82	0.3%	98	0.3%	62	0.2%	77	0.2%
First dispensing for an Intrauterine Device (IUD) POC	27	0.1%	29	0.1%	19	0.1%	29	0.1%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	*****	*****	17	0.1%	17	0.1%	*****	*****
First dispensing for an oral POC	64	0.3%	72	0.4%	44	0.2%	57	0.3%
First dispensing for an implant POC	11	0.1%	18	0.1%	*****	*****	*****	*****

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length							
	323-329 days		330-336 days		337-343 days		344-350 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)								
First dispensing for any CHC	51	0.0%	57	0.0%	45	0.0%	44	0.0%
First dispensing for an oral CHC	51	0.0%	51	0.0%	39	0.0%	39	0.0%
First dispensing for a partch CHC	*****	*****	*****	*****	*****	*****	*****	*****
First dispensing for a CHC ring	*****	*****	*****	*****	*****	*****	*****	*****
First dispensing for any POC	62	0.2%	64	0.2%	57	0.2%	55	0.2%
First dispensing for an Intrauterine Device (IUD) POC	15	0.0%	*****	*****	*****	*****	14	0.0%
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	*****	*****	*****	*****	*****	*****	*****	*****
First dispensing for an oral POC	50	0.3%	61	0.3%	52	0.3%	44	0.2%
First dispensing for an implant POC	12	0.1%	*****	*****	*****	*****	*****	*****

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5a. Categorical Summary of Time to Censoring Due to Initiation of a Different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) Among Patients with Live-birth or Stillbirth Delivery in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024 (Continued)

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	351-357 days		358-365 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)				
First dispensing for any CHC	54	0.0%	47	0.0%
First dispensing for an oral CHC	49	0.0%	43	0.0%
First dispensing for a partch CHC	*****	*****	*****	*****
First dispensing for a CHC ring	*****	*****	*****	*****
First dispensing for any POC	52	0.2%	43	0.1%
First dispensing for an Intrauterine Device (IUD) POC	*****	*****	*****	*****
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	*****	*****	*****	*****
First dispensing for an oral POC	48	0.2%	42	0.2%
First dispensing for an implant POC	*****	*****	*****	*****

[1]Represents episodes censored due to occurrence of additional user-defined criteria defined using drug, procedure, diagnosis, and/or laboratory codes.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 5b. Continuous Summary of Time to Censoring due to initiation of a different Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC) among Patients with Live-Birth or Stillbirth Delivery in the Sentinel Distributed Database from January 1, 2012 to January 31, 2024

			Distribution of At-Risk Time in Days, by Episode						
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Episodes with a live-birth or still birth delivery that had a first dispensing for a Combined Hormonal Contraceptive (CHC) or Progestin Only Contraceptive (POC)									
First dispensing for any CHC	458,204	117,235	0	35	43	55	365	51.9	44.7
First dispensing for an oral CHC	393,798	108,059	0	35	43	55	365	52.4	45.1
First dispensing for a partch CHC	35,512	9,505	0	32	44	65	360	58.3	54.1
First dispensing for a CHC ring	41,728	12,558	0	38	45	61	365	58.3	49.0
First dispensing for any POC	848,066	32,330	0	41	48	88	365	77.1	68.0
First dispensing for an Intrauterine Device (IUD)	275,225	33,808	0	36	44	56	359	54.5	45.7
First dispensing for a Depot-medroxyprogesterone Acetate (DMPA) POC	106,990	11,343	0	31	44	65	364	58.7	54.9
First dispensing for an oral POC	399,571	19,773	0	42	52	91	365	80.3	71.6
First dispensing for an implant POC	113,007	15,140	0	33	44	62	360	55.9	49.9

[1]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For Any Combined Hormonal Contraceptives (CHC)		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Oral CHC	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	437,218,621	N/A	437,218,621	N/A	437,218,621	N/A
Had required coverage type (medical and/or drug coverage)	324,225,790	112,992,831	324,225,790	112,992,831	324,225,790	112,992,831
Enrolled during specified age range	264,026,390	60,199,400	264,026,390	60,199,400	264,026,390	60,199,400
Had requestable medical charts	264,026,390	0	264,026,390	0	264,026,390	0
Met demographic requirements (sex, race, and Hispanic origin)	140,148,063	123,878,327	140,148,063	123,878,327	140,148,063	123,878,327
Members with a valid index event						
Had any cohort-defining claim during the query period	10,161,476	129,986,587	10,161,476	129,986,587	10,161,476	129,986,587
Cohort episodes with a valid index date						
Total number of claims with cohort-identifying codes during the query period	15,790,883	N/A	15,790,883	N/A	15,790,883	N/A
Claim recorded during specified age range	15,488,318	302,565	15,488,318	302,565	15,488,318	302,565
Episode defining index claim recorded during the query period	12,092,199	3,396,119	12,092,199	3,396,119	12,092,199	3,396,119

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For Any Combined Hormonal Contraceptives (CHC)		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Oral CHC	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Cohort episodes with required pre-index history						
Had sufficient pre-index continuous enrollment	5,702,966	6,389,233	5,702,966	6,389,233	5,702,966	6,389,233
Met inclusion and exclusion criteria[2]	5,702,966	0	622,731	5,080,235	532,567	5,170,399
Evidence of live or stillbirth deliveries within 365 days of the index date	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of no prior contraceptives	N/A	N/A	N/A	726,509	N/A	726,509
No evidence of CHC	N/A	N/A	N/A	4,875,325	N/A	N/A
No evidence of oral CHC	N/A	N/A	N/A	N/A	N/A	4,995,232
No evidence of DMPA POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of implant POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of evidence of live or stillbirth deliveries within 42 days before the index date	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of IUD POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of CHC patch	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of oral POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of CHC ring	N/A	N/A	N/A	N/A	N/A	N/A
Met event incidence criteria	5,702,966	0	622,731	0	532,567	0
Cohort episodes with required post-index follow-up						
Had sufficient post-index continuous enrollment	3,577,468	2,125,498	458,204	164,527	393,798	138,769
Met minimum episode duration criteria	3,577,468	0	458,204	0	393,798	0
Episode duration was longer than blackout period	3,577,468	0	458,204	0	393,798	0
Did not have an event during blackout period	3,577,468	0	458,204	0	393,798	0
Final cohort						
Number of members	3,096,104	N/A	444,220	N/A	382,381	N/A
Number of episodes	3,577,468	N/A	458,204	N/A	393,798	N/A

[1]Cohorts are formed by first evaluating enrollment and demographic requirements as well as index events among members, then evaluating index dates, pre-index history, and post-index follow-up among episodes. Because of this, the number remaining often increases from the member- to episode-level steps.

[2]Episodes can meet multiple inclusion and/or exclusion criteria; therefore, the total number of episodes excluded overall may not equal the sum of all episodes in each criterion.

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For a CHC Patch		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For a CHC Ring		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For Any Progestin-only Contraceptives (POC)	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	437,218,621	N/A	437,218,621	N/A	437,218,621	N/A
Had required coverage type (medical and/or drug coverage)	324,225,790	112,992,831	324,225,790	112,992,831	324,225,790	112,992,831
Enrolled during specified age range	264,026,390	60,199,400	264,026,390	60,199,400	264,026,390	60,199,400
Had requestable medical charts	264,026,390	0	264,026,390	0	264,026,390	0
Met demographic requirements (sex, race, and Hispanic origin)	140,148,063	123,878,327	140,148,063	123,878,327	140,148,063	123,878,327
Members with a valid index event						
Had any cohort-defining claim during the query period	10,161,476	129,986,587	10,161,476	129,986,587	10,161,476	129,986,587
Cohort episodes with a valid index date						
Total number of claims with cohort-identifying codes during the query period	15,790,883	N/A	15,790,883	N/A	15,790,883	N/A
Claim recorded during specified age range	15,488,318	302,565	15,488,318	302,565	15,488,318	302,565
Episode defining index claim recorded during the query period	12,092,199	3,396,119	12,092,199	3,396,119	12,092,199	3,396,119

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For a CHC Patch		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For a CHC Ring		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For Any Progestin-only Contraceptives (POC)	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Cohort episodes with required pre-index history						
Had sufficient pre-index continuous enrollment	5,702,966	6,389,233	5,702,966	6,389,233	5,702,966	6,389,233
Met inclusion and exclusion criteria[2]	50,031	5,652,935	56,062	5,646,904	1,234,298	4,468,668
Evidence of live or stillbirth deliveries within 365 days of the index date	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of no prior contraceptives	N/A	726,509	N/A	726,509	N/A	726,509
No evidence of CHC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of oral CHC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of DMPA POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of implant POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of evidence of live or stillbirth deliveries within 42 days before the index date	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of IUD POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of CHC patch	N/A	5,637,561	N/A	N/A	N/A	N/A
No evidence of oral POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of POC	N/A	N/A	N/A	N/A	N/A	4,180,065
No evidence of CHC ring	N/A	N/A	N/A	5,626,235	N/A	N/A
Met event incidence criteria	50,031	0	56,062	0	1,234,298	0
Cohort episodes with required post-index follow-up						
Had sufficient post-index continuous enrollment	35,512	14,519	41,728	14,334	848,066	386,232
Met minimum episode duration criteria	35,512	0	41,728	0	848,066	0
Episode duration was longer than blackout period	35,512	0	41,728	0	848,066	0
Did not have an event during blackout period	35,512	0	41,728	0	848,066	0
Final cohort						
Number of members	35,104	N/A	40,940	N/A	810,752	N/A
Number of episodes	35,512	N/A	41,728	N/A	848,066	N/A

[1]Cohorts are formed by first evaluating enrollment and demographic requirements as well as index events among members, then evaluating index dates, pre-index history, and post-index follow-up among episodes. Because of this, the number remaining often increases from the member- to episode-level steps.

[2]Episodes can meet multiple inclusion and/or exclusion criteria; therefore, the total number of episodes excluded overall may not equal the sum of all episodes in each criterion.

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Intrauterine Device (IUD)		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For a Depot-medroxyprogesterone Acetate (DMPA)		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Oral POC	
	Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	437,218,621	N/A	437,218,621	N/A	437,218,621	N/A
Had required coverage type (medical and/or drug coverage)	324,225,790	112,992,831	324,225,790	112,992,831	324,225,790	112,992,831
Enrolled during specified age range	264,026,390	60,199,400	264,026,390	60,199,400	264,026,390	60,199,400
Had requestable medical charts	264,026,390	0	264,026,390	0	264,026,390	0
Met demographic requirements (sex, race, and Hispanic origin)	140,148,063	123,878,327	140,148,063	123,878,327	140,148,063	123,878,327
Members with a valid index event						
Had any cohort-defining claim during the query period	10,161,476	129,986,587	10,161,476	129,986,587	10,161,476	129,986,587
Cohort episodes with a valid index date						
Total number of claims with cohort-identifying codes during the query period	15,790,883	N/A	15,790,883	N/A	15,790,883	N/A
Claim recorded during specified age range	15,488,318	302,565	15,488,318	302,565	15,488,318	302,565
Episode defining index claim recorded during the query period	12,092,199	3,396,119	12,092,199	3,396,119	12,092,199	3,396,119

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Intrauterine Device (IUD)		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For a Depot-medroxyprogesterone Acetate (DMPA)		Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Oral POC	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Cohort episodes with required pre-index history						
Had sufficient pre-index continuous enrollment	5,702,966	6,389,233	5,702,966	6,389,233	5,702,966	6,389,233
Met inclusion and exclusion criteria[2]	397,050	5,305,916	153,847	5,549,119	581,567	5,121,399
Evidence of exc	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of live or stillbirth deliveries within 365 days of the index date	N/A	726,509	N/A	726,509	N/A	726,509
Evidence of no prior contraceptives	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of CHC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of oral CHC	N/A	N/A	N/A	5,520,664	N/A	N/A
No evidence of DMPA POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of implant POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of evidence of live or stillbirth deliveries within 42 days before the index date	N/A	5,229,931	N/A	N/A	N/A	N/A
No evidence of IUD POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of CHC patch	N/A	N/A	N/A	N/A	N/A	4,949,221
No evidence of oral POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of POC	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of CHC ring	397,050	0	153,847	0	581,567	0
Cohort episodes with required post-index follow-up						
Had sufficient post-index continuous enrollment	275,225	121,825	106,990	46,857	399,571	181,996
Met minimum episode duration criteria	275,225	0	106,990	0	399,571	0
Episode duration was longer than blackout period	275,225	0	106,990	0	399,571	0
Did not have an event during blackout period	275,225	0	106,990	0	399,571	0
Final cohort						
Number of members	267,945	N/A	104,932	N/A	383,042	N/A
Number of episodes	275,225	N/A	106,990	N/A	399,571	N/A

[1]Cohorts are formed by first evaluating enrollment and demographic requirements as well as index events among members, then evaluating index dates, pre-index history, and post-index follow-up among episodes. Because of this, the number remaining often increases from the member- to episode-level steps.

[2]Episodes can meet multiple inclusion and/or exclusion criteria; therefore, the total number of episodes excluded overall may not equal the sum of all episodes in each criterion.

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Implant		Patients with Any CHC Dispensing or Administration with a Prior Live or Stillbirth Delivery and Subsequent Any Contraceptives	
	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	437,218,621	N/A	437,218,621	N/A
Had required coverage type (medical and/or drug coverage)	324,225,790	112,992,831	324,225,790	112,992,831
Enrolled during specified age range	264,026,390	60,199,400	264,026,390	60,199,400
Had requestable medical charts	264,026,390	0	264,026,390	0
Met demographic requirements (sex, race, and Hispanic origin)	140,148,063	123,878,327	140,148,063	123,878,327
Members with a valid index event				
Had any cohort-defining claim during the query period	10,161,476	129,986,587	17,561,313	122,586,750
Cohort episodes with a valid index date				
Total number of claims with cohort-identifying codes during the query period	15,790,883	N/A	188,016,832	N/A
Claim recorded during specified age range	15,488,318	302,565	169,912,995	18,103,837
Episode defining index claim recorded during the query period	12,092,199	3,396,119	16,436,981	153,476,014

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with a Live-birth or Stillbirth Delivery and a First Dispensing For an Implant		Patients with Any CHC Dispensing or Administration with a Prior Live or Stillbirth Delivery and Subsequent Any Contraceptives	
	Remaining	Excluded	Remaining	Excluded
Cohort episodes with required pre-index history				
Had sufficient pre-index continuous enrollment	5,702,966	6,389,233	6,023,545	10,413,436
Met inclusion and exclusion criteria[2]	161,879	5,541,087	107,418	5,916,127
Evidence of live or stillbirth deliveries within 365 days of the index date	N/A	N/A	N/A	121,778
Evidence of no prior contraceptives	N/A	726,509	N/A	N/A
No evidence of CHC	N/A	N/A	N/A	N/A
No evidence of oral CHC	N/A	N/A	N/A	N/A
No evidence of DMPA POC	N/A	N/A	N/A	N/A
No evidence of implant POC	N/A	5,511,105	N/A	N/A
No evidence of evidence of live or stillbirth deliveries within 42 days before the index date	N/A	N/A	N/A	5,913,857
No evidence of IUD POC	N/A	N/A	N/A	N/A
No evidence of CHC patch	N/A	N/A	N/A	N/A
No evidence of oral POC	N/A	N/A	N/A	N/A
No evidence of POC	N/A	N/A	N/A	N/A
No evidence of CHC ring	N/A	N/A	N/A	N/A
Met event incidence criteria	161,879	0	107,418	0
Cohort episodes with required post-index follow-up				
Had sufficient post-index continuous enrollment	113,007	48,872	74,676	32,742
Met minimum episode duration criteria	113,007	0	74,676	0
Episode duration was longer than blackout period	113,007	0	74,676	0
Did not have an event during blackout period	113,007	0	74,676	0
Final cohort				
Number of members	111,616	N/A	73,901	N/A
Number of episodes	113,007	N/A	74,676	N/A

[1]Cohorts are formed by first evaluating enrollment and demographic requirements as well as index events among members, then evaluating index dates, pre-index history, and post-index follow-up among episodes. Because of this, the number remaining often increases from the member- to episode-level steps.

[2]Episodes can meet multiple inclusion and/or exclusion criteria; therefore, the total number of episodes excluded overall may not equal the sum of all episodes in each criterion.

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with Any POC Dispensing or Administration with a Prior Live or Stillbirth Delivery and Subsequent Any Contraceptives		Patients with a DMPA Dispensing or Administration with a Prior Live or Stillbirth Delivery and Subsequent Any Contraceptives	
	Remaining	**Excluded**	**Remaining**	**Excluded**
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	437,218,621	N/A	437,218,621	N/A
Had required coverage type (medical and/or drug coverage)	324,225,790	112,992,831	324,225,790	112,992,831
Enrolled during specified age range	264,026,390	60,199,400	264,026,390	60,199,400
Had requestable medical charts	264,026,390	0	264,026,390	0
Met demographic requirements (sex, race, and Hispanic origin)	140,148,063	123,878,327	140,148,063	123,878,327
Members with a valid index event				
Had any cohort-defining claim during the query period	9,291,650	130,856,413	2,149,873	137,998,190
Cohort episodes with a valid index date				
Total number of claims with cohort-identifying codes during the query period	28,595,589	N/A	9,095,265	N/A
Claim recorded during specified age range	26,600,985	1,994,604	7,857,884	1,237,381
Episode defining index claim recorded during the query period	9,608,026	16,992,959	1,909,775	5,948,109

Table 6. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2012 to January 31, 2024

	Patients with Any POC Dispensing or Administration with a Prior Live or Stillbirth Delivery and Subsequent Any Contraceptives		Patients with a DMPA Dispensing or Administration with a Prior Live or Stillbirth Delivery and Subsequent Any Contraceptives	
	Remaining	**Excluded**	**Remaining**	**Excluded**
Cohort episodes with required pre-index history				
Had sufficient pre-index continuous enrollment	5,210,782	4,397,244	817,616	1,092,159
Met inclusion and exclusion criteria[2]	280,749	4,930,033	39,826	777,790
Evidence of live or stillbirth deliveries within 365 days of the index date	N/A	60,991	N/A	6,780
Evidence of no prior contraceptives	N/A	N/A	N/A	N/A
No evidence of CHC	N/A	N/A	N/A	N/A
No evidence of oral CHC	N/A	N/A	N/A	N/A
No evidence of DMPA POC	N/A	N/A	N/A	N/A
No evidence of implant POC	N/A	N/A	N/A	N/A
No evidence of evidence of live or stillbirth deliveries within 42 days before the index date	N/A	4,922,997	N/A	777,403
No evidence of IUD POC	N/A	N/A	N/A	N/A
No evidence of CHC patch	N/A	N/A	N/A	N/A
No evidence of oral POC	N/A	N/A	N/A	N/A
No evidence of POC	N/A	N/A	N/A	N/A
No evidence of CHC ring	N/A	N/A	N/A	N/A
Met event incidence criteria	280,749	0	39,826	0
Cohort episodes with required post-index follow-up				
Had sufficient post-index continuous enrollment	197,517	83,232	28,860	10,966
Met minimum episode duration criteria	197,517	0	28,860	0
Episode duration was longer than blackout period	197,517	0	28,860	0
Did not have an event during blackout period	197,517	0	28,860	0
Final cohort				
Number of members	192,764	N/A	28,672	N/A
Number of episodes	197,517	N/A	28,860	N/A

[1]Cohorts are formed by first evaluating enrollment and demographic requirements as well as index events among members, then evaluating index dates, pre-index history, and post-index follow-up among episodes. Because of this, the number remaining often increases from the member- to episode-level steps.

[2]Episodes can meet multiple inclusion and/or exclusion criteria; therefore, the total number of episodes excluded overall may not equal the sum of all episodes in each criterion.

Appendix A. Dates of Available Data for Each Data Partner (DP) As of Request Distribution Date (October 2, 2023)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2006	10/31/2023
DP02	01/01/2007	10/31/2023
DP03	01/01/2008	08/31/2023
DP04	01/01/2010	06/30/2023
DP05	01/01/2008	01/31/2024
DP06	01/01/2014	12/31/2021

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
	Live Birth Delivery		
65101	Twin pregnancy, delivered	Diagnosis	ICD-9-CM
65111	Triplet pregnancy, delivered	Diagnosis	ICD-9-CM
65121	Quadruplet pregnancy, delivered	Diagnosis	ICD-9-CM
65131	Twin pregnancy with fetal loss and retention of one fetus, delivered	Diagnosis	ICD-9-CM
65141	Triplet pregnancy with fetal loss and retention of one or more, delivered	Diagnosis	ICD-9-CM
65151	Quadruplet pregnancy with fetal loss and retention of one or more, delivered	Diagnosis	ICD-9-CM
65161	Other multiple pregnancy with fetal loss and retention of one or more fetus(es), delivered	Diagnosis	ICD-9-CM
65171	Multiple gestation following (elective) fetal reduction, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
65181	Other specified multiple gestation, delivered	Diagnosis	ICD-9-CM
65191	Unspecified multiple gestation, delivered	Diagnosis	ICD-9-CM
65261	Multiple gestation with malpresentation of one fetus or more, delivered	Diagnosis	ICD-9-CM
66051	Locked twins, delivered	Diagnosis	ICD-9-CM
66231	Delayed delivery of second twin, triplet, etc., delivered	Diagnosis	ICD-9-CM
67811	Fetal conjoined twins, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
O6012X1	Preterm labor second trimester with preterm delivery second trimester, fetus 1	Diagnosis	ICD-10-CM
O6012X2	Preterm labor second trimester with preterm delivery second trimester, fetus 2	Diagnosis	ICD-10-CM
O6012X3	Preterm labor second trimester with preterm delivery second trimester, fetus 3	Diagnosis	ICD-10-CM
O6012X4	Preterm labor second trimester with preterm delivery second trimester, fetus 4	Diagnosis	ICD-10-CM
O6012X5	Preterm labor second trimester with preterm delivery second trimester, fetus 5	Diagnosis	ICD-10-CM
O6012X9	Preterm labor second trimester with preterm delivery second trimester, other fetus	Diagnosis	ICD-10-CM
O6013X0	Preterm labor second trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6013X1	Preterm labor second trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O6013X2	Preterm labor second trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O6013X3	Preterm labor second trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O6013X4	Preterm labor second trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O6013X5	Preterm labor second trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O6013X9	Preterm labor second trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
O6014X1	Preterm labor third trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O6014X2	Preterm labor third trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O6014X3	Preterm labor third trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O6014X4	Preterm labor third trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O6014X5	Preterm labor third trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O6014X9	Preterm labor third trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O6022X1	Term delivery with preterm labor, second trimester, fetus 1	Diagnosis	ICD-10-CM
O6022X2	Term delivery with preterm labor, second trimester, fetus 2	Diagnosis	ICD-10-CM
O6022X3	Term delivery with preterm labor, second trimester, fetus 3	Diagnosis	ICD-10-CM
O6022X4	Term delivery with preterm labor, second trimester, fetus 4	Diagnosis	ICD-10-CM
O6022X5	Term delivery with preterm labor, second trimester, fetus 5	Diagnosis	ICD-10-CM
O6022X9	Term delivery with preterm labor, second trimester, other fetus	Diagnosis	ICD-10-CM
O6023X1	Term delivery with preterm labor, third trimester, fetus 1	Diagnosis	ICD-10-CM
O6023X2	Term delivery with preterm labor, third trimester, fetus 2	Diagnosis	ICD-10-CM
O6023X3	Term delivery with preterm labor, third trimester, fetus 3	Diagnosis	ICD-10-CM
O6023X4	Term delivery with preterm labor, third trimester, fetus 4	Diagnosis	ICD-10-CM
O6023X5	Term delivery with preterm labor, third trimester, fetus 5	Diagnosis	ICD-10-CM
O6023X9	Term delivery with preterm labor, third trimester, other fetus	Diagnosis	ICD-10-CM
O632	Delayed delivery of second twin, triplet, etc	Diagnosis	ICD-10-CM
O690XX1	Labor and delivery complicated by prolapse of cord, fetus 1	Diagnosis	ICD-10-CM
O690XX2	Labor and delivery complicated by prolapse of cord, fetus 2	Diagnosis	ICD-10-CM
O690XX3	Labor and delivery complicated by prolapse of cord, fetus 3	Diagnosis	ICD-10-CM
O690XX4	Labor and delivery complicated by prolapse of cord, fetus 4	Diagnosis	ICD-10-CM
O690XX5	Labor and delivery complicated by prolapse of cord, fetus 5	Diagnosis	ICD-10-CM
O690XX9	Labor and delivery complicated by prolapse of cord, other fetus	Diagnosis	ICD-10-CM
O691XX1	Labor and delivery complicated by cord around neck, with compression, fetus 1	Diagnosis	ICD-10-CM
O691XX2	Labor and delivery complicated by cord around neck, with compression, fetus 2	Diagnosis	ICD-10-CM
O691XX3	Labor and delivery complicated by cord around neck, with compression, fetus 3	Diagnosis	ICD-10-CM
O691XX4	Labor and delivery complicated by cord around neck, with compression, fetus 4	Diagnosis	ICD-10-CM
O691XX5	Labor and delivery complicated by cord around neck, with compression, fetus 5	Diagnosis	ICD-10-CM
O691XX9	Labor and delivery complicated by cord around neck, with compression, other fetus	Diagnosis	ICD-10-CM
O692XX1	Labor and delivery complicated by other cord entanglement, with compression, fetus 1	Diagnosis	ICD-10-CM
O692XX2	Labor and delivery complicated by other cord entanglement, with compression, fetus 2	Diagnosis	ICD-10-CM
O692XX3	Labor and delivery complicated by other cord entanglement, with compression, fetus 3	Diagnosis	ICD-10-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
O692XX4	Labor and delivery complicated by other cord entanglement, with compression, fetus 4	Diagnosis	ICD-10-CM
O692XX5	Labor and delivery complicated by other cord entanglement, with compression, fetus 5	Diagnosis	ICD-10-CM
O692XX9	Labor and delivery complicated by other cord entanglement, with compression, other fetus	Diagnosis	ICD-10-CM
O693XX1	Labor and delivery complicated by short cord, fetus 1	Diagnosis	ICD-10-CM
O693XX2	Labor and delivery complicated by short cord, fetus 2	Diagnosis	ICD-10-CM
O693XX3	Labor and delivery complicated by short cord, fetus 3	Diagnosis	ICD-10-CM
O693XX4	Labor and delivery complicated by short cord, fetus 4	Diagnosis	ICD-10-CM
O693XX5	Labor and delivery complicated by short cord, fetus 5	Diagnosis	ICD-10-CM
O693XX9	Labor and delivery complicated by short cord, other fetus	Diagnosis	ICD-10-CM
O694XX1	Labor and delivery complicated by vasa previa, fetus 1	Diagnosis	ICD-10-CM
O694XX2	Labor and delivery complicated by vasa previa, fetus 2	Diagnosis	ICD-10-CM
O694XX3	Labor and delivery complicated by vasa previa, fetus 3	Diagnosis	ICD-10-CM
O694XX4	Labor and delivery complicated by vasa previa, fetus 4	Diagnosis	ICD-10-CM
O694XX5	Labor and delivery complicated by vasa previa, fetus 5	Diagnosis	ICD-10-CM
O694XX9	Labor and delivery complicated by vasa previa, other fetus	Diagnosis	ICD-10-CM
O695XX1	Labor and delivery complicated by vascular lesion of cord, fetus 1	Diagnosis	ICD-10-CM
O695XX2	Labor and delivery complicated by vascular lesion of cord, fetus 2	Diagnosis	ICD-10-CM
O695XX3	Labor and delivery complicated by vascular lesion of cord, fetus 3	Diagnosis	ICD-10-CM
O695XX4	Labor and delivery complicated by vascular lesion of cord, fetus 4	Diagnosis	ICD-10-CM
O695XX5	Labor and delivery complicated by vascular lesion of cord, fetus 5	Diagnosis	ICD-10-CM
O695XX9	Labor and delivery complicated by vascular lesion of cord, other fetus	Diagnosis	ICD-10-CM
O6981X2	Labor and delivery complicated by cord around neck, without compression, fetus 2	Diagnosis	ICD-10-CM
O6981X3	Labor and delivery complicated by cord around neck, without compression, fetus 3	Diagnosis	ICD-10-CM
O6981X4	Labor and delivery complicated by cord around neck, without compression, fetus 4	Diagnosis	ICD-10-CM
O6981X5	Labor and delivery complicated by cord around neck, without compression, fetus 5	Diagnosis	ICD-10-CM
O6981X9	Labor and delivery complicated by cord around neck, without compression, other fetus	Diagnosis	ICD-10-CM
O6982X1	Labor and delivery complicated by other cord entanglement, without compression, fetus 1	Diagnosis	ICD-10-CM
O6982X2	Labor and delivery complicated by other cord entanglement, without compression, fetus 2	Diagnosis	ICD-10-CM
O6982X3	Labor and delivery complicated by other cord entanglement, without compression, fetus 3	Diagnosis	ICD-10-CM
O6982X4	Labor and delivery complicated by other cord entanglement, without compression, fetus 4	Diagnosis	ICD-10-CM
O6982X5	Labor and delivery complicated by other cord entanglement, without compression, fetus 5	Diagnosis	ICD-10-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
O6982X9	Labor and delivery complicated by other cord entanglement, without compression, other fetus	Diagnosis	ICD-10-CM
O6989X1	Labor and delivery complicated by other cord complications, fetus 1	Diagnosis	ICD-10-CM
O6989X2	Labor and delivery complicated by other cord complications, fetus 2	Diagnosis	ICD-10-CM
O6989X3	Labor and delivery complicated by other cord complications, fetus 3	Diagnosis	ICD-10-CM
O6989X4	Labor and delivery complicated by other cord complications, fetus 4	Diagnosis	ICD-10-CM
O6989X5	Labor and delivery complicated by other cord complications, fetus 5	Diagnosis	ICD-10-CM
O6989X9	Labor and delivery complicated by other cord complications, other fetus	Diagnosis	ICD-10-CM
O699XX1	Labor and delivery complicated by cord complication, unspecified, fetus 1	Diagnosis	ICD-10-CM
O699XX2	Labor and delivery complicated by cord complication, unspecified, fetus 2	Diagnosis	ICD-10-CM
O699XX3	Labor and delivery complicated by cord complication, unspecified, fetus 3	Diagnosis	ICD-10-CM
O699XX4	Labor and delivery complicated by cord complication, unspecified, fetus 4	Diagnosis	ICD-10-CM
O699XX5	Labor and delivery complicated by cord complication, unspecified, fetus 5	Diagnosis	ICD-10-CM
O699XX9	Labor and delivery complicated by cord complication, unspecified, other fetus	Diagnosis	ICD-10-CM
V270	Outcome of delivery, single liveborn	Diagnosis	ICD-9-CM
V272	Outcome of delivery, twins, both liveborn	Diagnosis	ICD-9-CM
V273	Outcome of delivery, twins, one liveborn and one stillborn	Diagnosis	ICD-9-CM
V275	Outcome of delivery, other multiple birth, all liveborn	Diagnosis	ICD-9-CM
V276	Outcome of delivery, other multiple birth, some liveborn	Diagnosis	ICD-9-CM
V30	Single liveborn	Diagnosis	ICD-9-CM
V300	Single liveborn, born in hospital	Diagnosis	ICD-9-CM
V3000	Single liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3001	Single liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V301	Single liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V302	Single liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V31	Twin birth, mate liveborn	Diagnosis	ICD-9-CM
V310	Twin, mate liveborn, born in hospital	Diagnosis	ICD-9-CM
V3100	Twin, mate liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3101	Twin, mate liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V311	Twin birth, mate liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V312	Twin birth, mate liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V32	Twin birth, mate stillborn	Diagnosis	ICD-9-CM
V320	Twin, mate stillborn, born in hospital	Diagnosis	ICD-9-CM
V3200	Twin, mate stillborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3201	Twin, mate stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V321	Twin birth, mate stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V322	Twin birth, mate stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V33	Twin birth, unspecified whether mate liveborn or stillborn	Diagnosis	ICD-9-CM
V330	Twin, unspecified, born in hospital	Diagnosis	ICD-9-CM
V3300	Twin, unspecified whether mate stillborn or liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
V3301	Twin, unspecified whether mate stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V331	Twin birth, unspecified whether mate liveborn or stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V332	Twin birth, unspecified whether mate liveborn or stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V34	Other multiple birth (three or more), mates all liveborn	Diagnosis	ICD-9-CM
V340	Other multiple, mates all liveborn, born in hospital	Diagnosis	ICD-9-CM
V3400	Other multiple, mates all liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3401	Other multiple, mates all liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V341	Other multiple birth (three or more), mates all liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V342	Other multiple birth (three or more), mates all liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V36	Other multiple birth (three or more), mates liveborn and stillborn	Diagnosis	ICD-9-CM
V360	Other multiple, mates liveborn and stillborn, born in hospital	Diagnosis	ICD-9-CM
V3600	Other multiple, mates liveborn and stillborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3601	Other multiple, mates liveborn and stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V361	Other multiple birth (three or more), mates liveborn and stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V362	Other multiple birth (three or more), mates liveborn and stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V37	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn	Diagnosis	ICD-9-CM
V370	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital	Diagnosis	ICD-9-CM
V3700	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3701	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V371	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V372	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born outside of hospital	Diagnosis	ICD-9-CM
Z370	Single live birth	Diagnosis	ICD-10-CM
Z372	Twins, both liveborn	Diagnosis	ICD-10-CM
Z373	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z3750	Multiple births, unspecified, all liveborn	Diagnosis	ICD-10-CM
Z3751	Triplets, all liveborn	Diagnosis	ICD-10-CM
Z3752	Quadruplets, all liveborn	Diagnosis	ICD-10-CM
Z3753	Quintuplets, all liveborn	Diagnosis	ICD-10-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
Z3754	Sextuplets, all liveborn	Diagnosis	ICD-10-CM
Z3759	Other multiple births, all liveborn	Diagnosis	ICD-10-CM
Z3760	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z3761	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z3762	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z3763	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z3764	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z3769	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
Z3800	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3801	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z381	Single liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z382	Single liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3830	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3831	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z384	Twin liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z385	Twin liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3861	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3862	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3863	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3864	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3865	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3866	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3868	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3869	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z387	Other multiple liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z388	Other multiple liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
	Still Birth Delivery		
64601	PAPYRACEOUS FETUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND	Diagnosis	ICD-9-CM
65641	Intrauterine death, affecting management of mother, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
7680	Fetal death from asphyxia or anoxia before onset of labor or at unspecified time	Diagnosis	ICD-9-CM
7681	Fetal death from asphyxia or anoxia during labor	Diagnosis	ICD-9-CM
O31.00X0	Papyraceous fetus, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.00X1	Papyraceous fetus, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.00X2	Papyraceous fetus, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.00X3	Papyraceous fetus, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.00X4	Papyraceous fetus, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.00X5	Papyraceous fetus, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.00X9	Papyraceous fetus, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.02X0	Papyraceous fetus, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.02X1	Papyraceous fetus, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.02X2	Papyraceous fetus, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.02X3	Papyraceous fetus, second trimester, fetus 3	Diagnosis	ICD-10-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
O31.02X4	Papyraceous fetus, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.02X5	Papyraceous fetus, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.02X9	Papyraceous fetus, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.03X0	Papyraceous fetus, third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.03X1	Papyraceous fetus, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.03X2	Papyraceous fetus, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.03X3	Papyraceous fetus, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.03X4	Papyraceous fetus, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.03X5	Papyraceous fetus, third trimester, fetus 5	Diagnosis	ICD-10-CM
O31.03X9	Papyraceous fetus, third trimester, other fetus	Diagnosis	ICD-10-CM
O31.2	Continuing pregnancy after intrauterine death of one fetus or more	Diagnosis	ICD-10-CM
O31.20X	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester	Diagnosis	ICD-10-CM
O31.20X0	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.20X1	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 1	Diagnosis	ICD-10-CM
O31.20X2	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 2	Diagnosis	ICD-10-CM
O31.20X3	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 3	Diagnosis	ICD-10-CM
O31.20X4	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 4	Diagnosis	ICD-10-CM
O31.20X5	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, fetus 5	Diagnosis	ICD-10-CM
O31.20X9	Continuing pregnancy after intrauterine death of one fetus or more, unspecified trimester, other fetus	Diagnosis	ICD-10-CM
O31.22X	Continuing pregnancy after intrauterine death of one fetus or more, second trimester	Diagnosis	ICD-10-CM
O31.22X0	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O31.22X1	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 1	Diagnosis	ICD-10-CM
O31.22X2	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 2	Diagnosis	ICD-10-CM
O31.22X3	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 3	Diagnosis	ICD-10-CM
O31.22X4	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 4	Diagnosis	ICD-10-CM
O31.22X5	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, fetus 5	Diagnosis	ICD-10-CM
O31.22X9	Continuing pregnancy after intrauterine death of one fetus or more, second trimester, other fetus	Diagnosis	ICD-10-CM
O31.23X	Continuing pregnancy after intrauterine death of one fetus or more, third trimester	Diagnosis	ICD-10-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
O31.23X1	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 1	Diagnosis	ICD-10-CM
O31.23X2	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 2	Diagnosis	ICD-10-CM
O31.23X3	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 3	Diagnosis	ICD-10-CM
O31.23X4	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 4	Diagnosis	ICD-10-CM
O31.23X5	Continuing pregnancy after intrauterine death of one fetus or more, third trimester, fetus 5	Diagnosis	ICD-10-CM
O36.4	Maternal care for intrauterine death	Diagnosis	ICD-10-CM
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified	Diagnosis	ICD-10-CM
O36.4XX1	Maternal care for intrauterine death, fetus 1	Diagnosis	ICD-10-CM
O36.4XX2	Maternal care for intrauterine death, fetus 2	Diagnosis	ICD-10-CM
O36.4XX3	Maternal care for intrauterine death, fetus 3	Diagnosis	ICD-10-CM
O36.4XX4	Maternal care for intrauterine death, fetus 4	Diagnosis	ICD-10-CM
O36.4XX5	Maternal care for intrauterine death, fetus 5	Diagnosis	ICD-10-CM
O36.4XX9	Maternal care for intrauterine death, other fetus	Diagnosis	ICD-10-CM
P95	Stillbirth	Diagnosis	ICD-10-CM
V271	Outcome of delivery, single stillborn	Diagnosis	ICD-9-CM
V273	Outcome of delivery, 1 liveborn & 1 stillborn	Diagnosis	ICD-9-CM
V274	Outcome of delivery, twins, both stillborn	Diagnosis	ICD-9-CM
V277	Outcome of delivery, other multiple birth, all stillborn	Diagnosis	ICD-9-CM
V32	Twin birth, mate stillborn	Diagnosis	ICD-9-CM
V320	Twin, mate stillborn, born in hospital	Diagnosis	ICD-9-CM
V3200	Twin birth, mate stillborn, born in hospital, delivered without mention of cesarean section	Diagnosis	ICD-9-CM
V3201	TWIN, BORN IN HOSPITAL, CESAREAN, MATE STILLBORN	Diagnosis	ICD-9-CM
V321	Twin birth, mate stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V322	Twin birth, mate stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V35	Other multiple birth (three or more), mates all stillborn	Diagnosis	ICD-9-CM
V350	Other multiple, mates all stillborn, born in hospital	Diagnosis	ICD-9-CM
V3500	Other multiple birth (three or more), mates all still born, born in hospital, delivered without mention of cesarean section	Diagnosis	ICD-9-CM
V3501	Other multiple birth (three or more), mates all still born, born in hospital, delivered by cesarean section	Diagnosis	ICD-9-CM
V351	Other multiple birth (three or more), mates all stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V352	Other multiple birth (three or more), mates all stillborn, born outside of hospital and not hospitalized	Diagnosis	ICD-9-CM
V36	Other multiple birth (three or more), mates liveborn and stillborn	Diagnosis	ICD-9-CM
V360	Other multiple, mates liveborn and stillborn, born in hospital	Diagnosis	ICD-9-CM
V3600	Other multiple birth (three or more), mates liveborn and stillborn, born in hospital, delivered without mention of cesarean section	Diagnosis	ICD-9-CM

Appendix B. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define live-birth or stillbirth deliveries in This Request

Code	Description	Code Category	Code Type
V3601	Other multiple birth (three or more), mates liveborn and stillborn, born in hospital, delivered without mention of cesarean section	Diagnosis	ICD-9-CM
V361	Other multiple birth (three or more), mates liveborn and stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V362	Other multiple birth (three or more), mates liveborn and stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
Z37.1	Single stillbirth	Diagnosis	ICD-10-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z37.4	Twins, both stillborn	Diagnosis	ICD-10-CM
Z37.7	Other multiple births, all stillborn	Diagnosis	ICD-10-CM

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
Combined Hormonal Contraceptives	
desogestrel-ethinyl estradiol	Apri
desogestrel-ethinyl estradiol	Caziant (28)
desogestrel-ethinyl estradiol	Cyclessa (28)
desogestrel-ethinyl estradiol	Cyred
desogestrel-ethinyl estradiol	Cyred EQ
desogestrel-ethinyl estradiol	Desogen
desogestrel-ethinyl estradiol	Emoquette
desogestrel-ethinyl estradiol	Enskyce
desogestrel-ethinyl estradiol	Isibloom
desogestrel-ethinyl estradiol	Juleber
desogestrel-ethinyl estradiol	Kalliga
desogestrel-ethinyl estradiol	Ortho-Cept (28)
desogestrel-ethinyl estradiol	Reclipsen (28)
desogestrel-ethinyl estradiol	Solia
desogestrel-ethinyl estradiol	Velivet Triphasic Regimen (28)
desogestrel-ethinyl estradiol	desogestrel-ethinyl estradiol
desogestrel-ethinyl estradiol/ethinyl estradiol	Azurette (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Bekyree (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Kariva (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Kimidess (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Mircette (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Pimtrea (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Simliya (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Viorele (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Volnea (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	desog-e.estradiol/e.estradiol
drospirenone/estetrol	Nextstellis
drospirenone/ethinyl estradiol/levomefolate calcium	Beyaz
drospirenone/ethinyl estradiol/levomefolate calcium	Rajani
drospirenone/ethinyl estradiol/levomefolate calcium	Safyral
drospirenone/ethinyl estradiol/levomefolate calcium	Tydemy
drospirenone/ethinyl estradiol/levomefolate calcium	drospirenone-e.estradiol-lm.FA
estradiol valerate/dienogest	Natazia
ethinyl estradiol/drospirenone	Gianvi (28)
ethinyl estradiol/drospirenone	Jasmiel (28)
ethinyl estradiol/drospirenone	Lo-Zumandimine (28)
ethinyl estradiol/drospirenone	Loryna (28)
ethinyl estradiol/drospirenone	Nikki (28)
ethinyl estradiol/drospirenone	Ocella
ethinyl estradiol/drospirenone	Syeda
ethinyl estradiol/drospirenone	Vestura (28)
ethinyl estradiol/drospirenone	YAZ (28)
ethinyl estradiol/drospirenone	Yasmin (28)
ethinyl estradiol/drospirenone	Zarah
ethinyl estradiol/drospirenone	Zumandimine (28)
ethinyl estradiol/drospirenone	drospirenone-ethinyl estradiol

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
ethynodiol diacetate-ethinyl estradiol	Demulen 1/50 (28)
ethynodiol diacetate-ethinyl estradiol	Kelnor 1-50 (28)
ethynodiol diacetate-ethinyl estradiol	Kelnor 1/35 (28)
ethynodiol diacetate-ethinyl estradiol	Zovia 1-35 (28)
ethynodiol diacetate-ethinyl estradiol	Zovia 1/35E (28)
ethynodiol diacetate-ethinyl estradiol	Zovia 1/50E (28)
ethynodiol diacetate-ethinyl estradiol	ethynodiol diac-eth estradiol
etonogestrel/ethinyl estradiol	EluRyng
etonogestrel/ethinyl estradiol	Haloette
etonogestrel/ethinyl estradiol	NuvaRing
etonogestrel/ethinyl estradiol	etonogestrel-ethinyl estradiol
levonorgestrel/ethinyl estradiol	Afirmelle
levonorgestrel/ethinyl estradiol	Altavera (28)
levonorgestrel/ethinyl estradiol	Amethyst (28)
levonorgestrel/ethinyl estradiol	Aubra
levonorgestrel/ethinyl estradiol	Aubra EQ
levonorgestrel/ethinyl estradiol	Aviane
levonorgestrel/ethinyl estradiol	Ayuna
levonorgestrel/ethinyl estradiol	Chateal (28)
levonorgestrel/ethinyl estradiol	Chateal EQ (28)
levonorgestrel/ethinyl estradiol	Delyla (28)
levonorgestrel/ethinyl estradiol	Dolishale
levonorgestrel/ethinyl estradiol	Enpresse
levonorgestrel/ethinyl estradiol	Falmina (28)
levonorgestrel/ethinyl estradiol	Iclevia
levonorgestrel/ethinyl estradiol	Introvale
levonorgestrel/ethinyl estradiol	Jolessa
levonorgestrel/ethinyl estradiol	Kurvelo (28)
levonorgestrel/ethinyl estradiol	Larissia
levonorgestrel/ethinyl estradiol	Lessina
levonorgestrel/ethinyl estradiol	Levonest (28)
levonorgestrel/ethinyl estradiol	Levora 0.15/30 (28)
levonorgestrel/ethinyl estradiol	Levora-28
levonorgestrel/ethinyl estradiol	Lillow (28)
levonorgestrel/ethinyl estradiol	Lutera (28)
levonorgestrel/ethinyl estradiol	Lybrel (28)
levonorgestrel/ethinyl estradiol	Marlissa (28)
levonorgestrel/ethinyl estradiol	Myzilra
levonorgestrel/ethinyl estradiol	Nordette (28)
levonorgestrel/ethinyl estradiol	Orsythia
levonorgestrel/ethinyl estradiol	Portia 28
levonorgestrel/ethinyl estradiol	Quasense
levonorgestrel/ethinyl estradiol	Seasonale (91)
levonorgestrel/ethinyl estradiol	Setlakin
levonorgestrel/ethinyl estradiol	Sronyx
levonorgestrel/ethinyl estradiol	Trivora (28)
levonorgestrel/ethinyl estradiol	Twirla

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
levonorgestrel/ethinyl estradiol	Tyblume
levonorgestrel/ethinyl estradiol	Vienva
levonorgestrel/ethinyl estradiol	levonorg-eth estrad triphasic
levonorgestrel/ethinyl estradiol	levonorgestrel-ethinyl estrad
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Amethia
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Amethia Lo
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Ashlyna
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Camrese
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Camrese Lo
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Daysee
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Fayosim
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Jaimiess
levonorgestrel/ethinyl estradiol and ethinyl estradiol	L norgest/e.estradiol-e.estrad
levonorgestrel/ethinyl estradiol and ethinyl estradiol	LoJaimiess
levonorgestrel/ethinyl estradiol and ethinyl estradiol	LoSeasonique
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Quartette
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Rivelsa
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Seasonique
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Simpesse
levonorgestrel/ethinyl estradiol/ferrous bisglycinate	Balcoltra
norelgestromin/ethinyl estradiol	Ortho Evra
norelgestromin/ethinyl estradiol	Xulane
norelgestromin/ethinyl estradiol	Zafemy
norethindrone acetate-ethinyl estradiol	Aurovela 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Aurovela 1/20 (21)
norethindrone acetate-ethinyl estradiol	Femhrt 1/5
norethindrone acetate-ethinyl estradiol	Femhrt Low Dose
norethindrone acetate-ethinyl estradiol	Fyavolv
norethindrone acetate-ethinyl estradiol	Gildess 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Gildess 1/20 (21)
norethindrone acetate-ethinyl estradiol	Hailey
norethindrone acetate-ethinyl estradiol	Jevantique
norethindrone acetate-ethinyl estradiol	Jevantique Lo
norethindrone acetate-ethinyl estradiol	Jinteli
norethindrone acetate-ethinyl estradiol	Junel 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Junel 1/20 (21)
norethindrone acetate-ethinyl estradiol	Larin 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Larin 1/20 (21)
norethindrone acetate-ethinyl estradiol	Loestrin 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Loestrin 1/20 (21)
norethindrone acetate-ethinyl estradiol	Microgestin 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Microgestin 1/20 (21)
norethindrone acetate-ethinyl estradiol	norethindrone ac-eth estradiol
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Aurovela 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Aurovela Fe 1-20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Aurovela Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Blisovi 24 Fe

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Blisovi Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Blisovi Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Charlotte 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Estrostep Fe-28
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Finzala
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gemmily
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gildess 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gildess FE 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gildess FE 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Hailey 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Hailey Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Hailey Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Junel FE 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Junel FE 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Junel Fe 24
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Larin 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Larin Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Larin Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Lo Loestrin Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Lo Minastrin Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Loestrin 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Loestrin Fe 1.5/30 (28-Day)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Loestrin Fe 1/20 (28-Day)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Lomedia 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Melodetta 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Merzee
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Mibelas 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Microgestin 24 FE
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Microgestin FE 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Microgestin Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Minastrin 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tarina 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tarina Fe 1-20 EQ (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tarina Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Taysofy
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Taytulla
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tilia Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tri-Legest Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	norethindrone-e.estradiol-iron
norethindrone-ethinyl estradiol	Alyacen 1/35 (28)
norethindrone-ethinyl estradiol	Alyacen 7/7/7 (28)
norethindrone-ethinyl estradiol	Aranelle (28)
norethindrone-ethinyl estradiol	Balziva (28)
norethindrone-ethinyl estradiol	Brevicon (28)
norethindrone-ethinyl estradiol	Briellyn
norethindrone-ethinyl estradiol	Cyclafem 1/35 (28)
norethindrone-ethinyl estradiol	Cyclafem 7/7/7 (28)

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
norethindrone-ethinyl estradiol	Dasetta 1/35 (28)
norethindrone-ethinyl estradiol	Dasetta 7/7/7 (28)
norethindrone-ethinyl estradiol	Gildagia
norethindrone-ethinyl estradiol	Leena 28
norethindrone-ethinyl estradiol	Modicon (28)
norethindrone-ethinyl estradiol	Necon 0.5/35 (28)
norethindrone-ethinyl estradiol	Necon 1/35 (28)
norethindrone-ethinyl estradiol	Necon 10/11 (28)
norethindrone-ethinyl estradiol	Necon 7/7/7 (28)
norethindrone-ethinyl estradiol	Norinyl 1/35 (28)
norethindrone-ethinyl estradiol	Nortrel 0.5/35 (28)
norethindrone-ethinyl estradiol	Nortrel 1/35 (21)
norethindrone-ethinyl estradiol	Nortrel 1/35 (28)
norethindrone-ethinyl estradiol	Nortrel 7/7/7 (28)
norethindrone-ethinyl estradiol	Nylia 1/35 (28)
norethindrone-ethinyl estradiol	Nylia 7/7/7 (28)
norethindrone-ethinyl estradiol	Ortho-Novum 1/35 (28)
norethindrone-ethinyl estradiol	Ortho-Novum 7/7/7 (21)
norethindrone-ethinyl estradiol	Ortho-Novum 7/7/7 (28)
norethindrone-ethinyl estradiol	Ovcon-35 (28)
norethindrone-ethinyl estradiol	Ovcon-50 (28)
norethindrone-ethinyl estradiol	Philith
norethindrone-ethinyl estradiol	Pirmella
norethindrone-ethinyl estradiol	Tri-Norinyl (28)
norethindrone-ethinyl estradiol	Vyfemla (28)
norethindrone-ethinyl estradiol	Wera (28)
norethindrone-ethinyl estradiol	Zenchent (28)
norethindrone-ethinyl estradiol/ferrous fumarate	Femcon Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Generess Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Kaitlib Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Layolis Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Wymzya Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Zenchent Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Zeosa
norethindrone-ethinyl estradiol/ferrous fumarate	noreth-ethinyl estradiol-iron
norethindrone-mestranol	Necon 1/50 (28)
norethindrone-mestranol	Norinyl 1+50 (28)
norgestimate-ethinyl estradiol	Estarylla
norgestimate-ethinyl estradiol	Femynor
norgestimate-ethinyl estradiol	Mili
norgestimate-ethinyl estradiol	Mono-Linyah
norgestimate-ethinyl estradiol	Mononessa (28)
norgestimate-ethinyl estradiol	Nymyo
norgestimate-ethinyl estradiol	Ortho Tri-Cyclen (28)
norgestimate-ethinyl estradiol	Ortho Tri-Cyclen LO (28)
norgestimate-ethinyl estradiol	Ortho-Cyclen (28)
norgestimate-ethinyl estradiol	Previfem

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
norgestimate-ethinyl estradiol	Sprintec (28)
norgestimate-ethinyl estradiol	Tri Femynor
norgestimate-ethinyl estradiol	Tri-Estarylla
norgestimate-ethinyl estradiol	Tri-Linyah
norgestimate-ethinyl estradiol	Tri-Lo-Estarylla
norgestimate-ethinyl estradiol	Tri-Lo-Marzia
norgestimate-ethinyl estradiol	Tri-Lo-Mili
norgestimate-ethinyl estradiol	Tri-Lo-Sprintec
norgestimate-ethinyl estradiol	Tri-Mili
norgestimate-ethinyl estradiol	Tri-Nymyo
norgestimate-ethinyl estradiol	Tri-Previfem (28)
norgestimate-ethinyl estradiol	Tri-Sprintec (28)
norgestimate-ethinyl estradiol	Tri-VyLibra
norgestimate-ethinyl estradiol	Tri-VyLibra Lo
norgestimate-ethinyl estradiol	TriNessa (28)
norgestimate-ethinyl estradiol	TriNessa Lo
norgestimate-ethinyl estradiol	VyLibra
norgestimate-ethinyl estradiol	norgestimate-ethinyl estradiol
norgestrel-ethinyl estradiol	Cryselle (28)
norgestrel-ethinyl estradiol	Elinest
norgestrel-ethinyl estradiol	Lo-Ovral (28)
norgestrel-ethinyl estradiol	Lo-Ovral (8)
norgestrel-ethinyl estradiol	Low-Ogestrel (28)
norgestrel-ethinyl estradiol	Ogestrel (28)
norgestrel-ethinyl estradiol	norgestrel-ethinyl estradiol
segesterone acetate/ethinyl estradiol	Annovera
Combined Hormonal Contraceptives - Oral	
desogestrel-ethinyl estradiol	Apri
desogestrel-ethinyl estradiol	Caziant (28)
desogestrel-ethinyl estradiol	Cyclessa (28)
desogestrel-ethinyl estradiol	Cyred
desogestrel-ethinyl estradiol	Cyred EQ
desogestrel-ethinyl estradiol	Desogen
desogestrel-ethinyl estradiol	Emoquette
desogestrel-ethinyl estradiol	Enskyce
desogestrel-ethinyl estradiol	Isibloom
desogestrel-ethinyl estradiol	Juleber
desogestrel-ethinyl estradiol	Kalliga
desogestrel-ethinyl estradiol	Ortho-Cept (28)
desogestrel-ethinyl estradiol	Reclipsen (28)
desogestrel-ethinyl estradiol	Solia
desogestrel-ethinyl estradiol	Velivet Triphasic Regimen (28)
desogestrel-ethinyl estradiol	desogestrel-ethinyl estradiol
desogestrel-ethinyl estradiol/ethinyl estradiol	Azurette (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Bekyree (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Kariva (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Kimidess (28)

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
desogestrel-ethinyl estradiol/ethinyl estradiol	Mircette (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Pimtrea (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Simliya (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Viorele (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	Volnea (28)
desogestrel-ethinyl estradiol/ethinyl estradiol	desog-e.estradiol/e.estradiol
drospirenone/estetrol	Nextstellis
drospirenone/ethinyl estradiol/levomefolate calcium	Beyaz
drospirenone/ethinyl estradiol/levomefolate calcium	Rajani
drospirenone/ethinyl estradiol/levomefolate calcium	Safyral
drospirenone/ethinyl estradiol/levomefolate calcium	Tydemy
drospirenone/ethinyl estradiol/levomefolate calcium	drospirenone-e.estradiol-lm.FA
estradiol valerate/dienogest	Natazia
ethinyl estradiol/drospirenone	Gianvi (28)
ethinyl estradiol/drospirenone	Jasmiel (28)
ethinyl estradiol/drospirenone	Lo-Zumandimine (28)
ethinyl estradiol/drospirenone	Loryna (28)
ethinyl estradiol/drospirenone	Nikki (28)
ethinyl estradiol/drospirenone	Ocella
ethinyl estradiol/drospirenone	Syeda
ethinyl estradiol/drospirenone	Vestura (28)
ethinyl estradiol/drospirenone	YAZ (28)
ethinyl estradiol/drospirenone	Yasmin (28)
ethinyl estradiol/drospirenone	Zarah
ethinyl estradiol/drospirenone	Zumandimine (28)
ethinyl estradiol/drospirenone	drospirenone-ethinyl estradiol
ethynodiol diacetate-ethinyl estradiol	Demulen 1/50 (28)
ethynodiol diacetate-ethinyl estradiol	Kelnor 1-50 (28)
ethynodiol diacetate-ethinyl estradiol	Kelnor 1/35 (28)
ethynodiol diacetate-ethinyl estradiol	Zovia 1-35 (28)
ethynodiol diacetate-ethinyl estradiol	Zovia 1/35E (28)
ethynodiol diacetate-ethinyl estradiol	Zovia 1/50E (28)
ethynodiol diacetate-ethinyl estradiol	ethynodiol diac-eth estradiol
levonorgestrel/ethinyl estradiol	Afirmelle
levonorgestrel/ethinyl estradiol	Altavera (28)
levonorgestrel/ethinyl estradiol	Amethyst (28)
levonorgestrel/ethinyl estradiol	Aubra
levonorgestrel/ethinyl estradiol	Aubra EQ
levonorgestrel/ethinyl estradiol	Aviane
levonorgestrel/ethinyl estradiol	Ayuna
levonorgestrel/ethinyl estradiol	Chateal (28)
levonorgestrel/ethinyl estradiol	Chateal EQ (28)
levonorgestrel/ethinyl estradiol	Delyla (28)
levonorgestrel/ethinyl estradiol	Dolishale
levonorgestrel/ethinyl estradiol	Enpresse
levonorgestrel/ethinyl estradiol	Falmina (28)
levonorgestrel/ethinyl estradiol	Iclevia

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
levonorgestrel/ethinyl estradiol	Introvale
levonorgestrel/ethinyl estradiol	Jolessa
levonorgestrel/ethinyl estradiol	Kurvelo (28)
levonorgestrel/ethinyl estradiol	Larissia
levonorgestrel/ethinyl estradiol	Lessina
levonorgestrel/ethinyl estradiol	Levonest (28)
levonorgestrel/ethinyl estradiol	Levora 0.15/30 (28)
levonorgestrel/ethinyl estradiol	Levora-28
levonorgestrel/ethinyl estradiol	Lillow (28)
levonorgestrel/ethinyl estradiol	Lutera (28)
levonorgestrel/ethinyl estradiol	Lybrel (28)
levonorgestrel/ethinyl estradiol	Marlissa (28)
levonorgestrel/ethinyl estradiol	Myzilra
levonorgestrel/ethinyl estradiol	Nordette (28)
levonorgestrel/ethinyl estradiol	Orsythia
levonorgestrel/ethinyl estradiol	Portia 28
levonorgestrel/ethinyl estradiol	Quasense
levonorgestrel/ethinyl estradiol	Seasonale (91)
levonorgestrel/ethinyl estradiol	Setlakin
levonorgestrel/ethinyl estradiol	Sronyx
levonorgestrel/ethinyl estradiol	Trivora (28)
levonorgestrel/ethinyl estradiol	Tyblume
levonorgestrel/ethinyl estradiol	Vienva
levonorgestrel/ethinyl estradiol	levonorg-eth estrad triphasic
levonorgestrel/ethinyl estradiol	levonorgestrel-ethinyl estrad
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Amethia
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Amethia Lo
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Ashlyna
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Camrese
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Camrese Lo
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Daysee
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Fayosim
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Jaimiess
levonorgestrel/ethinyl estradiol and ethinyl estradiol	L norgest/e.estradiol-e.estrad
levonorgestrel/ethinyl estradiol and ethinyl estradiol	LoJaimiess
levonorgestrel/ethinyl estradiol and ethinyl estradiol	LoSeasonique
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Quartette
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Rivelsa
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Seasonique
levonorgestrel/ethinyl estradiol and ethinyl estradiol	Simpesse
levonorgestrel/ethinyl estradiol/ferrous bisglycinate	Balcoltra
norethindrone acetate-ethinyl estradiol	Aurovela 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Aurovela 1/20 (21)
norethindrone acetate-ethinyl estradiol	Femhrt 1/5
norethindrone acetate-ethinyl estradiol	Femhrt Low Dose
norethindrone acetate-ethinyl estradiol	Fyavolv
norethindrone acetate-ethinyl estradiol	Gildess 1.5/30 (21)

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
norethindrone acetate-ethinyl estradiol	Gildess 1/20 (21)
norethindrone acetate-ethinyl estradiol	Hailey
norethindrone acetate-ethinyl estradiol	Jevantique
norethindrone acetate-ethinyl estradiol	Jevantique Lo
norethindrone acetate-ethinyl estradiol	Jinteli
norethindrone acetate-ethinyl estradiol	Junel 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Junel 1/20 (21)
norethindrone acetate-ethinyl estradiol	Larin 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Larin 1/20 (21)
norethindrone acetate-ethinyl estradiol	Loestrin 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Loestrin 1/20 (21)
norethindrone acetate-ethinyl estradiol	Microgestin 1.5/30 (21)
norethindrone acetate-ethinyl estradiol	Microgestin 1/20 (21)
norethindrone acetate-ethinyl estradiol	norethindrone ac-eth estradiol
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Aurovela 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Aurovela Fe 1-20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Aurovela Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Blisovi 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Blisovi Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Blisovi Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Charlotte 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Estrostep Fe-28
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Finzala
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gemmily
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gildess 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gildess FE 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Gildess FE 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Hailey 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Hailey Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Hailey Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Junel FE 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Junel FE 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Junel Fe 24
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Larin 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Larin Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Larin Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Lo Loestrin Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Lo Minastrin Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Loestrin 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Loestrin Fe 1.5/30 (28-Day)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Loestrin Fe 1/20 (28-Day)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Lomedia 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Melodetta 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Merzee
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Mibelas 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Microgestin 24 FE
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Microgestin FE 1/20 (28)

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Microgestin Fe 1.5/30 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Minastrin 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tarina 24 Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tarina Fe 1-20 EQ (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tarina Fe 1/20 (28)
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Taysofy
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Taytulla
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tilia Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	Tri-Legest Fe
norethindrone acetate-ethinyl estradiol/ferrous fumarate	norethindrone-e.estradiol-iron
norethindrone-ethinyl estradiol	Alyacen 1/35 (28)
norethindrone-ethinyl estradiol	Alyacen 7/7/7 (28)
norethindrone-ethinyl estradiol	Aranelle (28)
norethindrone-ethinyl estradiol	Balziva (28)
norethindrone-ethinyl estradiol	Brevicon (28)
norethindrone-ethinyl estradiol	Briellyn
norethindrone-ethinyl estradiol	Cyclafem 1/35 (28)
norethindrone-ethinyl estradiol	Cyclafem 7/7/7 (28)
norethindrone-ethinyl estradiol	Dasetta 1/35 (28)
norethindrone-ethinyl estradiol	Dasetta 7/7/7 (28)
norethindrone-ethinyl estradiol	Gildagia
norethindrone-ethinyl estradiol	Leena 28
norethindrone-ethinyl estradiol	Modicon (28)
norethindrone-ethinyl estradiol	Necon 0.5/35 (28)
norethindrone-ethinyl estradiol	Necon 1/35 (28)
norethindrone-ethinyl estradiol	Necon 10/11 (28)
norethindrone-ethinyl estradiol	Necon 7/7/7 (28)
norethindrone-ethinyl estradiol	Norinyl 1/35 (28)
norethindrone-ethinyl estradiol	Nortrel 0.5/35 (28)
norethindrone-ethinyl estradiol	Nortrel 1/35 (21)
norethindrone-ethinyl estradiol	Nortrel 1/35 (28)
norethindrone-ethinyl estradiol	Nortrel 7/7/7 (28)
norethindrone-ethinyl estradiol	Nylia 1/35 (28)
norethindrone-ethinyl estradiol	Nylia 7/7/7 (28)
norethindrone-ethinyl estradiol	Ortho-Novum 1/35 (28)
norethindrone-ethinyl estradiol	Ortho-Novum 7/7/7 (21)
norethindrone-ethinyl estradiol	Ortho-Novum 7/7/7 (28)
norethindrone-ethinyl estradiol	Ovcon-35 (28)
norethindrone-ethinyl estradiol	Ovcon-50 (28)
norethindrone-ethinyl estradiol	Philith
norethindrone-ethinyl estradiol	Pirmella
norethindrone-ethinyl estradiol	Tri-Norinyl (28)
norethindrone-ethinyl estradiol	Vyfemla (28)
norethindrone-ethinyl estradiol	Wera (28)
norethindrone-ethinyl estradiol	Zenchent (28)
norethindrone-ethinyl estradiol/ferrous fumarate	Femcon Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Generess Fe

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
norethindrone-ethinyl estradiol/ferrous fumarate	Kaitlib Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Layolis Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Wymzya Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Zenchent Fe
norethindrone-ethinyl estradiol/ferrous fumarate	Zeosa
norethindrone-ethinyl estradiol/ferrous fumarate	noreth-ethinyl estradiol-iron
norethindrone-mestranol	Necon 1/50 (28)
norethindrone-mestranol	Norinyl 1+50 (28)
norgestimate-ethinyl estradiol	Estarylla
norgestimate-ethinyl estradiol	Femynor
norgestimate-ethinyl estradiol	Mili
norgestimate-ethinyl estradiol	Mono-Linyah
norgestimate-ethinyl estradiol	Mononessa (28)
norgestimate-ethinyl estradiol	Nymyo
norgestimate-ethinyl estradiol	Ortho Tri-Cyclen (28)
norgestimate-ethinyl estradiol	Ortho Tri-Cyclen LO (28)
norgestimate-ethinyl estradiol	Ortho-Cyclen (28)
norgestimate-ethinyl estradiol	Previfem
norgestimate-ethinyl estradiol	Sprintec (28)
norgestimate-ethinyl estradiol	Tri Femynor
norgestimate-ethinyl estradiol	Tri-Estarylla
norgestimate-ethinyl estradiol	Tri-Linyah
norgestimate-ethinyl estradiol	Tri-Lo-Estarylla
norgestimate-ethinyl estradiol	Tri-Lo-Marzia
norgestimate-ethinyl estradiol	Tri-Lo-Mili
norgestimate-ethinyl estradiol	Tri-Lo-Sprintec
norgestimate-ethinyl estradiol	Tri-Mili
norgestimate-ethinyl estradiol	Tri-Nymyo
norgestimate-ethinyl estradiol	Tri-Previfem (28)
norgestimate-ethinyl estradiol	Tri-Sprintec (28)
norgestimate-ethinyl estradiol	Tri-VyLibra
norgestimate-ethinyl estradiol	Tri-VyLibra Lo
norgestimate-ethinyl estradiol	TriNessa (28)
norgestimate-ethinyl estradiol	TriNessa Lo
norgestimate-ethinyl estradiol	VyLibra
norgestimate-ethinyl estradiol	norgestimate-ethinyl estradiol
norgestrel-ethinyl estradiol	Cryselle (28)
norgestrel-ethinyl estradiol	Elinest
norgestrel-ethinyl estradiol	Lo-Ovral (28)
norgestrel-ethinyl estradiol	Lo-Ovral (8)
norgestrel-ethinyl estradiol	Low-Ogestrel (28)
norgestrel-ethinyl estradiol	Ogestrel (28)
norgestrel-ethinyl estradiol	norgestrel-ethinyl estradiol
Combined Hormonal Contraceptives - Ring	
etonogestrel/ethinyl estradiol	EluRyng
etonogestrel/ethinyl estradiol	Haloette
etonogestrel/ethinyl estradiol	NuvaRing

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
etonogestrel/ethinyl estradiol	etonogestrel-ethinyl estradiol
segesterone acetate/ethinyl estradiol	Annovera
Combined Hormonal Contraceptives - Patch	
levonorgestrel/ethinyl estradiol	Twirla
norelgestromin/ethinyl estradiol	Ortho Evra
norelgestromin/ethinyl estradiol	Xulane
norelgestromin/ethinyl estradiol	Zafemy
Progestin-only contraceptives	
drospirenone	Slynd
levonorgestrel	After Pill
levonorgestrel	Aftera
levonorgestrel	EContra EZ
levonorgestrel	Econtra One-Step
levonorgestrel	Fallback Solo
levonorgestrel	Her Style
levonorgestrel	Kyleena
levonorgestrel	Liletta
levonorgestrel	Mirena
levonorgestrel	My Choice
levonorgestrel	My Way
levonorgestrel	New Day
levonorgestrel	Next Choice
levonorgestrel	Next Choice One Dose
levonorgestrel	Opcicon One-Step
levonorgestrel	Option-2
levonorgestrel	Plan B One-Step
levonorgestrel	React
levonorgestrel	Skyla
levonorgestrel	Take Action
levonorgestrel	levonorgestrel
medroxyprogesterone acetate	
medroxyprogesterone acetate	Depo-Provera
medroxyprogesterone acetate	Depo-SubQ provera 104
medroxyprogesterone acetate	medroxyprogesterone
norethindrone	Camila
norethindrone	Deblitane
norethindrone	Errin
norethindrone	Heather
norethindrone	Incassia
norethindrone	Jencycla
norethindrone	Jolivette
norethindrone	Lyleq
norethindrone	Lyza
norethindrone	Nor-Q-D
norethindrone	Nora-BE
norethindrone	Norlyda
norethindrone	Norlyroc

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
norethindrone	Ortho Micronor
norethindrone	Sharobel
norethindrone	Tulana
norethindrone	norethindrone (contraceptive)
Progestin-only contraceptives - Oral	
drospirenone	Slynd
levonorgestrel	After Pill
levonorgestrel	Aftera
levonorgestrel	EContra EZ
levonorgestrel	Econtra One-Step
levonorgestrel	Fallback Solo
levonorgestrel	Her Style
levonorgestrel	My Choice
levonorgestrel	My Way
levonorgestrel	New Day
levonorgestrel	Next Choice
levonorgestrel	Next Choice One Dose
levonorgestrel	Opcicon One-Step
levonorgestrel	Option-2
levonorgestrel	Plan B One-Step
levonorgestrel	React
levonorgestrel	Take Action
levonorgestrel	levonorgestrel
norethindrone	Camila
norethindrone	Deblitane
norethindrone	Errin
norethindrone	Heather
norethindrone	Incassia
norethindrone	Jencycla
norethindrone	Jolivette
norethindrone	Lyleq
norethindrone	Lyza
norethindrone	Nor-Q-D
norethindrone	Nora-BE
norethindrone	Norlyda
norethindrone	Norlyroc
norethindrone	Ortho Micronor
norethindrone	Sharobel
norethindrone	Tulana
norethindrone	norethindrone (contraceptive)
Progestin-only contraceptives - Intrauterine Device	
levonorgestrel	Kyleena
levonorgestrel	Liletta
levonorgestrel	Mirena
levonorgestrel	Skyla
Progestin-only contraceptives - DMPA	
medroxyprogesterone acetate	

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Hormonal Contraceptive Exposures in this Request

Generic Name	Brand Name
Drosperinone	
drospirenone	Slynd

Appendix D. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Used to Define Hormonal Contraceptive Exposures in this Request

Code	Description	Code Category	Code Type
	Progestin-only contraceptives		
A4260	Levonorgestrel (contraceptive) implants system, including implants and supplies	Procedure	HCPCS
J1055	Injection, medroxyprogesterone acetate for contraceptive use, 150 mg	Procedure	HCPCS
J7296	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg	Procedure	HCPCS
J7297	Levonorgestrel-releasing intrauterine contraceptive system (Liletta), 52 mg	Procedure	HCPCS
J7298	Levonorgestrel-releasing intrauterine contraceptive system (Mirena), 52 mg	Procedure	HCPCS
J7301	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg	Procedure	HCPCS
J7302	Levonorgestrel-releasing intrauterine contraceptive system, 52 mg	Procedure	HCPCS
J7306	Levonorgestrel (contraceptive) implant system, including implants and supplies	Procedure	HCPCS
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	Procedure	HCPCS
Q0090	Levonorgestrel-releasing intrauterine contraceptive system, (Skyla), 13.5 mg	Procedure	HCPCS
Q9984	Levonorgestrel-releasing intrauterine contraceptive system (Kyleena), 19.5 mg	Procedure	HCPCS
S0180	Etonogestrel (contraceptive) implant system, including implant and supplies	Procedure	HCPCS
S4980	Levonorgestrel - releasing intrauterine system, each	Procedure	HCPCS
S4981	Insertion of levonorgestrel-releasing intrauterine system	Procedure	HCPCS
V25.5	Insertion of implantable subdermal contraceptive	Diagnosis	ICD-9-CM
	Progestin-only contraceptives - Intrauterine Device		
A4260	Levonorgestrel (contraceptive) implants system, including implants and supplies	Procedure	HCPCS
J7296	Levonorgestrel-releasing intrauterine contraceptive system, (Kyleena), 19.5 mg	Procedure	HCPCS
J7297	Levonorgestrel-releasing intrauterine contraceptive system (Liletta), 52 mg	Procedure	HCPCS
J7298	Levonorgestrel-releasing intrauterine contraceptive system (Mirena), 52 mg	Procedure	HCPCS
J7301	Levonorgestrel-releasing intrauterine contraceptive system (Skyla), 13.5 mg	Procedure	HCPCS
J7302	Levonorgestrel-releasing intrauterine contraceptive system, 52 mg	Procedure	HCPCS
J7306	Levonorgestrel (contraceptive) implant system, including implants and supplies	Procedure	HCPCS
Q0090	Levonorgestrel-releasing intrauterine contraceptive system, (Skyla), 13.5 mg	Procedure	HCPCS
Q9984	Levonorgestrel-releasing intrauterine contraceptive system (Kyleena), 19.5 mg	Procedure	HCPCS
S4980	Levonorgestrel - releasing intrauterine system, each	Procedure	HCPCS
S4981	Insertion of levonorgestrel-releasing intrauterine system	Procedure	HCPCS
	Progestin-only contraceptives - Implant		
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	Procedure	HCPCS
S0180	Etonogestrel (contraceptive) implant system, including implant and supplies	Procedure	HCPCS
V25.5	Insertion of implantable subdermal contraceptive	Diagnosis	ICD-9-CM
	Progestin-only contraceptives - DMPA		
J1055	Injection, medroxyprogesterone acetate for contraceptive use, 150 mg	Procedure	HCPCS

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
	Live Single Birth		
V270	Outcome of delivery, single liveborn	Diagnosis	ICD-9-CM
V30	Single liveborn	Diagnosis	ICD-9-CM
V300	Single liveborn, born in hospital	Diagnosis	ICD-9-CM
V3000	Single liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3001	Single liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V301	Single liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V302	Single liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
Z370	Single live birth	Diagnosis	ICD-10-CM
Z3800	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3801	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z381	Single liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z382	Single liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
	Live Multiple Births		
65101	Twin pregnancy, delivered	Diagnosis	ICD-9-CM
65111	Triplet pregnancy, delivered	Diagnosis	ICD-9-CM
65121	Quadruplet pregnancy, delivered	Diagnosis	ICD-9-CM
66051	Locked twins, delivered	Diagnosis	ICD-9-CM
66231	Delayed delivery of second twin, triplet, etc., delivered	Diagnosis	ICD-9-CM
67811	Fetal conjoined twins, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
O6012X1	Preterm labor second trimester with preterm delivery second trimester, fetus 1	Diagnosis	ICD-10-CM
O6012X2	Preterm labor second trimester with preterm delivery second trimester, fetus 2	Diagnosis	ICD-10-CM
O6012X3	Preterm labor second trimester with preterm delivery second trimester, fetus 3	Diagnosis	ICD-10-CM
O6012X4	Preterm labor second trimester with preterm delivery second trimester, fetus 4	Diagnosis	ICD-10-CM
O6012X5	Preterm labor second trimester with preterm delivery second trimester, fetus 5	Diagnosis	ICD-10-CM
O6012X9	Preterm labor second trimester with preterm delivery second trimester, other fetus	Diagnosis	ICD-10-CM
O6013X0	Preterm labor second trimester with preterm delivery third trimester, not applicable or unspecified	Diagnosis	ICD-10-CM
O6013X1	Preterm labor second trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O6013X2	Preterm labor second trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM
O6013X3	Preterm labor second trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O6013X4	Preterm labor second trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O6013X5	Preterm labor second trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O6013X9	Preterm labor second trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O6014X1	Preterm labor third trimester with preterm delivery third trimester, fetus 1	Diagnosis	ICD-10-CM
O6014X2	Preterm labor third trimester with preterm delivery third trimester, fetus 2	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O6014X3	Preterm labor third trimester with preterm delivery third trimester, fetus 3	Diagnosis	ICD-10-CM
O6014X4	Preterm labor third trimester with preterm delivery third trimester, fetus 4	Diagnosis	ICD-10-CM
O6014X5	Preterm labor third trimester with preterm delivery third trimester, fetus 5	Diagnosis	ICD-10-CM
O6014X9	Preterm labor third trimester with preterm delivery third trimester, other fetus	Diagnosis	ICD-10-CM
O6022X1	Term delivery with preterm labor, second trimester, fetus 1	Diagnosis	ICD-10-CM
O6022X2	Term delivery with preterm labor, second trimester, fetus 2	Diagnosis	ICD-10-CM
O6022X3	Term delivery with preterm labor, second trimester, fetus 3	Diagnosis	ICD-10-CM
O6022X4	Term delivery with preterm labor, second trimester, fetus 4	Diagnosis	ICD-10-CM
O6022X5	Term delivery with preterm labor, second trimester, fetus 5	Diagnosis	ICD-10-CM
O6022X9	Term delivery with preterm labor, second trimester, other fetus	Diagnosis	ICD-10-CM
O6023X1	Term delivery with preterm labor, third trimester, fetus 1	Diagnosis	ICD-10-CM
O6023X2	Term delivery with preterm labor, third trimester, fetus 2	Diagnosis	ICD-10-CM
O6023X3	Term delivery with preterm labor, third trimester, fetus 3	Diagnosis	ICD-10-CM
O6023X4	Term delivery with preterm labor, third trimester, fetus 4	Diagnosis	ICD-10-CM
O6023X5	Term delivery with preterm labor, third trimester, fetus 5	Diagnosis	ICD-10-CM
O6023X9	Term delivery with preterm labor, third trimester, other fetus	Diagnosis	ICD-10-CM
O632	Delayed delivery of second twin, triplet, etc	Diagnosis	ICD-10-CM
O690XX1	Labor and delivery complicated by prolapse of cord, fetus 1	Diagnosis	ICD-10-CM
O690XX2	Labor and delivery complicated by prolapse of cord, fetus 2	Diagnosis	ICD-10-CM
O690XX3	Labor and delivery complicated by prolapse of cord, fetus 3	Diagnosis	ICD-10-CM
O690XX4	Labor and delivery complicated by prolapse of cord, fetus 4	Diagnosis	ICD-10-CM
O690XX5	Labor and delivery complicated by prolapse of cord, fetus 5	Diagnosis	ICD-10-CM
O690XX9	Labor and delivery complicated by prolapse of cord, other fetus	Diagnosis	ICD-10-CM
O691XX1	Labor and delivery complicated by cord around neck, with compression, fetus 1	Diagnosis	ICD-10-CM
O691XX2	Labor and delivery complicated by cord around neck, with compression, fetus 2	Diagnosis	ICD-10-CM
O691XX3	Labor and delivery complicated by cord around neck, with compression, fetus 3	Diagnosis	ICD-10-CM
O691XX4	Labor and delivery complicated by cord around neck, with compression, fetus 4	Diagnosis	ICD-10-CM
O691XX5	Labor and delivery complicated by cord around neck, with compression, fetus 5	Diagnosis	ICD-10-CM
O691XX9	Labor and delivery complicated by cord around neck, with compression, other fetus	Diagnosis	ICD-10-CM
O692XX1	Labor and delivery complicated by other cord entanglement, with compression, fetus 1	Diagnosis	ICD-10-CM
O692XX2	Labor and delivery complicated by other cord entanglement, with compression, fetus 2	Diagnosis	ICD-10-CM
O692XX3	Labor and delivery complicated by other cord entanglement, with compression, fetus 3	Diagnosis	ICD-10-CM
O692XX4	Labor and delivery complicated by other cord entanglement, with compression, fetus 4	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O692XX5	Labor and delivery complicated by other cord entanglement, with compression, fetus 5	Diagnosis	ICD-10-CM
O692XX9	Labor and delivery complicated by other cord entanglement, with compression, other fetus	Diagnosis	ICD-10-CM
O693XX1	Labor and delivery complicated by short cord, fetus 1	Diagnosis	ICD-10-CM
O693XX2	Labor and delivery complicated by short cord, fetus 2	Diagnosis	ICD-10-CM
O693XX3	Labor and delivery complicated by short cord, fetus 3	Diagnosis	ICD-10-CM
O693XX4	Labor and delivery complicated by short cord, fetus 4	Diagnosis	ICD-10-CM
O693XX5	Labor and delivery complicated by short cord, fetus 5	Diagnosis	ICD-10-CM
O693XX9	Labor and delivery complicated by short cord, other fetus	Diagnosis	ICD-10-CM
O694XX1	Labor and delivery complicated by vasa previa, fetus 1	Diagnosis	ICD-10-CM
O694XX2	Labor and delivery complicated by vasa previa, fetus 2	Diagnosis	ICD-10-CM
O694XX3	Labor and delivery complicated by vasa previa, fetus 3	Diagnosis	ICD-10-CM
O694XX4	Labor and delivery complicated by vasa previa, fetus 4	Diagnosis	ICD-10-CM
O694XX5	Labor and delivery complicated by vasa previa, fetus 5	Diagnosis	ICD-10-CM
O694XX9	Labor and delivery complicated by vasa previa, other fetus	Diagnosis	ICD-10-CM
O695XX1	Labor and delivery complicated by vascular lesion of cord, fetus 1	Diagnosis	ICD-10-CM
O695XX2	Labor and delivery complicated by vascular lesion of cord, fetus 2	Diagnosis	ICD-10-CM
O695XX3	Labor and delivery complicated by vascular lesion of cord, fetus 3	Diagnosis	ICD-10-CM
O695XX4	Labor and delivery complicated by vascular lesion of cord, fetus 4	Diagnosis	ICD-10-CM
O695XX5	Labor and delivery complicated by vascular lesion of cord, fetus 5	Diagnosis	ICD-10-CM
O695XX9	Labor and delivery complicated by vascular lesion of cord, other fetus	Diagnosis	ICD-10-CM
O6981X2	Labor and delivery complicated by cord around neck, without compression, fetus 2	Diagnosis	ICD-10-CM
O6981X3	Labor and delivery complicated by cord around neck, without compression, fetus 3	Diagnosis	ICD-10-CM
O6981X4	Labor and delivery complicated by cord around neck, without compression, fetus 4	Diagnosis	ICD-10-CM
O6981X5	Labor and delivery complicated by cord around neck, without compression, fetus 5	Diagnosis	ICD-10-CM
O6981X9	Labor and delivery complicated by cord around neck, without compression, other fetus	Diagnosis	ICD-10-CM
O6982X1	Labor and delivery complicated by other cord entanglement, without compression, fetus 1	Diagnosis	ICD-10-CM
O6982X2	Labor and delivery complicated by other cord entanglement, without compression, fetus 2	Diagnosis	ICD-10-CM
O6982X3	Labor and delivery complicated by other cord entanglement, without compression, fetus 3	Diagnosis	ICD-10-CM
O6982X4	Labor and delivery complicated by other cord entanglement, without compression, fetus 4	Diagnosis	ICD-10-CM
O6982X5	Labor and delivery complicated by other cord entanglement, without compression, fetus 5	Diagnosis	ICD-10-CM
O6982X9	Labor and delivery complicated by other cord entanglement, without compression, other fetus	Diagnosis	ICD-10-CM
O6989X1	Labor and delivery complicated by other cord complications, fetus 1	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O6989X2	Labor and delivery complicated by other cord complications, fetus 2	Diagnosis	ICD-10-CM
O6989X3	Labor and delivery complicated by other cord complications, fetus 3	Diagnosis	ICD-10-CM
O6989X4	Labor and delivery complicated by other cord complications, fetus 4	Diagnosis	ICD-10-CM
O6989X5	Labor and delivery complicated by other cord complications, fetus 5	Diagnosis	ICD-10-CM
O6989X9	Labor and delivery complicated by other cord complications, other fetus	Diagnosis	ICD-10-CM
O699XX1	Labor and delivery complicated by cord complication, unspecified, fetus 1	Diagnosis	ICD-10-CM
O699XX2	Labor and delivery complicated by cord complication, unspecified, fetus 2	Diagnosis	ICD-10-CM
O699XX3	Labor and delivery complicated by cord complication, unspecified, fetus 3	Diagnosis	ICD-10-CM
O699XX4	Labor and delivery complicated by cord complication, unspecified, fetus 4	Diagnosis	ICD-10-CM
O699XX5	Labor and delivery complicated by cord complication, unspecified, fetus 5	Diagnosis	ICD-10-CM
O699XX9	Labor and delivery complicated by cord complication, unspecified, other fetus	Diagnosis	ICD-10-CM
V272	Outcome of delivery, twins, both liveborn	Diagnosis	ICD-9-CM
V275	Outcome of delivery, other multiple birth, all liveborn	Diagnosis	ICD-9-CM
V330	Twin, unspecified, born in hospital	Diagnosis	ICD-9-CM
V34	Other multiple birth (three or more), mates all liveborn	Diagnosis	ICD-9-CM
V340	Other multiple, mates all liveborn, born in hospital	Diagnosis	ICD-9-CM
V3400	Other multiple, mates all liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3401	Other multiple, mates all liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V341	Other multiple birth (three or more), mates all liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V342	Other multiple birth (three or more), mates all liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
Z372	Twins, both liveborn	Diagnosis	ICD-10-CM
Z3750	Multiple births, unspecified, all liveborn	Diagnosis	ICD-10-CM
Z3751	Triplets, all liveborn	Diagnosis	ICD-10-CM
Z3752	Quadruplets, all liveborn	Diagnosis	ICD-10-CM
Z3753	Quintuplets, all liveborn	Diagnosis	ICD-10-CM
Z3754	Sextuplets, all liveborn	Diagnosis	ICD-10-CM
Z3759	Other multiple births, all liveborn	Diagnosis	ICD-10-CM
Z3830	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3831	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z384	Twin liveborn infant, born outside hospital	Diagnosis	ICD-10-CM
Z385	Twin liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
Z3861	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3862	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3863	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3864	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3865	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3866	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3868	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3869	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z387	Other multiple liveborn infant, born outside hospital	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z388	Other multiple liveborn infant, unspecified as to place of birth	Diagnosis	ICD-10-CM
	Stillbirth - Single		
64601	PAPYRACEOUS FETUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND	Diagnosis	ICD-9-CM
65641	Intrauterine death, affecting management of mother, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
7680	Fetal death from asphyxia or anoxia before onset of labor or at unspecified time	Diagnosis	ICD-9-CM
7681	Fetal death from asphyxia or anoxia during labor	Diagnosis	ICD-9-CM
O36.4	Maternal care for intrauterine death	Diagnosis	ICD-10-CM
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified	Diagnosis	ICD-10-CM
P95	Stillbirth	Diagnosis	ICD-10-CM
V271	Outcome of delivery, single stillborn	Diagnosis	ICD-9-CM
Z37.1	Single stillbirth	Diagnosis	ICD-10-CM
	Stillbirth - Multiple		
O36.4XX1	Maternal care for intrauterine death, fetus 1	Diagnosis	ICD-10-CM
O36.4XX2	Maternal care for intrauterine death, fetus 2	Diagnosis	ICD-10-CM
O36.4XX3	Maternal care for intrauterine death, fetus 3	Diagnosis	ICD-10-CM
O36.4XX4	Maternal care for intrauterine death, fetus 4	Diagnosis	ICD-10-CM
O36.4XX5	Maternal care for intrauterine death, fetus 5	Diagnosis	ICD-10-CM
O36.4XX9	Maternal care for intrauterine death, other fetus	Diagnosis	ICD-10-CM
V274	Outcome of delivery, twins, both stillborn	Diagnosis	ICD-9-CM
V277	Outcome of delivery, other multiple birth, all stillborn	Diagnosis	ICD-9-CM
Z37.4	Twins, both stillborn	Diagnosis	ICD-10-CM
Z37.7	Other multiple births, all stillborn	Diagnosis	ICD-10-CM
	Multiple Birth - live and stillborn		
65131	Twin pregnancy with fetal loss and retention of one fetus, delivered	Diagnosis	ICD-9-CM
65141	Triplet pregnancy with fetal loss and retention of one or more, delivered	Diagnosis	ICD-9-CM
65151	Quadruplet pregnancy with fetal loss and retention of one or more, delivered	Diagnosis	ICD-9-CM
65161	Other multiple pregnancy with fetal loss and retention of one or more fetus(es), delivered	Diagnosis	ICD-9-CM
65171	Multiple gestation following (elective) fetal reduction, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
65181	Other specified multiple gestation, delivered	Diagnosis	ICD-9-CM
65191	Unspecified multiple gestation, delivered	Diagnosis	ICD-9-CM
65261	Multiple gestation with malpresentation of one fetus or more, delivered	Diagnosis	ICD-9-CM
V273	Outcome of delivery, twins, one liveborn and one stillborn	Diagnosis	ICD-9-CM
V276	Outcome of delivery, other multiple birth, some liveborn	Diagnosis	ICD-9-CM
V31	Twin birth, mate liveborn	Diagnosis	ICD-9-CM
V310	Twin, mate liveborn, born in hospital	Diagnosis	ICD-9-CM
V3100	Twin, mate liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3101	Twin, mate liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
V311	Twin birth, mate liveborn, born before admission to hospital	Diagnosis	ICD-9-CM
V312	Twin birth, mate liveborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V32	Twin birth, mate stillborn	Diagnosis	ICD-9-CM
V320	Twin, mate stillborn, born in hospital	Diagnosis	ICD-9-CM
V3200	Twin, mate stillborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3201	Twin, mate stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V321	Twin birth, mate stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V322	Twin birth, mate stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V33	Twin birth, unspecified whether mate liveborn or stillborn	Diagnosis	ICD-9-CM
V3300	Twin, unspecified whether mate stillborn or liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3301	Twin, unspecified whether mate stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V331	Twin birth, unspecified whether mate liveborn or stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V332	Twin birth, unspecified whether mate liveborn or stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V35	Other multiple birth (three or more), mates all stillborn	Diagnosis	ICD-9-CM
V350	Other multiple, mates all stillborn, born in hospital	Diagnosis	ICD-9-CM
V3500	Other multiple birth (three or more), mates all still born, born in hospital, delivered without mention of cesarean section	Diagnosis	ICD-9-CM
V3501	Other multiple birth (three or more), mates all still born, born in hospital, delivered by cesarean section	Diagnosis	ICD-9-CM
V351	Other multiple birth (three or more), mates all stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V352	Other multiple birth (three or more), mates all stillborn, born outside of hospital and not hospitalized	Diagnosis	ICD-9-CM
V36	Other multiple birth (three or more), mates liveborn and stillborn	Diagnosis	ICD-9-CM
V360	Other multiple, mates liveborn and stillborn, born in hospital	Diagnosis	ICD-9-CM
V3600	Other multiple, mates liveborn and stillborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM
V3601	Other multiple, mates liveborn and stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V361	Other multiple birth (three or more), mates liveborn and stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V362	Other multiple birth (three or more), mates liveborn and stillborn, born outside hospital and not hospitalized	Diagnosis	ICD-9-CM
V37	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn	Diagnosis	ICD-9-CM
V370	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital	Diagnosis	ICD-9-CM
V3700	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital, delivered without mention of cesarean delivery	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
V3701	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V371	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born before admission to hospital	Diagnosis	ICD-9-CM
V372	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born outside of hospital	Diagnosis	ICD-9-CM
Z37.3	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z373	Twins, one liveborn and one stillborn	Diagnosis	ICD-10-CM
Z3760	Multiple births, unspecified, some liveborn	Diagnosis	ICD-10-CM
Z3761	Triplets, some liveborn	Diagnosis	ICD-10-CM
Z3762	Quadruplets, some liveborn	Diagnosis	ICD-10-CM
Z3763	Quintuplets, some liveborn	Diagnosis	ICD-10-CM
Z3764	Sextuplets, some liveborn	Diagnosis	ICD-10-CM
Z3769	Other multiple births, some liveborn	Diagnosis	ICD-10-CM
	Cesarean Section		
59500	Cesarean Section, Low Cervical, Including In-hospital	Procedure	CPT-4
59501	Cesarean Section, Low Cervical, Including In-hospital	Procedure	CPT-4
59510	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care	Procedure	CPT-4
59514	Cesarean delivery only;	Procedure	CPT-4
59515	Cesarean delivery only; including postpartum care	Procedure	CPT-4
59540	Cesarean Section, Extraperitoneal, Including In-hospital	Procedure	CPT-4
59541	Cesarean Section, Extraperitoneal, Including In-hospital	Procedure	CPT-4
59560	Cesarean Section With Hysterectomy, Subtotal, Including	Procedure	CPT-4
59561	Cesarean Section With Hysterectomy, Subtotal, Including	Procedure	CPT-4
59580	Cesarean Section With Hysterectomy, Total, Including	Procedure	CPT-4
59581	Cesarean Section With Hysterectomy, Total, Including	Procedure	CPT-4
59620	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery;	Procedure	CPT-4
59622	Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery; including postpartum care	Procedure	CPT-4
64981	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
64982	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66971	Cesarean delivery, without mention of indication, delivered, with or without mention of antepartum condition	Diagnosis	ICD-9-CM
67412	Disruption of cesarean wound, with delivery, with mention of postpartum complication	Diagnosis	ICD-9-CM
740	Classical cesarean section	Procedure	ICD-9-CM
741	Low cervical cesarean section	Procedure	ICD-9-CM
742	Extraperitoneal cesarean section	Procedure	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
744	Cesarean section of other specified type	Procedure	ICD-9-CM
749	Cesarean section of unspecified type	Procedure	ICD-9-CM
7499	Other cesarean section of unspecified type	Procedure	ICD-9-CM
7634	Fetus or newborn affected by cesarean delivery	Diagnosis	ICD-9-CM
O7582	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section	Diagnosis	ICD-10-CM
O82	Encounter for cesarean delivery without indication	Diagnosis	ICD-10-CM
P034	Newborn affected by Cesarean delivery	Diagnosis	ICD-10-CM
V3001	Single liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V3101	Twin, mate liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V3201	Twin, mate stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V3301	Twin, unspecified whether mate stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V3401	Other multiple, mates all liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V3501	Other multiple birth (three or more), mates all still born, born in hospital, delivered by cesarean section	Diagnosis	ICD-9-CM
V3601	Other multiple, mates liveborn and stillborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V3701	Other multiple, unspecified whether mates stillborn or liveborn, born in hospital, delivered by cesarean delivery	Diagnosis	ICD-9-CM
V3901	Liveborn infant, unspecified whether single, twin, or multiple, born in hospital, delivered by cesarean	Diagnosis	ICD-9-CM
Z3801	Single liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3831	Twin liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3862	Triplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3864	Quadruplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3866	Quintuplet liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
Z3869	Other multiple liveborn infant, delivered by cesarean	Diagnosis	ICD-10-CM
	Removal of Implanted Contraceptive		
11976	Removal, implantable contraceptive capsules	Procedure	CPT-4
11982	Removal, non-biodegradable drug delivery implant	Procedure	CPT-4
58301	Removal of IUD	Procedure	CPT-4
	Vaginal Delivery		
59400	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care	Procedure	CPT-4
59409	Vaginal delivery only (with or without episiotomy and/or forceps);	Procedure	CPT-4
59410	Vaginal delivery only (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59610	Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery	Procedure	CPT-4
59612	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps);	Procedure	CPT-4

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
59614	Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps); including postpartum care	Procedure	CPT-4
59618	Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery	Procedure	CPT-4
65471	Congenital or acquired abnormality of vagina, with delivery	Diagnosis	ICD-9-CM
65472	Congenital or acquired abnormality of vagina, delivered, with mention of postpartum complication	Diagnosis	ICD-9-CM
66541	High vaginal laceration, with delivery	Diagnosis	ICD-9-CM
Z3800	Single liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3830	Twin liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3861	Triplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3863	Quadruplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3865	Quintuplet liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM
Z3868	Other multiple liveborn infant, delivered vaginally	Diagnosis	ICD-10-CM

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool 12.1.0 to investigate the use of combined hormonal contraceptives among post partum patients in the Sentinel Distributed Database (SDD).

Query period: 1/1/2012 to 12/31/2023
Coverage requirement: *Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index requirement: 365
Post-episode requirement for Type 2 analyses: N/A
Enrollment gap: 45
Age groups: 18-24, 25-34, 35-45, 46+ years
Stratifications: N/A
Follow-up time output categorization: 1-7 days, 8 - 14, 15 - 21, etc. up to 365 days
Restrictions: N/A
Envelope macro: *Reclassify encounters during inpatient stay as inpatient
Distribution of index-defining codes: No
Never-exposed cohort: No
Freeze data: No

			Exposure						
Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Principal diagnosis position	Forced supply to attach to dispensings	Create Baseline Table?	Censor treatment episode at evidence of:	Follow-Up Time Categories:
1	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event;	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days

Appendix F. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Principal diagnosis position	Forced supply to attach to dispensings	Create Baseline Table?	Censor treatment episode at evidence of:	Follow-Up Time Categories:
2	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days
3	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days

Appendix F. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Principal diagnosis position	Forced supply to attach to dispensings	Create Baseline Table?	Censor treatment episode at evidence of:	Follow-Up Time Categories:
4	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days
5	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days

Appendix F. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Principal diagnosis position	Forced supply to attach to dispensings	Create Baseline Table?	Censor treatment episode at evidence of:	Follow-Up Time Categories:
6	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days
7	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days

Appendix F. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Principal diagnosis position	Forced supply to attach to dispensings	Create Baseline Table?	Censor treatment episode at evidence of:	Follow-Up Time Categories:
8	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days
9	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days

Appendix F. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Principal diagnosis position	Forced supply to attach to dispensings	Create Baseline Table?	Censor treatment episode at evidence of:	Follow-Up Time Categories:
10	Live Birth or stillbirth delivery	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	*Any	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event; *At occurance of any contraceptive other than index type	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days
11	combined hormonal contraceptives	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	N/A	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event;	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days

Appendix F. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Principal diagnosis position	Forced supply to attach to dispensings	Create Baseline Table?	Censor treatment episode at evidence of:	Follow-Up Time Categories:
12	Any Progestin-only contraceptives (POCs) -	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	N/A	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event;	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days
13	Progestin-only contraceptives (POCs) - DMPA only	*All valid exposure episodes during query period;	365	*Washout lookback period should search for only evidence of a dispensing date	N/A	N/A	*Yes	*Death; *DP end date; *Query end date; *Occurence of an exposure or event;	1-7 days, 8 - 14, 15 - 21, etc. up to 365 days

Appendix F. Specifications Defining Parameters for this Request

	Inclusion/Exclusion Criteria									
Scenario	Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Minimum Days Supplied	Forced supply to attach to dispensings
1										
2	Any CHC	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
3	Oral CHC	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A

Appendix F. Specifications Defining Parameters for this Request

	Inclusion/Exclusion Criteria									
Scenario	Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Minimum Days Supplied	Forced supply to attach to dispensings
4	Patch CHC	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
5	Ring CHC	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
6	Any POC dispensing	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
7	POC - DMPA	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A

Appendix F. Specifications Defining Parameters for this Request

	Inclusion/Exclusion Criteria									
Scenario	Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Minimum Days Supplied	Forced supply to attach to dispensings
8	POC - Oral	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
9	POC - IUD	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
10	POC - Implant	Inclusion	NA	NA	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Any Contraceptive	Exclusion	NA	NA	-365	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A

Appendix F. Specifications Defining Parameters for this Request

	Inclusion/Exclusion Criteria									
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care setting**	**Principal diagnosis position**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings**	**Number of instances the criteria should be found in evaluation period**	**Minimum Days Supplied**	**Forced supply to attach to dispensings**
11	Live Birth or stillbirth delivery	Inclusion	IP	Any	-42	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Live Birth or stillbirth delivery	Exlusion	Any	Any	0	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	any contraceptive post live or still birth delivery (**combo: CHCPOC_BIRTH**)	Inclusion	Any	Any	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
12	Live Birth or stillbirth delivery	Inclusion	IP	Any	-42	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Live Birth or stillbirth delivery	Exlusion	Any	Any	0	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	any contraceptive post live or still birth delivery (combo: CHCPOC_BIRTH)	Inclusion	Any	Any	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A

Appendix F. Specifications Defining Parameters for this Request

	Inclusion/Exclusion Criteria									
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care setting**	**Principal diagnosis position**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings**	**Number of instances the criteria should be found in evaluation period**	**Minimum Days Supplied**	**Forced supply to attach to dispensings**
13	Live Birth or stillbirth delivery	Inclusion	IP	Any	-42	-1	Yes - looking at dispensing date only, not days supply	1	1	N/A
	Live Birth or stillbirth delivery	Exlusion	Any	Any	0	365	Yes - looking at dispensing date only, not days supply	1	1	N/A
	any contraceptive post live or still birth delivery (combo: CHCPOC_BIRTH)	Inclusion	Any	Any	1	365	Yes - looking at dispensing date only, not days supply	1	1	N/A

Appendix F. Specifications Defining Parameters for this Request

	Event Outcome								
Scenario	Event	Incident event washout period	Care setting	Principal diagnosis position	Exclude evidence of days supply if event washout includes dispensings	Event de-duplication	Forced supply to attach to dispensings	Blackout period	Risk Window Interval Start
1	No outcome								
2	Any CHC	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1
3	Oral POC	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1
4	Patch CHC	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1
5	Ring CHC	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1

Appendix F. Specifications Defining Parameters for this Request

		Event Outcome							
Scenario	Event	Incident event washout period	Care setting	Principal diagnosis position	Exclude evidence of days supply if event washout includes dispensings	Event de-duplication	Forced supply to attach to dispensings	Blackout period	Risk Window Interval Start
6	Any POC	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1
7	DMPA	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1
8	Oral POC	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1
9	IUD	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1

Appendix F. Specifications Defining Parameters for this Request

		Event Outcome							
Scenario	Event	Incident event washout period	Care setting	Principal diagnosis position	Exclude evidence of days supply if event washout includes dispensings	Event de-duplication	Forced supply to attach to dispensings	Blackout period	Risk Window Interval Start
10	Implant	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	.	1
11	Second contraceptives ecncounter (**COMBO: CHC_OUT**)	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	0	0
12	Second contraceptives ecncounter (COMBO: CHC_OUT)	0	N/A	N/A	*Washout lookback period should search for only evidence of a dispensing date	*De-duplicates occurrences of the same event group on the same day	N/A	0	0
					*Washout lookback period	*De-duplicates occurrences of the			

Appendix F. Specifications Defining Parameters for this Request

	Event Outcome								
Scenario	Event	Incident event washout period	Care setting	Principal diagnosis position	Exclude evidence of days supply if event washout includes dispensings	Event de-duplication	Forced supply to attach to dispensings	Blackout period	Risk Window Interval Start
13	Second contraceptives ecncounter (COMBO: CHC_OUT)	0	N/A	N/A	should search for only evidence of a dispensing date	same event group on the same day	N/A	0	0

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
1	Any CHC	NA	RX	1	365	Y	1	1	N	
2	Oral CHC	NA	RX	1	365	Y	1	1	N	
3	Patch CHC	NA	RX	1	365	Y	1	1	N	
4	Ring CHC	NA	RX	1	365	Y	1	1	N	
5	Any POC	NA	RX	1	365	Y	1	1	N	
6	Non-oral POCs	NA	RX	1	365	Y	1	1	N	
7	Oral POCs	NA	RX	1	365	Y	1	1	N	
8	No use of CHC								Y	Not 1
9	No use of POC								Y	Not 5
10	Any CHC (2 instances)	NA	RX	1	365	Y	2	1	N	
11	Oral CHC (2 instances)	NA	RX	1	365	Y	2	1	N	
12	Patch CHC (2 instances)	NA	RX	1	365	Y	2	1	N	
13	Ring CHC (2 instances)	NA	RX	1	365	Y	2	1	N	
14	Any POC (2 instances)	NA	RX	1	365	Y	2	1	N	
15	Oral POC (2 instances)	NA	RX	1	365	Y	2	1	N	
16	Non-oral POC (2 instances)	NA	RX	1	365	Y	2	1	N	
17	Live birth	IP	DX/PX	0	0	Y	1	1	N	
18	Still Birth	IP	DX/PX	0	0	Y	1	1	N	
435	Live birth singleton	IP	DX/PX	0	0	Y	1	NA	N	
436	Live birth multiple	IP	DX/PX	0	0	Y	1	NA	N	
437	Still birth singleton	IP	DX/PX	0	0	Y	1	NA	N	
438	Still birth multiple	IP	DX/PX	0	0	Y	1	NA	N	
439	Live and still birth multiple	IP	DX/PX	0	0	Y	1	NA	N	
440	C-section	IP	DX/PX	0	0	Y	1	NA	N	
441	Vaginal delivery	IP	DX/PX	0	0	Y	1	NA	N	
442	IUD or Implant removal code	Any	PX	1	365	Y	1	NA	N	
443	Drosperinone	NA	RX	0	0	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
Keep these covariates for the preg cohort										
19	COC Week 1	Any	RX	1	7	Y	1	1	N	
20	COC Week 2	Any	RX	8	14	Y	1	1	N	
21	COC Week 3	Any	RX	15	21	Y	1	1	N	
22	COC Week 4	Any	RX	22	28	Y	1	1	N	
23	COC Week 5	Any	RX	29	35	Y	1	1	N	
24	COC Week 6	Any	RX	36	42	Y	1	1	N	
25	COC Week 7	Any	RX	43	49	Y	1	1	N	
26	COC Week 8	Any	RX	50	56	Y	1	1	N	
27	COC Week 9	Any	RX	57	63	Y	1	1	N	
28	COC Week 10	Any	RX	64	70	Y	1	1	N	
29	COC Week 11	Any	RX	71	77	Y	1	1	N	
30	COC Week 12	Any	RX	78	84	Y	1	1	N	
31	COC Week 13	Any	RX	85	91	Y	1	1	N	
32	COC Week 14	Any	RX	92	98	Y	1	1	N	
33	COC Week 15	Any	RX	99	105	Y	1	1	N	
34	COC Week 16	Any	RX	106	112	Y	1	1	N	
35	COC Week 17	Any	RX	113	119	Y	1	1	N	
36	COC Week 18	Any	RX	120	126	Y	1	1	N	
37	COC Week 19	Any	RX	127	133	Y	1	1	N	
38	COC Week 20	Any	RX	134	140	Y	1	1	N	
39	COC Week 21	Any	RX	141	147	Y	1	1	N	
40	COC Week 22	Any	RX	148	154	Y	1	1	N	
41	COC Week 23	Any	RX	155	161	Y	1	1	N	
42	COC Week 24	Any	RX	162	168	Y	1	1	N	
43	COC Week 25	Any	RX	169	175	Y	1	1	N	
44	COC Week 26	Any	RX	176	182	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
45	COC Week 27	Any	RX	183	189	Y	1	1	N	
46	COC Week 28	Any	RX	190	196	Y	1	1	N	
47	COC Week 29	Any	RX	197	203	Y	1	1	N	
48	COC Week 30	Any	RX	204	210	Y	1	1	N	
49	COC Week 31	Any	RX	211	217	Y	1	1	N	
50	COC Week 32	Any	RX	218	224	Y	1	1	N	
51	COC Week 33	Any	RX	225	231	Y	1	1	N	
52	COC Week 34	Any	RX	232	238	Y	1	1	N	
53	COC Week 35	Any	RX	239	245	Y	1	1	N	
54	COC Week 36	Any	RX	246	252	Y	1	1	N	
55	COC Week 37	Any	RX	253	259	Y	1	1	N	
56	COC Week 38	Any	RX	260	266	Y	1	1	N	
57	COC Week 39	Any	RX	267	273	Y	1	1	N	
58	COC Week 40	Any	RX	274	280	Y	1	1	N	
59	COC Week 41	Any	RX	281	287	Y	1	1	N	
60	COC Week 42	Any	RX	288	294	Y	1	1	N	
61	COC Week 43	Any	RX	295	301	Y	1	1	N	
62	COC Week 44	Any	RX	302	308	Y	1	1	N	
63	COC Week 45	Any	RX	309	315	Y	1	1	N	
64	COC Week 46	Any	RX	316	322	Y	1	1	N	
65	COC Week 47	Any	RX	323	329	Y	1	1	N	
66	COC Week 48	Any	RX	330	336	Y	1	1	N	
67	COC Week 49	Any	RX	337	343	Y	1	1	N	
68	COC Week 50	Any	RX	344	350	Y	1	1	N	
69	COC Week 51	Any	RX	351	357	Y	1	1	N	
70	COC Week 52	Any	RX	358	364	Y	1	1	N	
71	Patch Week 1	Any	RX	1	7	Y	1	1	N	

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
72	Patch Week 2	Any	RX	8	14	Y	1	1	N	
73	Patch Week 3	Any	RX	15	21	Y	1	1	N	
74	Patch Week 4	Any	RX	22	28	Y	1	1	N	
75	Patch Week 5	Any	RX	29	35	Y	1	1	N	
76	Patch Week 6	Any	RX	36	42	Y	1	1	N	
77	Patch Week 7	Any	RX	43	49	Y	1	1	N	
78	Patch Week 8	Any	RX	50	56	Y	1	1	N	
79	Patch Week 9	Any	RX	57	63	Y	1	1	N	
80	Patch Week 10	Any	RX	64	70	Y	1	1	N	
81	Patch Week 11	Any	RX	71	77	Y	1	1	N	
82	Patch Week 12	Any	RX	78	84	Y	1	1	N	
83	Patch Week 13	Any	RX	85	91	Y	1	1	N	
84	Patch Week 14	Any	RX	92	98	Y	1	1	N	
85	Patch Week 15	Any	RX	99	105	Y	1	1	N	
86	Patch Week 16	Any	RX	106	112	Y	1	1	N	
87	Patch Week 17	Any	RX	113	119	Y	1	1	N	
88	Patch Week 18	Any	RX	120	126	Y	1	1	N	
89	Patch Week 19	Any	RX	127	133	Y	1	1	N	
90	Patch Week 20	Any	RX	134	140	Y	1	1	N	
91	Patch Week 21	Any	RX	141	147	Y	1	1	N	
92	Patch Week 22	Any	RX	148	154	Y	1	1	N	
93	Patch Week 23	Any	RX	155	161	Y	1	1	N	
94	Patch Week 24	Any	RX	162	168	Y	1	1	N	
95	Patch Week 25	Any	RX	169	175	Y	1	1	N	
96	Patch Week 26	Any	RX	176	182	Y	1	1	N	
97	Patch Week 27	Any	RX	183	189	Y	1	1	N	
98	Patch Week 28	Any	RX	190	196	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
99	Patch Week 29	Any	RX	197	203	Y	1	1	N	
100	Patch Week 30	Any	RX	204	210	Y	1	1	N	
101	Patch Week 31	Any	RX	211	217	Y	1	1	N	
102	Patch Week 32	Any	RX	218	224	Y	1	1	N	
103	Patch Week 33	Any	RX	225	231	Y	1	1	N	
104	Patch Week 34	Any	RX	232	238	Y	1	1	N	
105	Patch Week 35	Any	RX	239	245	Y	1	1	N	
106	Patch Week 36	Any	RX	246	252	Y	1	1	N	
107	Patch Week 37	Any	RX	253	259	Y	1	1	N	
108	Patch Week 38	Any	RX	260	266	Y	1	1	N	
109	Patch Week 39	Any	RX	267	273	Y	1	1	N	
110	Patch Week 40	Any	RX	274	280	Y	1	1	N	
111	Patch Week 41	Any	RX	281	287	Y	1	1	N	
112	Patch Week 42	Any	RX	288	294	Y	1	1	N	
113	Patch Week 43	Any	RX	295	301	Y	1	1	N	
114	Patch Week 44	Any	RX	302	308	Y	1	1	N	
115	Patch Week 45	Any	RX	309	315	Y	1	1	N	
116	Patch Week 46	Any	RX	316	322	Y	1	1	N	
117	Patch Week 47	Any	RX	323	329	Y	1	1	N	
118	Patch Week 48	Any	RX	330	336	Y	1	1	N	
119	Patch Week 49	Any	RX	337	343	Y	1	1	N	
120	Patch Week 50	Any	RX	344	350	Y	1	1	N	
121	Patch Week 51	Any	RX	351	357	Y	1	1	N	
122	Patch Week 52	Any	RX	358	364	Y	1	1	N	
123	Ring Week 1	Any	RX	1	7	Y	1	1	N	
124	Ring Week 2	Any	RX	8	14	Y	1	1	N	
125	Ring Week 3	Any	RX	15	21	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
126	Ring Week 4	Any	RX	22	28	Y	1	1	N	
127	Ring Week 5	Any	RX	29	35	Y	1	1	N	
128	Ring Week 6	Any	RX	36	42	Y	1	1	N	
129	Ring Week 7	Any	RX	43	49	Y	1	1	N	
130	Ring Week 8	Any	RX	50	56	Y	1	1	N	
131	Ring Week 9	Any	RX	57	63	Y	1	1	N	
132	Ring Week 10	Any	RX	64	70	Y	1	1	N	
133	Ring Week 11	Any	RX	71	77	Y	1	1	N	
134	Ring Week 12	Any	RX	78	84	Y	1	1	N	
135	Ring Week 13	Any	RX	85	91	Y	1	1	N	
136	Ring Week 14	Any	RX	92	98	Y	1	1	N	
137	Ring Week 15	Any	RX	99	105	Y	1	1	N	
138	Ring Week 16	Any	RX	106	112	Y	1	1	N	
139	Ring Week 17	Any	RX	113	119	Y	1	1	N	
140	Ring Week 18	Any	RX	120	126	Y	1	1	N	
141	Ring Week 19	Any	RX	127	133	Y	1	1	N	
142	Ring Week 20	Any	RX	134	140	Y	1	1	N	
143	Ring Week 21	Any	RX	141	147	Y	1	1	N	
144	Ring Week 22	Any	RX	148	154	Y	1	1	N	
145	Ring Week 23	Any	RX	155	161	Y	1	1	N	
146	Ring Week 24	Any	RX	162	168	Y	1	1	N	
147	Ring Week 25	Any	RX	169	175	Y	1	1	N	
148	Ring Week 26	Any	RX	176	182	Y	1	1	N	
149	Ring Week 27	Any	RX	183	189	Y	1	1	N	
150	Ring Week 28	Any	RX	190	196	Y	1	1	N	
151	Ring Week 29	Any	RX	197	203	Y	1	1	N	
152	Ring Week 30	Any	RX	204	210	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
153	Ring Week 31	Any	RX	211	217	Y	1	1	N	
154	Ring Week 32	Any	RX	218	224	Y	1	1	N	
155	Ring Week 33	Any	RX	225	231	Y	1	1	N	
156	Ring Week 34	Any	RX	232	238	Y	1	1	N	
157	Ring Week 35	Any	RX	239	245	Y	1	1	N	
158	Ring Week 36	Any	RX	246	252	Y	1	1	N	
159	Ring Week 37	Any	RX	253	259	Y	1	1	N	
160	Ring Week 38	Any	RX	260	266	Y	1	1	N	
161	Ring Week 39	Any	RX	267	273	Y	1	1	N	
162	Ring Week 40	Any	RX	274	280	Y	1	1	N	
163	Ring Week 41	Any	RX	281	287	Y	1	1	N	
164	Ring Week 42	Any	RX	288	294	Y	1	1	N	
165	Ring Week 43	Any	RX	295	301	Y	1	1	N	
166	Ring Week 44	Any	RX	302	308	Y	1	1	N	
167	Ring Week 45	Any	RX	309	315	Y	1	1	N	
168	Ring Week 46	Any	RX	316	322	Y	1	1	N	
169	Ring Week 47	Any	RX	323	329	Y	1	1	N	
170	Ring Week 48	Any	RX	330	336	Y	1	1	N	
171	Ring Week 49	Any	RX	337	343	Y	1	1	N	
172	Ring Week 50	Any	RX	344	350	Y	1	1	N	
173	Ring Week 51	Any	RX	351	357	Y	1	1	N	
174	Ring Week 52	Any	RX	358	364	Y	1	1	N	
175	IUD Week 1	Any	RX	1	7	Y	1	1	N	
176	IUD Week 2	Any	RX	8	14	Y	1	1	N	
177	IUD Week 3	Any	RX	15	21	Y	1	1	N	
178	IUD Week 4	Any	RX	22	28	Y	1	1	N	
179	IUD Week 5	Any	RX	29	35	Y	1	1	N	

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
180	IUD Week 6	Any	RX	36	42	Y	1	1	N	
181	IUD Week 7	Any	RX	43	49	Y	1	1	N	
182	IUD Week 8	Any	RX	50	56	Y	1	1	N	
183	IUD Week 9	Any	RX	57	63	Y	1	1	N	
184	IUD Week 10	Any	RX	64	70	Y	1	1	N	
185	IUD Week 11	Any	RX	71	77	Y	1	1	N	
186	IUD Week 12	Any	RX	78	84	Y	1	1	N	
187	IUD Week 13	Any	RX	85	91	Y	1	1	N	
188	IUD Week 14	Any	RX	92	98	Y	1	1	N	
189	IUD Week 15	Any	RX	99	105	Y	1	1	N	
190	IUD Week 16	Any	RX	106	112	Y	1	1	N	
191	IUD Week 17	Any	RX	113	119	Y	1	1	N	
192	IUD Week 18	Any	RX	120	126	Y	1	1	N	
193	IUD Week 19	Any	RX	127	133	Y	1	1	N	
194	IUD Week 20	Any	RX	134	140	Y	1	1	N	
195	IUD Week 21	Any	RX	141	147	Y	1	1	N	
196	IUD Week 22	Any	RX	148	154	Y	1	1	N	
197	IUD Week 23	Any	RX	155	161	Y	1	1	N	
198	IUD Week 24	Any	RX	162	168	Y	1	1	N	
199	IUD Week 25	Any	RX	169	175	Y	1	1	N	
200	IUD Week 26	Any	RX	176	182	Y	1	1	N	
201	IUD Week 27	Any	RX	183	189	Y	1	1	N	
202	IUD Week 28	Any	RX	190	196	Y	1	1	N	
203	IUD Week 29	Any	RX	197	203	Y	1	1	N	
204	IUD Week 30	Any	RX	204	210	Y	1	1	N	
205	IUD Week 31	Any	RX	211	217	Y	1	1	N	
206	IUD Week 32	Any	RX	218	224	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
207	IUD Week 33	Any	RX	225	231	Y	1	1	N	
208	IUD Week 34	Any	RX	232	238	Y	1	1	N	
209	IUD Week 35	Any	RX	239	245	Y	1	1	N	
210	IUD Week 36	Any	RX	246	252	Y	1	1	N	
211	IUD Week 37	Any	RX	253	259	Y	1	1	N	
212	IUD Week 38	Any	RX	260	266	Y	1	1	N	
213	IUD Week 39	Any	RX	267	273	Y	1	1	N	
214	IUD Week 40	Any	RX	274	280	Y	1	1	N	
215	IUD Week 41	Any	RX	281	287	Y	1	1	N	
216	IUD Week 42	Any	RX	288	294	Y	1	1	N	
217	IUD Week 43	Any	RX	295	301	Y	1	1	N	
218	IUD Week 44	Any	RX	302	308	Y	1	1	N	
219	IUD Week 45	Any	RX	309	315	Y	1	1	N	
220	IUD Week 46	Any	RX	316	322	Y	1	1	N	
221	IUD Week 47	Any	RX	323	329	Y	1	1	N	
222	IUD Week 48	Any	RX	330	336	Y	1	1	N	
223	IUD Week 49	Any	RX	337	343	Y	1	1	N	
224	IUD Week 50	Any	RX	344	350	Y	1	1	N	
225	IUD Week 51	Any	RX	351	357	Y	1	1	N	
226	IUD Week 52	Any	RX	358	364	Y	1	1	N	
227	DMPA Week 1	Any	RX	1	7	Y	1	1	N	
228	DMPA Week 2	Any	RX	8	14	Y	1	1	N	
229	DMPA Week 3	Any	RX	15	21	Y	1	1	N	
230	DMPA Week 4	Any	RX	22	28	Y	1	1	N	
231	DMPA Week 5	Any	RX	29	35	Y	1	1	N	
232	DMPA Week 6	Any	RX	36	42	Y	1	1	N	
233	DMPA Week 7	Any	RX	43	49	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
234	DMPA Week 8	Any	RX	50	56	Y	1	1	N	
235	DMPA Week 9	Any	RX	57	63	Y	1	1	N	
236	DMPA Week 10	Any	RX	64	70	Y	1	1	N	
237	DMPA Week 11	Any	RX	71	77	Y	1	1	N	
238	DMPA Week 12	Any	RX	78	84	Y	1	1	N	
239	DMPA Week 13	Any	RX	85	91	Y	1	1	N	
240	DMPA Week 14	Any	RX	92	98	Y	1	1	N	
241	DMPA Week 15	Any	RX	99	105	Y	1	1	N	
242	DMPA Week 16	Any	RX	106	112	Y	1	1	N	
243	DMPA Week 17	Any	RX	113	119	Y	1	1	N	
244	DMPA Week 18	Any	RX	120	126	Y	1	1	N	
245	DMPA Week 19	Any	RX	127	133	Y	1	1	N	
246	DMPA Week 20	Any	RX	134	140	Y	1	1	N	
247	DMPA Week 21	Any	RX	141	147	Y	1	1	N	
248	DMPA Week 22	Any	RX	148	154	Y	1	1	N	
249	DMPA Week 23	Any	RX	155	161	Y	1	1	N	
250	DMPA Week 24	Any	RX	162	168	Y	1	1	N	
251	DMPA Week 25	Any	RX	169	175	Y	1	1	N	
252	DMPA Week 26	Any	RX	176	182	Y	1	1	N	
253	DMPA Week 27	Any	RX	183	189	Y	1	1	N	
254	DMPA Week 28	Any	RX	190	196	Y	1	1	N	
255	DMPA Week 29	Any	RX	197	203	Y	1	1	N	
256	DMPA Week 30	Any	RX	204	210	Y	1	1	N	
257	DMPA Week 31	Any	RX	211	217	Y	1	1	N	
258	DMPA Week 32	Any	RX	218	224	Y	1	1	N	
259	DMPA Week 33	Any	RX	225	231	Y	1	1	N	
260	DMPA Week 34	Any	RX	232	238	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
261	DMPA Week 35	Any	RX	239	245	Y	1	1	N	
262	DMPA Week 36	Any	RX	246	252	Y	1	1	N	
263	DMPA Week 37	Any	RX	253	259	Y	1	1	N	
264	DMPA Week 38	Any	RX	260	266	Y	1	1	N	
265	DMPA Week 39	Any	RX	267	273	Y	1	1	N	
266	DMPA Week 40	Any	RX	274	280	Y	1	1	N	
267	DMPA Week 41	Any	RX	281	287	Y	1	1	N	
268	DMPA Week 42	Any	RX	288	294	Y	1	1	N	
269	DMPA Week 43	Any	RX	295	301	Y	1	1	N	
270	DMPA Week 44	Any	RX	302	308	Y	1	1	N	
271	DMPA Week 45	Any	RX	309	315	Y	1	1	N	
272	DMPA Week 46	Any	RX	316	322	Y	1	1	N	
273	DMPA Week 47	Any	RX	323	329	Y	1	1	N	
274	DMPA Week 48	Any	RX	330	336	Y	1	1	N	
275	DMPA Week 49	Any	RX	337	343	Y	1	1	N	
276	DMPA Week 50	Any	RX	344	350	Y	1	1	N	
277	DMPA Week 51	Any	RX	351	357	Y	1	1	N	
278	DMPA Week 52	Any	RX	358	364	Y	1	1	N	
279	POC Week 1	Any	RX	1	7	Y	1	1	N	
280	POC Week 2	Any	RX	8	14	Y	1	1	N	
281	POC Week 3	Any	RX	15	21	Y	1	1	N	
282	POC Week 4	Any	RX	22	28	Y	1	1	N	
283	POC Week 5	Any	RX	29	35	Y	1	1	N	
284	POC Week 6	Any	RX	36	42	Y	1	1	N	
285	POC Week 7	Any	RX	43	49	Y	1	1	N	
286	POC Week 8	Any	RX	50	56	Y	1	1	N	
287	POC Week 9	Any	RX	57	63	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
288	POC Week 10	Any	RX	64	70	Y	1	1	N	
289	POC Week 11	Any	RX	71	77	Y	1	1	N	
290	POC Week 12	Any	RX	78	84	Y	1	1	N	
291	POC Week 13	Any	RX	85	91	Y	1	1	N	
292	POC Week 14	Any	RX	92	98	Y	1	1	N	
293	POC Week 15	Any	RX	99	105	Y	1	1	N	
294	POC Week 16	Any	RX	106	112	Y	1	1	N	
295	POC Week 17	Any	RX	113	119	Y	1	1	N	
296	POC Week 18	Any	RX	120	126	Y	1	1	N	
297	POC Week 19	Any	RX	127	133	Y	1	1	N	
298	POC Week 20	Any	RX	134	140	Y	1	1	N	
299	POC Week 21	Any	RX	141	147	Y	1	1	N	
300	POC Week 22	Any	RX	148	154	Y	1	1	N	
301	POC Week 23	Any	RX	155	161	Y	1	1	N	
302	POC Week 24	Any	RX	162	168	Y	1	1	N	
303	POC Week 25	Any	RX	169	175	Y	1	1	N	
304	POC Week 26	Any	RX	176	182	Y	1	1	N	
305	POC Week 27	Any	RX	183	189	Y	1	1	N	
306	POC Week 28	Any	RX	190	196	Y	1	1	N	
307	POC Week 29	Any	RX	197	203	Y	1	1	N	
308	POC Week 30	Any	RX	204	210	Y	1	1	N	
309	POC Week 31	Any	RX	211	217	Y	1	1	N	
310	POC Week 32	Any	RX	218	224	Y	1	1	N	
311	POC Week 33	Any	RX	225	231	Y	1	1	N	
312	POC Week 34	Any	RX	232	238	Y	1	1	N	
313	POC Week 35	Any	RX	239	245	Y	1	1	N	
314	POC Week 36	Any	RX	246	252	Y	1	1	N	

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
315	POC Week 37	Any	RX	253	259	Y	1	1	N	
316	POC Week 38	Any	RX	260	266	Y	1	1	N	
317	POC Week 39	Any	RX	267	273	Y	1	1	N	
318	POC Week 40	Any	RX	274	280	Y	1	1	N	
319	POC Week 41	Any	RX	281	287	Y	1	1	N	
320	POC Week 42	Any	RX	288	294	Y	1	1	N	
321	POC Week 43	Any	RX	295	301	Y	1	1	N	
322	POC Week 44	Any	RX	302	308	Y	1	1	N	
323	POC Week 45	Any	RX	309	315	Y	1	1	N	
324	POC Week 46	Any	RX	316	322	Y	1	1	N	
325	POC Week 47	Any	RX	323	329	Y	1	1	N	
326	POC Week 48	Any	RX	330	336	Y	1	1	N	
327	POC Week 49	Any	RX	337	343	Y	1	1	N	
328	POC Week 50	Any	RX	344	350	Y	1	1	N	
329	POC Week 51	Any	RX	351	357	Y	1	1	N	
330	POC Week 52	Any	RX	358	364	Y	1	1	N	
331	Any CHC Week 1	Any	RX	1	7	Y	1	1	Y	19 OR 71 OR 123
332	Any CHC Week 2	Any	RX	8	14	Y	1	1	Y	20 OR 72 OR 124
333	Any CHC Week 3	Any	RX	15	21	Y	1	1	Y	21 OR 73 OR 125
334	Any CHC Week 4	Any	RX	22	28	Y	1	1	Y	22 OR 74 OR 126
335	Any CHC Week 5	Any	RX	29	35	Y	1	1	Y	23 OR 75 OR 127

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
336	Any CHC Week 6	Any	RX	36	42	Y	1	1	Y	24 OR 76 OR 128
337	Any CHC Week 7	Any	RX	43	49	Y	1	1	Y	25 OR 77 OR 129
338	Any CHC Week 8	Any	RX	50	56	Y	1	1	Y	26 OR 78 OR 130
339	Any CHC Week 9	Any	RX	57	63	Y	1	1	Y	27 OR 79 OR 131
340	Any CHC Week 10	Any	RX	64	70	Y	1	1	Y	28 OR 80 OR 132
341	Any CHC Week 11	Any	RX	71	77	Y	1	1	Y	29 OR 81 OR 133
342	Any CHC Week 12	Any	RX	78	84	Y	1	1	Y	30 OR 82 OR 134
343	Any CHC Week 13	Any	RX	85	91	Y	1	1	Y	31 OR 83 OR 135
344	Any CHC Week 14	Any	RX	92	98	Y	1	1	Y	32 OR 84 OR 136
345	Any CHC Week 15	Any	RX	99	105	Y	1	1	Y	33 OR 85 OR 137
346	Any CHC Week 16	Any	RX	106	112	Y	1	1	Y	34 OR 86 OR 138
347	Any CHC Week 17	Any	RX	113	119	Y	1	1	Y	35 OR 87 OR 139
348	Any CHC Week 18	Any	RX	120	126	Y	1	1	Y	36 OR 88 OR 140

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
349	Any CHC Week 19	Any	RX	127	133	Y	1	1	Y	37 OR 89 OR 141
350	Any CHC Week 20	Any	RX	134	140	Y	1	1	Y	38 OR 90 OR 142
351	Any CHC Week 21	Any	RX	141	147	Y	1	1	Y	39 OR 91 OR 143
352	Any CHC Week 22	Any	RX	148	154	Y	1	1	Y	40 OR 92 OR 144
353	Any CHC Week 23	Any	RX	155	161	Y	1	1	Y	41 OR 93 OR 145
354	Any CHC Week 24	Any	RX	162	168	Y	1	1	Y	42 OR 94 OR 146
355	Any CHC Week 25	Any	RX	169	175	Y	1	1	Y	43 OR 95 OR 147
356	Any CHC Week 26	Any	RX	176	182	Y	1	1	Y	44 OR 96 OR 148
357	Any CHC Week 27	Any	RX	183	189	Y	1	1	Y	45 OR 97 OR 149
358	Any CHC Week 28	Any	RX	190	196	Y	1	1	Y	46 OR 98 OR 150
359	Any CHC Week 29	Any	RX	197	203	Y	1	1	Y	47 OR 99 OR 151
360	Any CHC Week 30	Any	RX	204	210	Y	1	1	Y	48 OR 100 OR 152
361	Any CHC Week 31	Any	RX	211	217	Y	1	1	Y	49 OR 101 OR 153

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
362	Any CHC Week 32	Any	RX	218	224	Y	1	1	Y	50 OR 102 OR 154
363	Any CHC Week 33	Any	RX	225	231	Y	1	1	Y	51 OR 103 OR 155
364	Any CHC Week 34	Any	RX	232	238	Y	1	1	Y	52 OR 104 OR 156
365	Any CHC Week 35	Any	RX	239	245	Y	1	1	Y	53 OR 105 OR 157
366	Any CHC Week 36	Any	RX	246	252	Y	1	1	Y	54 OR 106 OR 158
367	Any CHC Week 37	Any	RX	253	259	Y	1	1	Y	55 OR 107 OR 159
368	Any CHC Week 38	Any	RX	260	266	Y	1	1	Y	56 OR 108 OR 160
369	Any CHC Week 39	Any	RX	267	273	Y	1	1	Y	57 OR 109 OR 161
370	Any CHC Week 40	Any	RX	274	280	Y	1	1	Y	58 OR 110 OR 162
371	Any CHC Week 41	Any	RX	281	287	Y	1	1	Y	59 OR 111 OR 163
372	Any CHC Week 42	Any	RX	288	294	Y	1	1	Y	60 OR 112 OR 164
373	Any CHC Week 43	Any	RX	295	301	Y	1	1	Y	61 OR 113 OR 165
374	Any CHC Week 44	Any	RX	302	308	Y	1	1	Y	62 OR 114 OR 166

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
375	Any CHC Week 45	Any	RX	309	315	Y	1	1	Y	63 OR 115 OR 167
376	Any CHC Week 46	Any	RX	316	322	Y	1	1	Y	64 OR 116 OR 168
377	Any CHC Week 47	Any	RX	323	329	Y	1	1	Y	65 OR 117 OR 169
378	Any CHC Week 48	Any	RX	330	336	Y	1	1	Y	66 OR 118 OR 170
379	Any CHC Week 49	Any	RX	337	343	Y	1	1	Y	67 OR 119 OR 171
380	Any CHC Week 50	Any	RX	344	350	Y	1	1	Y	68 OR 120 OR 172
381	Any CHC Week 51	Any	RX	351	357	Y	1	1	Y	69 OR 121 OR 173
382	Any CHC Week 52	Any	RX	358	364	Y	1	1	Y	70 OR 122 OR 174
383	Any POC Week 1	Any	RX	1	7	Y	1	1	Y	175 OR 227 OR 279
384	Any POC Week 2	Any	RX	8	14	Y	1	1	Y	176 OR 228 OR 280
385	Any POC Week 3	Any	RX	15	21	Y	1	1	Y	177 OR 229 OR 281

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
386	Any POC Week 4	Any	RX	22	28	Y	1	1	Y	178 OR 230 OR 282
387	Any POC Week 5	Any	RX	29	35	Y	1	1	Y	179 OR 231 OR 283
388	Any POC Week 6	Any	RX	36	42	Y	1	1	Y	180 OR 232 OR 284
389	Any POC Week 7	Any	RX	43	49	Y	1	1	Y	181 OR 233 OR 285
390	Any POC Week 8	Any	RX	50	56	Y	1	1	Y	182 OR 234 OR 286
391	Any POC Week 9	Any	RX	57	63	Y	1	1	Y	183 OR 235 OR 287
392	Any POC Week 10	Any	RX	64	70	Y	1	1	Y	184 OR 236 OR 288

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
393	Any POC Week 11	Any	RX	71	77	Y	1	1	Y	185 OR 237 OR 289
394	Any POC Week 12	Any	RX	78	84	Y	1	1	Y	186 OR 238 OR 290
395	Any POC Week 13	Any	RX	85	91	Y	1	1	Y	187 OR 239 OR 291
396	Any POC Week 14	Any	RX	92	98	Y	1	1	Y	188 OR 240 OR 292
397	Any POC Week 15	Any	RX	99	105	Y	1	1	Y	189 OR 241 OR 293
398	Any POC Week 16	Any	RX	106	112	Y	1	1	Y	190 OR 242 OR 294
399	Any POC Week 17	Any	RX	113	119	Y	1	1	Y	191 OR 243 OR 295

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
400	Any POC Week 18	Any	RX	120	126	Y	1	1	Y	192 OR 244 OR 296
401	Any POC Week 19	Any	RX	127	133	Y	1	1	Y	193 OR 245 OR 297
402	Any POC Week 20	Any	RX	134	140	Y	1	1	Y	194 OR 246 OR 298
403	Any POC Week 21	Any	RX	141	147	Y	1	1	Y	195 OR 247 OR 299
404	Any POC Week 22	Any	RX	148	154	Y	1	1	Y	196 OR 248 OR 300
405	Any POC Week 23	Any	RX	155	161	Y	1	1	Y	197 OR 249 OR 301
406	Any POC Week 24	Any	RX	162	168	Y	1	1	Y	198 OR 250 OR 302

Sentinel

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
407	Any POC Week 25	Any	RX	169	175	Y	1	1	Y	199 OR 251 OR 303
408	Any POC Week 26	Any	RX	176	182	Y	1	1	Y	200 OR 252 OR 304
409	Any POC Week 27	Any	RX	183	189	Y	1	1	Y	201 OR 253 OR 305
410	Any POC Week 28	Any	RX	190	196	Y	1	1	Y	202 OR 254 OR 306
411	Any POC Week 29	Any	RX	197	203	Y	1	1	Y	203 OR 255 OR 307
412	Any POC Week 30	Any	RX	204	210	Y	1	1	Y	204 OR 256 OR 308
413	Any POC Week 31	Any	RX	211	217	Y	1	1	Y	205 OR 257 OR 309

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
414	Any POC Week 32	Any	RX	218	224	Y	1	1	Y	206 OR 258 OR 310
415	Any POC Week 33	Any	RX	225	231	Y	1	1	Y	207 OR 259 OR 311
416	Any POC Week 34	Any	RX	232	238	Y	1	1	Y	208 OR 260 OR 312
417	Any POC Week 35	Any	RX	239	245	Y	1	1	Y	209 OR 261 OR 313
418	Any POC Week 36	Any	RX	246	252	Y	1	1	Y	210 OR 262 OR 314
419	Any POC Week 37	Any	RX	253	259	Y	1	1	Y	211 OR 263 OR 315
420	Any POC Week 38	Any	RX	260	266	Y	1	1	Y	212 OR 264 OR 316

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
421	Any POC Week 39	Any	RX	267	273	Y	1	1	Y	213 OR 265 OR 317
422	Any POC Week 40	Any	RX	274	280	Y	1	1	Y	214 OR 266 OR 318
423	Any POC Week 41	Any	RX	281	287	Y	1	1	Y	215 OR 267 OR 319
424	Any POC Week 42	Any	RX	288	294	Y	1	1	Y	216 OR 268 OR 320
425	Any POC Week 43	Any	RX	295	301	Y	1	1	Y	217 OR 269 OR 321
426	Any POC Week 44	Any	RX	302	308	Y	1	1	Y	218 OR 270 OR 322
427	Any POC Week 45	Any	RX	309	315	Y	1	1	Y	219 OR 271 OR 323

Appendix G. Specifications Defining Baseline Characteristics for this Request

Covariates

Covariate Number	Covariate	Care setting	Code Category	Evaluation period start	Evaluation period end	Dispensing Date Only?	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	CC Covar?	Covarnum Components
428	Any POC Week 46	Any	RX	316	322	Y	1	1	Y	220 OR 272 OR 324
429	Any POC Week 47	Any	RX	323	329	Y	1	1	Y	221 OR 273 OR 325
430	Any POC Week 48	Any	RX	330	336	Y	1	1	Y	222 OR 274 OR 326
431	Any POC Week 49	Any	RX	337	343	Y	1	1	Y	223 OR 275 OR 327
432	Any POC Week 50	Any	RX	344	350	Y	1	1	Y	224 OR 276 OR 328
433	Any POC Week 51	Any	RX	351	357	Y	1	1	Y	225 OR 277 OR 329
434	Any POC Week 52	Any	RX	358	364	Y	1	1	Y	226 OR 278 OR 330

Appendix H. Specifications Defining Combinations for this Request

Combo name	Combination description	Condition	Observation window from Base	Encounter type for each combination component	Inclusion or Exclusion	Final Date of Combo
CHCPOC_BIRTH	Second contraceptive encounter withing a year of a live or still birth delivery	CHC or POC dispensing 2 Live or still birth delivery	---- (-365, -1)	Any care setting IP*	inclusion	
CHC_OUT	**Dummy variable for any CHC or POC to be**	CHC or POC dispensing/administrati	0,0	Any care setting		CHC dispensing/administrati

Appendix I. Design Diagram for this Request

Type 2 design diagram for cder_mpl1r_wp262 Cohort Def 02

For scenario: *preg*



***Exclusion Criteria**

Window 1: *N/A*

****Inclusion Criteria**

Window A: *N/A*

*****Covariates:**

Window I: Age, year, race, sex,
Delivery characteristics
Window II: Any CHC and Any POC use, CHC and POC use broken down by type.
Type of CHC and POC use overall in 365 days and by week

Appendix I. Design Diagram for this Request

Type 2 design diagram for cder_mpl1r_wp262 Cohort Def 02

For scenarios: *preg_allchc, preg_coc, preg_patch, preg_ring, preg_allpoc, preg_iud, preg_dmpa, preg_poc_oral, preg_implant*



***Exclusion Criteria**

Window 1: *Any Contraceptive*[1]

[1]Each inclusion/exclusion criteria applies to each of the respective scenarios based on the outcome of interest

****Inclusion Criteria**

Window A: *Any CHC/Oral CHC/Patch CHC/Ring CHC/Any POC/IUD/DMPA/POC Oral/Implant*[1]

[1]Each inclusion/exclusion criteria applies to each of the respective scenarios based on the outcome of interest

*****Covariates:**

Window I: Age, year, race, sex, Delivery characteristics

Appendix I. Design Diagram for this Request

Type 2 design diagram for cder_mpl1r_wp262 Cohort Def 02

For scenarios: *chc_inter, poc_any_inter, poc_dmpa_inter*



***Exclusion Criteria**
Window 1: *Live birth or stillbirth delivery*[1]

****Inclusion Criteria**
Window A: Live or stillbirth delivery

Window B: Second dispensing of Any CHC or POC following *a live birth or stillbirth delivery in the previous 365 days. This must also happen after the first dispensing (index date).*

[1]Each inclusion/exclusion criteria applies to each of the respective scenarios based on the index event and outcome of interest

*****Covariates:**
Window I: Age, year, race, sex, Delivery characteristics